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Abstract	  
Human	  herpes	  virus	  6	  (HHV6)	  infects	  the	  majority	  of	  individuals	  in	  childhood,	  followed	  by	  a	  
lifelong	   asymptomatic	   latent	   infection.	   	   However,	   in	   immunosuppressed	   individuals	  
reactivation	   of	   HHV6	   can	   cause	   significant	   clinical	   pathology.	   	   Recent	   successes	   with	  
adoptive	   T	   cell	   therapy	   against	   other	   viral	   infections,	   notably	   the	   human	   herpes	   viruses	  
Epstein-­‐Barr	   virus	   (EBV)	   and	   Human	   cytomegalovirus	   (HCMV),	   suggest	   that	   this	  may	   be	   a	  
useful	   therapeutic	   approach	   for	   HHV6-­‐driven	   disease	   in	   immunosuppressed	   individuals.	  	  
However,	  very	  few	  studies	  have	  been	  carried	  out	  analysing	  the	  immune	  response	  to	  HHV6	  in	  
any	  detail.	   	  This	   thesis	  was	  aimed	  at	  characterising	   the	  CD8+	  T	  cell	   response	   to	  HHV6	   in	  a	  
group	  of	  healthy	   individuals,	  with	  the	  aim	  of	  mapping	  and	  characterising	  novel	  CD8+	  T	  cell	  
epitopes.	  	  	  
Initial	   studies	   included	   four	   HHV6B	   antigens	   (U11,	   U39,	   U54	   and	   U90),	   predicted	   to	   be	  
immunogenic	  based	  on	  their	  HCMV	  homologues.	  	  Whole	  antigen	  peptide	  mixes	  (pepmixes)	  
were	  used	  to	  stimulate	  peripheral	  blood	  mononuclear	  cells	  (PBMC)	  from	  healthy	  subjects.	  	  T	  
cell	   responses	   were	   analysed	   by	   intracellular	   cytokine	   staining	   (ICS)	   after	   overnight	  
stimulation	   and/or	   by	   interferon-­‐γ	   (IFN-­‐γ)	   ELISpot	   assay	   after	   10	   days	   of	   stimulation.	   	   For	  
responses	   to	  U11	  and	  U90,	  peptides	   libraries	  were	  used	   to	  map	  minimum	  CD8+	  restricted	  
epitopes.	   	  Further	  characterisation	  of	  HHV6B-­‐specific	  T	  cells	  was	  carried	  out	  by	   identifying	  
the	  HLA	  restriction	  elements	  and	  determining	  whether	  these	  T	  cells	  were	  capable	  of	  killing	  
HHV6B-­‐infected	  cells.	  
PBMC	   from	   30	   healthy	   donors	   were	   stimulated	   with	   pepmixes	   corresponding	   to	   HHV-­‐6B	  
antigens	  U11,	  U39,	  U54	  and	  U90.	   	  A	  weak	  CD8+	  response	  (0.02-­‐0.2%)	  to	  U90	  and	  U54	  was	  
observed	  in	  a	  number	  of	  donors.	  	  	  
Short-­‐term	   in-­‐vitro	   reactivations	   of	   PBMC	   (in	   25	   healthy	   donors)	   with	   HHV6B	   pepmixes	  
followed	   by	   analysis	   of	   antigen	   and	   peptide	   specific	   response	   were	   performed	   by	   IFN-­‐γ	  
ELISpot	  assay.	  	  T	  cell	  responses	  to	  U54,	  U90,	  U11	  and	  U39	  were	  observed	  in	  88%,	  84%,	  76%	  
and	  72%	  of	  the	  donors,	  respectively.	  	  	  
Subsequently,	   the	   breadth	   of	   epitope	   specificity	   within	   U90	   and	   U11	   was	   screened	   for	   9	  
healthy	   donors;	  with	   successful	   identification	   of	   10	   CD8+	   T	   cells	   specific	   (9-­‐mer)	   epitopes	  
within	   these	   antigens.	   	   Seven	  of	   them	  were	  within	  U90	   antigens	   and	   three	   of	   them	  were	  
within	   U11	   antigens.	   	   Allelic	   association	   of	   the	   U90	   epitopes	   were;	   VEESIKEIL	   -­‐	   B40	   (60),	  
FESLLFPEL	   -­‐	   B40	   (60),	   NLITAAKNI	   -­‐	   A2,	   ITAAKNIGI	   -­‐	   A2,	   LNIDPSESI	   -­‐	   A1,	   PSKSKKIKL	   -­‐	   A29,	  
NHCFINHFV	   -­‐	   B39.	   	   Allelic	   association	   of	   the	   2	   U11	   epitopes	   were	   LKTQRRHKF	   -­‐	   B37	   and	  
GILDFGVKL	   -­‐	   A2;	   the	   HLA	   association	   for	   FNAVYSQRV	   was	   not	   identified.	   	   CD8+	   T	   cell	  
populations	  specific	  to	  some	  of	  these	  epitopes	  were	  also	  able	  to	  kill	  HHV6B	  infected	  cells.	  
HHV6B	   T	   cells	   responses	   are	   detectable	   in	   healthy	   donors.	   	   Peptide	   specific	   responses	  
against	  U11	  and	  U90	  have	  been	  mapped	  and	  characterised.	   	  These	  findings	  are	  relevant	  to	  
the	  development	  of	  T	  cell	  mediated	  immunotherapy	  of	  HHV6-­‐associated	  diseases.	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1.	  	  Introduction	  
Human	   herpes	   viruses	   (HHVs)	   are	   ancient,	   widespread	   pathogens	   that	   have	   co-­‐
evolved	   with	   humans	   to	   achieve	   a	   fine	   host-­‐pathogen	   balance	   of	   mutual	   co-­‐
existence.	  	  Unlike	  with	  many	  other	  viruses,	  primary	  infection	  with	  HHVs	  is	  followed	  
by	  a	  persistent	  phase	  of	  infection.	  	  The	  work	  in	  this	  thesis	  concentrates	  on	  two	  such	  
HHVs	  that	  fall	  in	  the	  beta-­‐herpes	  virus	  sub-­‐family.	  	  These	  are	  human	  herpes	  virus	  6	  
(HHV6)	  and	  Cytomegalovirus	  (HCMV)	  as	  a	  control.	  
1.1	  Herpes	  virus	  classification	  and	  basic	  biology	  	  
Herpes	   virus	   family	   is	   known	   as	   Herpesviridae	   (Table	   1.1)	   and	   can	   infect	   a	   wide	  
variety	  of	  living	  organisms.	  	  There	  are	  eight	  viruses	  of	  the	  Herpesviridae	  family	  that	  
can	  infect	  human.	  	  The	  genome	  of	  the	  virus	  consists	  of	  a	  linear	  double-­‐stranded	  DNA	  
surrounded	  by	  a	  capsid,	  which	  is	  covered	  with	  a	  protein	  layer	  called	  the	  tegument,	  
and	   an	   envelope	   composed	   of	   glycoproteins.	   	   These	   viruses	   are	   intracellular	  
parasites	   and	   the	   host	   immune	   system	   can	   respond	   to	   unique	   antigens	   that	   are	  
present	   in	   the	   virus	   glycoproteins.	   	   Herpes	   virus	   family	   members	   share	   several	  
features	  beside	  genome	  and	  virion	  structure.	  	  They	  are	  capable	  of	  persisting	  within	  
the	   body	   over	   long	   periods	   in	   a	   latent	   phase,	   enabling	   them	   to	   establish	   chronic	  
infections.	   	   In	   latency,	  their	  genomes	  adopt	  an	  episomal	  form	  when	  they	  express	  a	  
minimum	  of	  genes	  necessary	  for	  their	  maintenance	  thereby	  reducing	  recognition	  of	  
the	  infected	  cell	  by	  the	  immune	  system	  (Whitley	  et	  al.,	  2009).	  	  	  
Human	   herpes	   viruses	   are	   divided	   into	   three	   subfamilies	   Alphaherpesvirinae,	  
Betaherpesvirinae	   and	  Gammaherpesvirinae	   (Mettenleiter	   et	   al.,	   2009).	   	   The	  alpha	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herpes	  viruses	  include	  herpes	  simplex	  virus	  1	  (HSV-­‐1),	  herpes	  simplex	  virus	  2	  (HSV-­‐2)	  
and	  varicella	  zoster	  virus	  (chicken	  pox).	   	  The	  gamma	  herpes	  viruses	   include	  Epstein	  
Barr	  virus	  (EBV)	  and	  Kaposi’s	  sarcoma-­‐associated	  herpes	  virus	  (KSHV),	  also	  known	  as	  
human	  herpes	  virus	  8	  (HHV-­‐8)	  (Moss,	  2007;	  Motta	  and	  Martins,	  2008).	  
Finally,	   the	   beta	   herpes	   viruses	   include	   human	   cytomegalovirus	   (HCMV),	   human	  
herpes	  virus	  6	  (HHV6)	  and	  human	  herpes	  virus	  7	  (HHV7).	  	  Beta	  herpes	  viruses	  have	  
common	   growth	   characteristics,	   induces	   a	   cytopathology	   containing	   characteristic	  
nuclear	  and	  cytoplasmic	   inclusions	   (Mocarski,	  2002).	  They	  can	  remain	   latent	   in	   the	  
secretory	   glands,	   lymphoreticular	   system	   and	   epithelial	   cells.	   	   HCMV	   is	   associated	  
with	   severe	   congenital	   infections.	   	   HHV6	   variant	   B	   (which	   is	   the	   common	   variant)	  
and	  HHV7	  are	   associated	  with	   a	  disease	   affecting	   young	   children	   called	   roseola	  or	  
exanthema	  subitum	  (Arvin	  and	  Campadelli-­‐Fiume,	  2007).	  
Table	  1.1	  General	  information	  on	  the	  human	  herpes	  viruses	  family	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1.2	  Human	  Herpes	  virus	  6	  	  
Human	   herpes	   virus	   6	   (HHV6)	   was	   originally	   isolated	   in	   1986	   from	   the	   peripheral	  
blood	  of	  six	  patients	  with	  lymphoproliferative	  disorders	  and/or	  infected	  with	  human	  
immunodeficiency	  virus	  (HIV)	  (Salahuddin	  et	  al.,	  1986).	  	  HHV6	  and	  HCMV	  are	  closely	  
related	  and	  belong	  to	  the	  β-­‐	  herpes	  virus	  group	  (Efstathiou	  et	  al.,	  1988).	  	  There	  are	  
two	   known	   variants	   of	   HHV6	   (A	   and	   B),	   of	   which	   variant	   B	   is	   the	   commoner	  
(Dewhurst	   et	   al.,	   1993).	   	   They	   have	   differences	   in	   DNA	   sequence,	   reaction	   to	  
monoclonal	   antibodies,	   cell	   tropism	   and	   disease	   association	   (Pellett	   and	   Black,	  
1996).	  	  The	  GS	  or	  Uganda	  (U1102)	  like	  strain	  belongs	  to	  the	  variant	  A	  group,	  and	  the	  
Zaire	  (Z29)	  or	  (HST)	   like	  strain	  belongs	  to	  the	  variant	  B	  group	  (Ablashi	  et	  al.,	  1993).	  	  
The	   HHV6A	   (strain	   GS)	   variant	   was	   the	   original	   isolate	   retrieved	   from	   an	  
immunocompromised	  patient	  (Salahuddin	  et	  al.,	  1986).	  	  The	  type	  B	  variant	  of	  HHV6	  
is	  associated	  with	  roseola	  (exanthem	  subitum)	  (Dewhurst	  et	  al.,	  1993;	  Yamanishi	  et	  
al.,	  1988),	  while	  the	  pathogenesis	  of	  HHV6A	  is	  still	  unknown	  (Matsuura	  et	  al.,	  2011;	  
Isegawa	   et	   al.,	   1999).	   	   Roseola	   is	   characterised	   by	   3–5	   days	   of	   fever	   with	  
maculopapular	   rash.	   	  Moreover,	   HHV6	   infection	   is	   reported	   to	   be	   associated	  with	  
central	   nervous	   system	   infection,	   rejection	   of	   kidney	   transplant	   and	   hepatitis	  
(Whitley	  et	  al.,	  2009).	  




Figure	  1.1	  Human	  Herpes	  virus	  6	  (HHV6)	  structure	  
Figure	  showing	  HHV6	  virion	  structure;	  which	  is	  enveloped,	  spherical	  to	  pleomorphic,	  
approximately	  200	  nm	  in	  diameter.	  	  HHV6	  has	  double	  linear	  DNA	  genomes	  covered	  
by	   capsid	   proteins,	   consisting	   of	   162	   capsomers,	   encircled	   by	   an	   amorphous	  
tegument.	   	  The	   lipid	  envelope	   is	  embedded	  with	  glycoprotein	  complexes.	   	   (Hulo	  et	  
al.,	  2011)	  
	  
1.3	  Classification	  and	  basic	  biology	  of	  HHV6	  
Similar	  to	  other	  herpes	  viruses,	  the	  HHV6	  virion	  is	  enveloped	  Figure	  (1.1),	  spherical,	  
200	  nm	  in	  diameter,	  containing	  a	  single	  molecule	  of	  dsDNA	  which	  is	  160	  to	  162kb	  in	  
size	  (encoding	  about	  100	  proteins),	  with	  terminal	  direct	  repeats	  (DRleft	  and	  DRright)	  of	  
8-­‐9	   kb	   in	   both	   flanks	   (De	   Bolle	   et	   al.,	   2005;	   Tang	   and	  Mori,	   2010).	   	   The	   genome	  
contains	  7	  regions	  of	  genes	  conserved	  in	  all	  herpes	  viruses	  (Clark,	  2000).	  	  There	  are	  
three	   intermediate	   repeats	   (R1,	  R2	  and	  R3)	   (Figure	  1.2)	   interrupting	  a	  unique	   long	  
(UL)	   region,	   at	   the	   immediate-­‐early	  A	   (IE-­‐A)	   region.	   	   The	   genomic	   structure	   of	   the	  
unique	  long	  region	  is	  similar	  to	  that	  of	  human	  CMV	  and	  co-­‐linear	  with	  that	  of	  HHV7.	  	  
The	   genes	   in	   UL	   are	   designated	   as	   U1	   to	   U100	   and	   open	   reading	   frames	   (ORFs)	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within	   the	   direct	   repeats	   are	   termed	   as	   DR1	   to	   DR7.	   	   Genes	   coding	   for	   virion	  
structure	   or	   enzymes	   needed	   for	   nucleotide	  metabolism	   and	   DNA	   replication,	   are	  
seen	  to	  cluster	  in	  seven	  gene	  blocks.	  	  These	  features	  are	  common	  to	  all	  the	  herpes	  
viruses.	  	  The	  HHV6B	  genome	  contains	  119	  ORFs	  from	  97	  genes,	  whereas	  the	  HHV6A	  
genome	  has	  110	  (Dominguez	  et	  al.,	  1999a),	  (Gompels	  et	  al.,	  1995b).	   	  HHV6A	  and	  B	  
variants	   share	   an	   overall	   nucleotide	   sequence	   identity	   of	   90%	   (Dominguez	   et	   al.,	  
1999a).	   	  The	  IE-­‐region	  of	  the	  genome	  is	  the	  most	  variable	  region	  between	  A	  and	  B	  
variants	  (Chou	  and	  Marousek,	  1994).	  
	  
	  
Figure	  1.2	  HHV6	  genome	  
Figure	   showing	   the	  HHV6	  genome	   structure,	   a	   double-­‐stranded	  DNA	  of	   about	   160	  
kbp,	   consisting	  of	   one	   long	  unique	   sequence	   (U)	  with	   identical	   direct	   repeats	   (DRL	  
and	   DRR)	   in	   both	   flanks.	   	   The	   genome	   contains	   7	   regions	   conserved	   in	   all	   herpes	  
viruses.	  	  (Matsuura	  et	  al.,	  2011)	  
	  	  	  
Interaction	   with	   CD46	   is	   required	   for	   the	   entrance	   of	   both	   the	   HHV6	   (A	   and	   B)	  
variants.	  	  All	  nucleated	  human	  cells	  express	  CD46,	  a	  type	  1	  glycoprotein	  (see	  Figure	  
1.3	  below)	  (Santoro	  et	  al.,	  1999),	  which	  acts	  as	  a	  regulator	  of	  complement	  activation.	  	  
It	  has	  been	  shown	  that	  the	  gH-­‐gL-­‐gQ	  complex	  of	  HHV6	  (the	  glycoproteins	  H,	  L	  and	  Q	  
encoded	   by	   the	   HHV6	   genes	   U48,	   U82	   and	   U100),	   serves	   as	   the	   viral	   ligand	   for	  
human	   CD46	   (Mori	   et	   al.,	   2003).	   	   HHV6	   gB	   (encoded	   by	   U39)	   is	   also	   crucial	   for	  
penetration	  of	  the	  virion	  into	  the	  cell	  (Takeda	  et	  al.,	  1996)	  (Figure	  1.3).	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Figure	  1.3	  Human	  herpes	  virus	  6	  entry	  into	  host	  cells	  
This	  figure	  shows	  HHV6	  enters	  the	  cell	  through	  interaction	  with	  CD46.	  	  Glycoprotein	  
complex	  (the	  glycoproteins	  H,	  L	  and	  Q)	  of	  HHV6	  acts	  as	  the	  viral	  ligand	  for	  human	  
CD46.	  	  (Tang	  and	  Mori,	  2010)	  
After	   binding	   to	   the	   cell	  membrane	   receptor,	   fusion	   of	   viral	   envelope	   is	  mediated	  
through	  gH-­‐gL-­‐gQ	  (Figure	  1.4).	  	  The	  nucleocapsid	  is	  transported	  via	  the	  cytoplasm	  to	  
the	  nuclear	  pore	  complexes,	   followed	  by	  the	  release	  of	   the	  viral	  DNA	  genome	   into	  
the	  nucleoplasm	  (De	  Bolle	  et	  al.,	  2005b;	  Zhoua	  et	  al.,	  2006).	  	  Within	  the	  nucleus,	  the	  
virus	   exploits	   the	   host	   cellular	   transcription	   and	   translation	   apparatus	   for	   its	   gene	  
expression	   in	   an	   orchestrated	   manner.	   	   Expression	   of	   immediate	   early	   (IE)	   gene	  
(such	   as	   U90	   transcription	   factor)	   is	   activated	   first	   (within	   a	   few	   hours	   after	  
infection);	  which	  is	  followed	  by	  early	  (E)	  and	  late	  (L)	  gene	  expression.	  	  The	  IE	  proteins	  
are	   trans	  activators	  of	  gene	  expression	  having	  a	   regulatory	  effect	  on	  expression	  of	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other	  genes.	  	  The	  E	  proteins	  take	  part	  in	  viral	  DNA	  replication	  (via	  DNA	  polymerase);	  
and	  the	  L	  proteins	  (structural	  protein)	  take	  part	  in	  the	  formation	  of	  the	  mature	  virus	  
particles,	   such	  as	  U54	  and	  U11	   (tegument	  protein).	   	  While	   exiting	   the	  nucleus	   the	  
mature	   capsids	   acquire	   a	   tegument	   and	   become	   encircled	   with	   a	   viral	   envelope	  
containing	  glycoprotein	  spikes,	  which	  undergo	  sequential	  glycosylation	   in	  transport	  




Figure	  1.4	  Representation	  life	  cycle	  of	  HHV6	  
Figure	  showing	  the	  schematic	  representation	  of	  the	  HHV6	  lytic	  replication	  cycle.	  	  (De	  
Bolle	  et	  al.,	  2005)	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1.4	  Epidemiology	  and	  Transmission	  of	  HHV6	  
HHV6	  is	  a	  common	  virus,	  which	  is	  prevalent	  throughout	  the	  world.	  	  Seroprevalence	  
is	   high	   (more	   than	   90%)	   among	   the	   adult	   population,	   and	   seroconversion	   usually	  
occurs	   before	   2	   years	   of	   age	   (Hall,	   1997;	   Yoshikawa	   et	   al.,	   1989).	   	   Maternal	  
antibodies	   that	  are	  present	   in	   the	  new-­‐born	  decline	  with	  advancing	  age	  and	  by	  six	  
months	   may	   become	   undetectable.	   	   After	   that,	   children	   are	   at	   risk	   of	   primary	  
infection.	  	  Pre-­‐natal	  infection	  is	  also	  reported	  with	  detection	  of	  the	  virus	  in	  cervical	  
swabs	   during	   pregnancy,	   suggesting	   the	   possibility	   of	   transplacental	   viral	  
transmission	   (Okuno	   et	   al.,	   1995;	   Caserta	   et	   al.,	   2007).	   	   The	   commonest	   site	   of	  
localisation	  of	  HHV6	   is	   in	   salivary	   glands	   (Chen	   and	  Hudnall,	   2006;	   Fujiwara	   et	   al.,	  
2000),	   therefore,	   the	  most	   likely	   source	  of	  person	   to	  person	   transmission	   is	   saliva.	  	  
Unfortunately,	  there	  is	  no	  specific	  serological	  test	  to	  differentiate	  between	  the	  two	  
HHV6	  subsets.	  	  Generally,	  the	  acquisition	  of	  HHV6	  occurs	  between	  6	  and	  15	  months	  
of	  age.	  	  The	  incubation	  period	  before	  overt	  infection	  varies	  from	  1-­‐2	  weeks	  (Enders	  
et	   al.,	   1990;	   Okuno	   et	   al.,	   1989).	   	   Almost	   all	   roseola	   cases	   are	   caused	   by	   HHV6B	  
infection	   (Braun	   et	   al.,	   1997;	   Dewhurst	   et	   al.,	   1993;	   Hall	   et	   al.,	   1998).	   	   However,	  
HHV6A	   is	   also	   found	   to	   be	   responsible	   for	   roseola	   in	   a	   few	  patients	   (Braun	   et	   al.,	  
1997;	   Dewhurst	   et	   al.,	   1993).	   	   HHV6A	   sero-­‐conversion	   is	   believed	   to	   happen	  
following	  acquisition	  of	  HHV6B	  (De	  Bolle	  et	  al.,	  2005).	  	  Reports	  suggest	  that	  HHV6A	  is	  
more	  neurotropic	  than	  HHV6B	  (Hall	  et	  al.,	  1998;	  Portolani	  et	  al.,	  2001;	  Borghi	  et	  al.,	  
2005).	  	  Studies	  also	  showed	  a	  selective	  reactivation	  of	  HHV6A	  in	  immunocompetent	  
patients	  while	  they	  are	  severely	  ill	  (Razonable	  et	  al.,	  2002).	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1.5	  HHV6	  Chromosomal	  Integration	  
Since	   the	   discovery	   of	   chromosomally	   integrated	   HHV6	   (CIHHV6)	   in	   1993,	   this	  
uncommon	   phenomenon	   has	   raised	   the	   curiosity	   of	   researchers	   and	   troubled	  
clinicians	  (Luppi	  et	  al.,	  1993).	  	  Using	  FISH	  analysis,	  several	  studies	  have	  proposed	  that	  
both	  HHV6A	  and	  B	  are	  capable	  of	  integrating	  into	  human	  chromosomes	  (Daibata	  et	  
al.,	   1998;	   Nacheva	   et	   al.,	   2008;	   Torelli	   et	   al.,	   1995)	   and	   transmitting	   vertically	  
through	   the	  germ	   line	   (Tanaka	  Taya	   et	   al.,	   2004).	   	   Previous	   studies	   also	   suggested	  
the	   infrequent	   passage	   of	   viral	   genome	   through	   the	   germ	   line,	   resulting	   in	   a	   high	  
prevalence	   of	   inherited-­‐integrated	   HHV6.	   	   Reports	   from	   several	   British	   and	   US	  
groups	  (Nam	  Leong	  et	  al.,	  2007;	  Ward	  et	  al.,	  2005)	  showed	  high	  HHV6	  viral	  load	  (106-­‐
107	   copies/ml)	   in	   peripheral	   blood	   of	   normal	   healthy	   donors	   (prevalence	   0.8%	   -­‐	  
1.5%),	   which	   is	   accredited	   to	   integrated-­‐inherited	   HHV6	   (Ward	   et	   al.,	   2005).	  	  
Interestingly,	   in	   hospitalised	   patients	   an	   even	   higher	   prevalence	   (2.9%	   -­‐	   3.3%)	   has	  
been	  reported	  (Nam	  Leong	  et	  al.,	  2007).	  	  	  
Chromosomal	   integration	   is	   one	   of	   the	   mechanisms	   by	   which	   HHV6	   could	  
accomplish	  its	  latency,	  mimicking	  inherited	  HHV6	  (Clark	  et	  al.,	  2006).	  	  Evidence	  that	  
chromosomally	   integrated	   viruses	   are	   capable	   of	   producing	   free	   virus	   in-­‐vitro,	  
indicates	  that	  this	  could	  also	  happen	  in-­‐vivo	  (Arbuckle	  et	  al.,	  2010).	  
So	   far,	  CIHHV6	  genotypes	  are	  not	  associated	  with	  any	  definite	  pathology.	   	  Most	  of	  
the	  studies	  analysing	  the	  association	  of	  herpes	  viruses	  among	  unhealthy	  cohorts	  did	  
not	   include	   detection	   of	   CIHHV6	   as	   priority	   objective	   (Morissette	   and	   Flamand,	  
2010).	  	  The	  assumption	  that	  CIHHV6	  DNA	  would	  certainly	  produce	  free	  virus	  leading	  
to	   human	   infection	   followed	   by	   transcription	   of	   viral	   proteins	   and	   production	   of	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cytokines	   leading	   to	   cell	   damage	   or	   triggering	   of	   an	   autoimmune	   response,	   is	   not	  
well	  supported	  (Flamand	  et	  al.,	  2010).	  	  A	  number	  of	  hypothetical	  explanations	  of	  the	  
fate	   of	   CIHHV6	   exists	   (schematically	   represented	   in	   Figure	   1.5)	   (Morissette	   and	  
Flamand,	  2010).	   	  Activation	  of	   the	   telomeric	   regions	  at	   the	  sites	  of	  HHV6	   insertion	  
contributes	  to	  chromosomal	   integrity	  and	  cellular	  homeostasis,	  as	  well	  as	  encoding	  
several	  transcripts	  (Calado	  and	  Young,	  2009;	  Riethman,	  2008).	   	  Others	  (Arbuckle	  et	  
al.,	  2010),	  suggest	  that	  since	  CIHHV6	  is	  transplacentally	  transmitted,	   it	  may	   lead	  to	  
immunological	   tolerance	   to	   several	  HHV6	   antigens	   owing	   to	   the	   expression	   of	   the	  
viral	  proteins	  during	  embryogenesis.	  	  	  
Figure	  1.5	  Schematic	  representation	  of	  the	  hypothetical	  cellular	  consequences	  of	  
CIHHV6	  
(1)	   absence	   of	   viral	   gene	   transcription;	   (2)	   expression	   of	   gene,	   replication	   and	  
production	  of	  virion;	  (3)	  expression	  of	  a	  subset	  of	  HHV6	  genes;	  (4	  and	  5)	  the	  impact	  
of	   integration	   of	   HHV6	   on	   function	   and	   architecture	   of	   the	   telomere,	   and	  
chromosomal	  stability;	  (6)	  activation	  of	  gene	  expression	  following	  integration	  in	  the	  
cell;	   (7)	   development	   of	   immune	   tolerance	   following	   expression	   of	   HHV6	   genes	  
during	   embryogenesis;	   (8)	   damage	  of	   tissues	  or	   cells	   expressing	  HHV6	  antigens	  by	  
naturally	  developed	  	  immune	  response.	  	  (Morissette	  and	  Flamand,	  2010)	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1.6	  Pathology	  and	  Treatment	  of	  HHV6	  
1.6.1	  Pathology	  
Primary	  HHV6	  infection	  in	  children	  is	  associated	  with	  fever	  and	  roseola	  (Figure	  1.6;	  
Yamanishi	  et	  al.,	  1988).	  	  The	  typical	  manifestation	  of	  roseola	  is	  high	  temperature	  (≥	  
40°C)	  for	  a	  few	  days;	  after	  that	  the	  fever	  subsides	  concurrent	  with	  appearance	  of	  a	  
skin	  rash.	  	  The	  rash	  typically	  appears	  on	  the	  chest	  first,	  and	  after	  that	  extends	  to	  the	  
face,	  legs	  and	  arms.	  	  It	  contains	  small	  sores	  that	  do	  not	  itch	  and	  more	  often	  vanishes	  
within	  a	  few	  days	  to	  a	  week.	  	  Some	  cases	  of	  primary	  HHV6	  infections	  manifest	  with	  
variable	  clinical	  pictures;	  such	  as,	  absence	  of	  skin	  rash	  and	  immediate	  onset	  of	  high	  
pyrexia.	   	  The	  prognosis	  of	  roseola	  is	  generally	  good,	  but	  may	  become	  worse	  with	  a	  
number	  of	  complications.	  	  The	  commonest	  complication	  results	  from	  CNS	  infection,	  
manifested	  by	  seizures	  and	  others	  signs	  of	  encephalitis	   (Asano	  et	  al.,	   1994;	  Hall	  et	  
al.,	  1994;	  Suga	   et	  al.,	  1993;	   Ishiguro	   et	  al.,	  1990).	   	  Primary	  HHV6	   infection	  may	  be	  
associated	  with	  a	  mild	  hepatic	  dysfunction,	  which	  may	  proceed	  to	  a	  severe	  form	  of	  
fulminant	  hepatitis	   (Ohashi	  et	  al.,	  2004;	   Ishikawa	  et	  al.,	  2002;	  Mendel	  et	  al.,	  1995;	  
Sobue	  et	  al.,	  1991;	  Asano	  et	  al.,	  1990).	  
Briefly,	   HHV6	   infection	   can	   cause	   a	   self-­‐limiting	   rash-­‐like	   illness	   in	   infancy	   but	   is	  
followed	  by	   lifelong	  asymptomatic	   infection,	  typical	  of	  other	  herpes	  viruses.	   	  HHV6	  
reactivation	   from	   latency	   can	   lead	   to	   severe	   diseases	   in	   immunocompromised	  
individuals,	  such	  as	  encephalitis	  (Zerr	  et	  al.,	  2001;	  Singh	  and	  Paterson,	  2000;	  Corti	  et	  
al.,	  2011),	  hepatitis	  (Härmä	  et	  al.,	  2006;	  Chang	  et	  al.,	  2009)	  and	  pneumonitis	  (Cone	  
et	  al.,	  1993;	  Carrigan	  et	  al.,	  1991)	  in	  AIDS	  patients	  and	  transplant	  recipients	  (Figure	  
1.6).	  	  	  





Figure	  1.6	  Stages	  of	  HHV6	  Infection	  
Figure	   showing	   stages	   of	   the	   natural	   course	   of	   HHV6	   infection:	   I.	   Primary	   HHV6	  
infection	  occurs	   in	  new-­‐borns,	  commonly	  causing	  roseola	  (exanthem	  subitum),	  and	  
may	   spread	   to	   organs.	   	   II.	   In	   healthy	   adults,	   HHV6	   may	   persist	   in	   the	   lymphatic	  
system	  and	  salivary	  glands;	  the	  commonest	  source	  of	  transmission	  is	  via	  saliva.	   	   III.	  
HHV6	   infection	   or	   reactivation	   occurs	   in	   immunocompromised	   patients	   either	  




In	   immunocompetent	   individuals,	   HHV6	   infections	   may	   resolve	   without	   any	  
treatment	   in	  a	   self-­‐limiting	  manner.	   	  However,	   in	   immunocompromised	   individuals	  
reactivation	  of	  HHV6	  infection	  from	  latency	  can	   lead	  to	  severe	  disease.	   	  Until	  now,	  
no	  specific	  medication	  is	  available	  for	  treating	  HHV6	  infection	  after	  transplantation.	  	  
Nevertheless,	   in-­‐vitro	   experiments	   have	   revealed	   a	   number	   of	   drugs	   (ganciclovir,	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cidofovir	  and	  foscarnet)	  are	  active	  against	  the	  virus	  (De	  Clercq	  et	  al.,	  2001).	  	  Antiviral	  
therapy	   in	  post-­‐transplant	  HHV6	   infection	   is	  very	   limited	   in	  clinical	  practice.	   	  There	  
are	   reports	   of	   successful	   application	   of	   ganciclovir	   and	   foscarnet	   in	   symptomatic	  
HHV6	   infection	   among	   recipients	   of	   bone	   marrow	   transplantation	   (Bethge	   et	   al.,	  
1999;	   Zerr	   et	   al.,	   2002).	   	   There	   are	   also	   reports	   of	   decreased	   HHV6	   viral	   loads	  
following	  ganciclovir	  therapy	  among	  liver	  transplant	  patients	  (Mendez	  et	  al.,	  2001).	  	  
So	  far,	  no	  information	  is	  available	  regarding	  the	  treatment	  or	  prevention	  of	  HHV6	  in	  
transplant	  patients	  in	  controlled	  studies.	  
In	  addition	  to	  the	  cost	  of	  antiviral	  drugs,	  there	  are	  many	  side	  effects	  as	  well	  as	  their	  
lack	   of	   effectiveness	   for	   all	   viruses.	   	   Therefore	   it	   is	   important	   to	   understand	   the	  
immune	  response	  to	  HHV6,	  since	  this	  is	  the	  natural	  way	  to	  control	  this	  virus	  without	  
incurring	  side	  effects.	  
1.7	  Adoptive	  immunotherapy	  
In	   immunocompromised	   individuals	   (such	  as	   transplant	   recipients	  or	  HIV	  patients),	  
viral	   reactivation	   of	   EBV	   and	   HCMV	   is	   associated	   with	   high	   morbidity	   and	   even	  
mortality	  due	   to	   lack	  of	   cellular	   immunity	  against	   viral	   antigens.	   	  Because	  antiviral	  
drugs	  are	  not	  effective	  enough	  to	  eliminate	  the	  virus	  besides	  being	  costly	  and	  having	  
many	  side	  effects,	  an	  alternative	  had	  to	  be	  found.	  	  Adoptive	  T	  cell	  immunotherapy	  is	  
a	   promising	   therapeutic	   approach	   for	   the	   treatment	   of	   diseases	   associated	   with	  
reactivation	   of	   herpes	   viruses	   in	   immunosuppressed	   patients.	   	   The	   purpose	   of	  
adoptive	   immunotherapy	   is	   to	   passively	   immunise	   an	   individual	   with	   an	   external	  
source	  of	  specific	  T	  cells	  that	  could	  be	  used	  as	  an	  anti-­‐viral	  treatment	  and	  be	  capable	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of	  providing	  protection.	  	  This	  can	  be	  done	  by	  isolation	  of	  T	  cells	  from	  a	  healthy	  donor	  
previously	  exposed	  to	  the	  virus,	   followed	  by	   in-­‐vitro	   stimulation	  of	   these	  cells	  with	  
specific	   viral	   peptides.	   	   After	   that,	   specific	   polyclonal	   T	   cells	   are	   expanded	   with	  
addition	  of	  cytokines	  (such	  as	  IL-­‐2)	  to	  help	  T	  cell	  growth	  and	  differentiation.	  	  Finally,	  
these	  T	  cells	  can	  be	  re-­‐injected	  into	  the	  same	  recipient	  directly	  after	  transplantation	  
(Figure	   1.7)	   (Leen	   et	   al.,	   2007).	   	   Adoptive	   immunotherapy	   is	   well	   characterised	  
against	   EBV	   and	   HCMV	   with	   encouraging	   results	   (Leen	   et	   al.,	   2009;	   Nickel	   et	   al.,	  
2009).	  	  The	  first	  promising	  results	  using	  antigen-­‐specific	  adoptive	  immunotherapy	  in	  
humans	   were	   observed	   in	   the	   early	   1990s	   using	   passively	   transferred,	   in-­‐vitro	  
expanded	  donor	  PBMC.	  	  HCMV-­‐specific	  cytotoxic	  T	  lymphocytes	  for	  the	  treatment	  of	  
HCMV	   infection	   in	   immunocompromised	   allogeneic	   BMT	   recipients	   have	   been	  
shown	  to	  provide	  immunity	  to	  transplant	  recipients	  (Greenberg	  et	  al.,	  1991;	  Riddell	  
et	  al.,	  1991;	  Riddell	  et	  al.,	  1992).	  
At	  present,	  adoptive	  T	  cell	   immunotherapy	  can	  successfully	  prevent	  and	  treat	   fatal	  
infections	  in	  the	  immunocompromised	  host.	  	  These	  benefits	  have	  been	  restricted	  to	  
EBV,	  HCMV	  and	  adenovirus	  (Leen	  et	  al.,	  2006;	  Karlsson	  et	  al.,	  2007;	  Leen	  et	  al.,	  2009;	  
Barker	  et	  al.,	  2010).	  	  In	  the	  case	  of	  HCMV,	  the	  two	  major	  protein	  of	  the	  CD8+	  T	  cell	  
immune	   response,	   IE1	   (UL123)	   and	   pp65	   (UL83),	   have	   been	   used	   successfully	   in	  
adoptive	   transfer	   (Bao	  et	  al.,	  2008).	   	  This	   therapy	  has	  not	  been	  available	   for	  HHV6	  
infections;	   in	   part	   due	   to	   lack	   of	   identified	   immunodominant	   CD8+	   T	   cell	   epitopes	  
with	  defined	  protective	  activity.	  	  Adoptive	  immunotherapy	  can	  be	  extended	  to	  HHV6	  
to	  develop	  BMT	  engraftment	  and	  control	  recipients’	  viral	  reactivation.	  
	  






Figure	  1.7	  Illustration	  diagram	  of	  the	  general	  steps	  in	  an	  adoptive	  immunotherapy.	  
Figure	  showing:	  1.	  T	  cell	   isolation	   from	  the	  healthy	  donor;	  2.	  Stimulation	  of	  T	  cells	  
with	  viral	  antigens;	  3.	  Expansion	  of	  polyclonal	  T	  cells;	  4.	  Re-­‐infusion	  of	  T	  lymphocytes	  
to	  the	  recipient	  after	  transplantation.	  	  (Adapted	  from	  Reddy	  et	  al.,	  2001)	  
1.8	  Immunity	  against	  herpes	  viruses	  	  
The	   immune	   response	   against	   herpes	   viruses	   involves	   all	   the	   arms	  of	   the	   immune	  
system	   including	   both	   innate	   and	   adaptive	   immune	   responses.	   	   However,	   antigen	  
specific	  CD8+	  T	   cells,	  CD4+	  T	   cells,	   and	  Natural	  Killer	   (NK)	   cells	   are	   the	   three	  main	  
immune	  cells	  that	  play	  an	  important	  role	  in	  the	  immune	  response	  to	  control	  herpes	  
virus	  infection;	  humoral	  immunity	  is	  also	  involved	  in	  providing	  such	  protection.	  
Ag	  stimulation	  
HCMV,	  EBV	  and	  Adv	  
Peptide	  epitopes.	  
Blood	  draw	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1.8.1	  Innate	  immunity	  
The	  innate	  immune	  systems	  provide	  a	  first	  line	  of	  defence	  against	  infection.	  	  Unlike	  
the	  adaptive	  immune	  system,	  which	  provides	  long-­‐lasting	  or	  protective	  immunity	  to	  
the	   host,	   the	   cells	   of	   the	   innate	   system	   recognise	   and	   respond	   to	   pathogens	   in	   a	  
generic	   way.	   	   Herpes	   viruses	   induce	   an	   innate	   immune	   response	   that	   will	   control	  
viral	  replication	  before	  the	  establishment	  of	  the	  adaptive	  immune	  response.	  	  Innate	  
immune	   cells	   do	  not	   recognise	  every	   antigen	   that	   is	   expressed	  on	  microorganisms	  
but	  instead	  recognise	  some	  microbial	  molecular	  signatures	  that	  are	  shared	  by	  large	  
groups	  of	  microorganisms	  through	  pattern-­‐recognition	  receptors	  (PRRs).	  
Recognition	  of	  herpes	  viruses	  by	  Pattern-­‐recognition	  receptors	  
PRRs	  are	  expressed	  on	  most	  innate	  immune	  cells	  such	  as	  macrophages	  and	  dendritic	  
cells	  and	  are	  expressed	  constitutively.	  	  The	  innate	  immune	  system	  is	  activated	  when	  
the	   infection	   is	   sensed	  by	  PRRs,	   via	  detection	  of	   specific	   components	  of	   the	  virion	  
known	   as	   the	   pathogen-­‐associated	   molecular	   patterns	   (PAMPs).	   	   Many	   PRRs	   are	  
involved	  in	  recognition	  of	  herpes	  viruses	   infection,	  however	  Toll-­‐like	  receptors	  (TLR)	  
are	  the	  most	  studied	  PRRs	  (Takeuchi	  and	  Akira,	  2010).	  	  Genomic	  DNA	  of	  herpes	  virus	  
can	   be	   recognised	   by	   endosomal	   TLR,	   such	   as	   TLR9	   (Tabeta	   et	   al.,	   2004).	   	   RNA	  
produced	   during	   herpes	   virus	   replication	   could	   also	   be	   recognised	   by	   other	   PRRs	  
such	  as	  retinoic	  acid-­‐inducible	  gene	  I	  (RIG-­‐I)	  and	  RIG-­‐I	  like	  receptors	  (RLRs)	  (Paludan	  
et	   al.,	   2011).	   	   Following	   the	   binding	   of	   the	   ligand	   to	   its	   receptor,	   an	   intracellular	  
signal	  will	  be	   released	   to	  enable	   the	  expression	  and	  secretion	  of	  pro-­‐inflammatory	  
cytokines	  such	  as	  type	  I	  interferon	  (type	  I	  IFN)	  that	  includes	  (IFN-­‐α	  and	  IFN-­‐β).	  	  	  
	  	  P a g e |	  35	  
	  
Recognition	  of	  HHV6	  by	  the	  Pattern-­‐recognition	  receptors	  
Expression	   of	   TLRs	   for	   the	   reconnaissance	   of	   PAMPs	   and	   induction	   of	   an	  
antimicrobial	   interferon	   response	   were	   investigated	   in	   CD4+	   T	   cells	   and	   dendritic	  
cells.	  	  In	  CD4+	  T	  cells	  infected	  with	  HHV6A,	  it	  was	  demonstrated	  that	  TLR-­‐9	  was	  over-­‐
expressed	  and	  induced	  apoptotic	  signal	  transduction	  (Chi	  et	  al.,	  2012).	  	  TLR	  signalling	  
leads	   to	   the	   expression	   of	   antiviral	   defences	   via	   type	   I	   IFN	   that	   inhibit	   viral	  
replication.	   	   It	   has	   been	   shown	   that	  HHV6A	   and	  HHV6B	  were	   able	   to	   limit	   this	   by	  
acting	   on	   the	   response	   signal	   or	   the	   effect	   of	   these	   cytokines	   (Murakami	   et	   al.,	  
2010).	  
Role	  of	  NK	  cells	  in	  immunity	  to	  herpes	  viruses	  	  	  
NK	  cells	   are	  a	  part	  of	   the	   innate	   immune	   system	  and	  provide	  a	  protection	  against	  
viral	  infection	  without	  previous	  stimulation.	  	  NK	  cells	  play	  a	  key	  role	  in	  early	  herpes	  
virus	  infection	  control.	  	  For	  example,	  observations	  from	  the	  murine	  model	  of	  HCMV	  
(mCMV),	  provide	  direct	  evidence	  of	   the	   importance	  of	  NK	  cells	   in	   cytomegalovirus	  
immunity;	  it	  has	  been	  used	  to	  study	  the	  role	  of	  NK	  cells	  in	  CMV	  immune	  surveillance.	  	  
Mice	  were	  infected	  with	  mCMV	  and,	  after	  it	  became	  latent,	  T	  cells	  and	  NK	  cells	  were	  
depleted.	  	  A	  high	  viral	  replication	  was	  found	  just	  three	  days	  after	  depletion	  (Tay	  and	  
Welsh,	  1997).	   	   In	  NK	  cell	  deficient	  patients,	  studies	  have	  shown	  that	  severe	  herpes	  
infections	  can	  occur	  (Notarangelo	  and	  Mazzolari,	  2006).	  
Role	  of	  NK	  cells	  in	  immunity	  to	  HHV6	  	  	  
NK	   cell	   deficient	   patients	   are	  more	   susceptible	   to	   herpes	   virus	   diseases,	   including	  
HHV6	  (Orange,	  2012).	  	  NK	  cells	  respond	  rapidly	  following	  infection	  and	  their	  activity	  
is	  greatly	  increased	  by	  pro-­‐inflammatory	  cytokines.	  	  The	  NK	  response	  reaches	  a	  peak	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in	   HHV6	   infected	   children	   during	   the	   acute	   phase	   and	   does	   not	   decline	   until	   the	  
adaptive	  immune	  response	  takes	  over	  (Takahashi	  et	  al.,	  1992;	  Kumagai	  et	  al.,	  2006).	  	  
These	   findings	   suggest	   that	   NK	   cells	   are	   one	   of	   the	   elements	   of	   the	   control	   of	  
proliferation	  of	  HHV6	  in	  a	  primary	  infection	  (Kumagai	  et	  al.,	  2006).	   	  HHV6	  infection	  
also	   enhances	   NK	   cell	   activity,	   possibly	   by	   inducing	   IL-­‐15	   production,	   which	  
stimulates	  the	  proliferation	  of	  NK	  cells	  and	  T	  cells	  (Flamand	  et	  al.,	  1996;	  Atedzoe	  et	  
al.,	  1997).	   	   IL-­‐15	  also	   stimulates	   the	  production	  of	  a	  Type	   II	   interferon	   (IFN-­‐II)	   that	  
include	   IFN-­‐γ	   (Gosselin	   et	   al.,	   1999).	   	   IFN-­‐I	   and	   IFN-­‐γ	   promote	   the	   expansion	   and	  
activation	  of	  CD4+	  and	  CD8+.	  	  Little	  is	  still	  known	  about	  the	  NK	  cell	  mechanisms	  that	  
eliminate	  HHV6	  infected	  cells.	  	  It	  has	  been	  suggested	  that	  NK	  cells	  are	  very	  effective	  
in	   killing	   HHV6	   infected	   cells,	   and	   possibly	   play	   a	   main	   role	   in	   controlling	   viral	  
infection	  (Malnati	  et	  al.,	  1993).	  
1.8.2	  The	  adaptive	  immune	  response	  to	  herpes	  viruses	  	  	  
The	  major	   functions	   of	   the	   adaptive	   immune	   system	   are	   to	   generate	   an	   immune	  
response	  that	  is	  capable	  of	  eliminating	  specific	  pathogens	  or	  pathogen	  infected	  cells	  
and	  to	  develop	  memory	  cells.	  
Effector	  cells	  
T	   and	   B	   cells	   are	   the	   major	   lymphocyte	   types	   that	   have	   a	   vital	   function	   in	   the	  
adaptive	   immune	  response.	  T	  cells	  are	   involved	   in	  cell-­‐mediated	   immunity,	  while	  B	  
cells	   in	   the	  humoral	   immunity.	  T	  and	  B	  cells	  are	  created	  via	  stem	  cells	   in	   the	  bone	  
marrow.	   T	   lymphocytes	   travel	   to	   thymus	   and	   develop	   in	   there.	   T	   and	   B	   cells	   are	  
located	   in	   lymphoid	   tissues	   in	  at	   least	   three	  differentiation	  stages;	   initially,	  a	  naive	  
	  	  P a g e |	  37	  
	  
cell	   which	   has	   not	   activated	   yet	   with	   an	   antigen.	   Then,	   effector	   cells	   which	   have	  
been	  activated	  and	  involved	  in	  pathogen	  removing.	  Finally,	  memory	  cells	  which	  are	  
the	  cells	  that	  met	  specific	  antigen	  during	  a	  previous	  infection	  (Janeway	  et	  al.,	  2001).	  
Antigen	  processing	  and	  presentation	  
The	  MHC	   system	  plays	   an	   important	   role	   in	   the	   immune	   responses	  by	   recognising	  
non-­‐self	  antigen,	  which	  is	  expressed	  on	  hosts'	  cells.	  The	  MHC	  molecules	  can	  be	  split	  
into	   two	   classes;	  MHC	   class	   I	   and	  MHC	   class	   II.	   CD8+	   and	   CD4+	   T	   cells	   have	   been	  
shown	  to	  be	  important	  against	  herpes	  virus	  replication.	  	  CD8+	  T	  cells	  recognise	  short	  
viral	   peptides	   presented	   by	   class	   I	  MHC	  molecules,	  whereas	   CD4	   T	   cells	   recognise	  
longer	   peptides	   presented	   by	   class	   II	   MHC	   molecules	   (Figure	   1.8).	   	   Herpes	   virus-­‐
specific	  CD4+	  T	  helper	  cells	  prevent	  herpes	  virus	  infection	  through	  secreting	  tumour	  
necrosis	   factor	   alpha	   (TNF-­‐α),	   interferon	   gamma	   (IFN-­‐γ)	   and	   other	   cytokines.	  	  
However,	   some	   herpes	   viruses	   like	   HCMV	   have	   the	   ability	   to	   escape	   from	   the	  
immune	  system	  via	  decreasing	  MHC	  Class	  I	  and	  MHC	  Class	  II	  expression	  on	  infected	  
cells,	  which	  results	   in	  a	  decrease	   in	  cytotoxic	  CD8+	  T	  cell	   surveillance;	  CD8+	  T	  cells	  
are	  the	  primary	  cells	  that	  recognise	  herpes	  virus	  infected	  cells	  (Hertel	  et	  al.,	  2003).	  	  	  
MHC	  class	  I	  
MHC	   class	   I	   molecules	   are	   expressed	   by	   most	   nucleated	   cells.	   MHC	   class	   I	   bind	  
peptides	   from	   intracellular	   or	   endogenously	   synthesised	   antigens.	   The	   host	   cells	  
breakdown	   the	  non-­‐self	  protein,	   for	  example	  virus	  protein,	   to	  a	   small	  pieces	   (8-­‐13	  
amino	  acids	  in	  length)	  called	  peptides.	  Peptides	  have	  anchor	  residues	  at	  2nd	  and	  C-­‐
terminal	   positions.	   These	   peptides	   are	   generally	   made	   by	   the	   proteasome	   then	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released	  into	  the	  cytosol.	  Viruses	  are	  unable	  to	  make	  own	  proteins	  so	  use	  host	  cell	  
ribosomes.	  Endogenously	  synthesised	  proteins	  labelled	  for	  degradation	  by	  ubiquitin.	  
Also,	   mis-­‐folded	   or	   mis-­‐translated	   proteins	   degraded	   prematurely.	   Proteins	   are	  
broken	   by	   the	   proteasome	   	   (via	   proteolysis):	   a	   multi-­‐subunit	   enzyme	   complex.	  
Selected	   peptides	   are	   transported	   by	   the	   transporter	   associated	   with	   antigen	  
processing	   (TAP)	   into	   the	  endoplasmic	   reticulum	   (ER),	  where	   they	  are	   loaded	  onto	  
MHC	   class	   I	   molecule.	   The	   MHC	   class	   I-­‐peptide	   complexes	   leaves	   the	   ER	   and	  
transported	  to	  the	  Golgi	  apparatus	  and	  then	  to	  the	  surface	  of	  the	  cell.	  	  	  Complex	  of	  
MHC	   class	   I-­‐foreign	   peptide	   then	   will	   be	   screened	   by	   CD8+	   T	   cells	   for	   foreign	  
peptides	  (Klein	  et	  al.,	  2000).	  
MHC	  class	  II	  
MHC	  class	  II	  are	  expressed	  on	  professional	  APCs	  of	  the	  immune	  system	  that	  take	  up	  
exogenous	   or	   extracellular	   antigens;	   dendritic	   cells,	   B	   cells,	   macrophages	   and	  
activated	  T	  cells.	  	  The	  exogenous	  antigens	  that	  are	  taken	  up	  by	  APCs	  are	  sequestered	  
into	  endosomes.	  Class	  II	  MHC	  molecule	  is	  synthesised	  in	  the	  ER	  and	  then	  travel	  via	  
the	   Golgi	   apparatus.	   Newly	   synthesised	   class	   II	   in	   ER	   prevented	   from	   binding	  
endogenous	  peptides	  by	  the	  invariant	  chain	  (Ii).	  Ii	  is	  digested	  by	  acid	  proteases	  in	  the	  
endosomal	  compartment.	  	  Leaves	  CLIP	  (Class	  II	  associated	  invariant-­‐chain	  peptide)	  in	  
peptide	   binding	   groove.	   	   HLA-­‐DM	   molecule	   that	   is	   synthesised	   in	   the	   ER	   helps	  
dissociate	   CLIP,	   freeing	   the	   binding	   groove	   to	   bind	   exogenous	   peptide.	   	   Traffic	   to	  
endosomal	   compartment	   where	   acid	   pH,	   proteases	   release	   invariant	   chain	   and	  
permit	  binding	  of	  exogenous	  peptide.	  MHC	  peptide	  complexe	  are	  then	  traffic	  to	  cell	  
surface	  and	  presented	  to	  CD4+	  T	  cells	  (Klein	  et	  al.,	  2000).	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Figure	  1.8	  	  MHC	  Class	  I	  and	  MHC	  Class	  II	  	  Antigen	  Processing	  Pathways	  	  
Figure	  showing	  antigen	  presentation	  to	  the	  immune	  system:	  (A)	  The	  MHC	  I	  pathway	  
presents	  intracellular	  or	  endogenously	  produced	  proteins	  that	  split	  into	  peptides	  (8-­‐
13	   aa)	   and	   then	   absorbed	   into	   the	   endoplasmic	   reticulum	   (ER)	   through	   transport-­‐
associated	   protein	   (TAP)	   molecules;	   MHC	   I	   pathway	   leads	   to	   the	   cell-­‐
mediated/cytotoxic	  CD8	  T	  cell	  mediated	  immune	  response.	  	  (B)	  The	  MHC	  II	  pathway	  
presents	   extracellular	   or	   exogenous	   antigens	   in	   antigen	   presenting	   cells	   then	  
presenting	   them	   to	   CD4+	   helper	   T	   cells,	   leading	   to	   an	   antibody	   biased	   immune	  
response.	  	  (Klein	  et	  al.,	  2000)	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T	  lymphocytes	  
T	  lymphocyte	  cells	  have	  different	  types,	  two	  of	  which	  are	  CD4	  that	  recognise	  foreign	  
antigen	   in	   association	   with	   class	   II	   MHC	   and	   CD8	   that	   recognise	   antigen	   in	  
association	  with	  class	   I	  MHC.	  T	  are	  expressed	  a	  specific	   receptor	  called	  TCR	   (T	  Cell	  
Antigen	   Receptor).	   TCR	   has	   alpha	   and	   beta	   polypeptide	   chains	   that	   have	   variable	  
domains.	   The	   variable	   domain	   has	   3	   hyper-­‐variable	   regions	   which	   can	   recognise	  
specific	   antigens.	   After	   antigen	   recognition,	   CD3	   molecule	   pass	   signal	   into	   the	   T	  
lymphocyte	   that	   led	   to	   T	   lymphocytes	   activation,	   proliferation,	   differentiation	   or	  
cytokine	  production	  (Okkenhaug	  et	  al.,	  2004).	  	  
Cytotoxic	   CD8	   T	   lymphocytes	   can	   attack	   cells	   that	   carrying	   foreign	   molecule	   and	  
cause	  rapid	  death	  to	  these	  abnormal	  cells,	  which	  eliminate	  pathogen	  in	  a	  short	  time	  
(Janeway	  et	  al.,	  2001).	  CD4	  lymphocyte	  called	  T	  helper	  cell	  because	  is	  not	  normally	  
cytotoxic	   but	   help	   other	   cells,	   such	   as	  macrophage	   and	  CD8	   T	   cells,	   to	   induce	   the	  
killing	   activity	   and	   eliminate	   the	   pathogen.	   CD4	   T	   helper	   lymphocytes	   have	   two	  
types,	  which	  are	  Th1	  and	  Th2.	  Th1	   is	  effective	   to	   intracellular	  pathogen,	  while	  Th2	  
response	  is	  more	  effective	  to	  extracellular	  pathogens.	  Regulatory	  T	  cells	  (Treg)	  are	  a	  
third	  type	  of	  T	  lymphocyte	  that	  can	  suppress	  the	  immune	  responses,	  and	  control	  the	  
autoimmune	  disease	  development	  (Janeway	  et	  al.,	  2001).	  	  
Role	  of	  CD8+	  T	  cells	  in	  herpes	  virus	  infection	  and	  HCMV	  
CD8+	  T	  cells	  are	  known	  to	  be	  involved	  in	  herpes	  virus	  immunity.	  	  This	  evidence,	  for	  
example	   in	  HCMV,	   comes	   from	  both	   transplant	  patients	   (Reusser	   et	  al.,	   1991)	  and	  
mCMV,	   the	   animal	   model	   for	   HCMV	   infection.	   	   In	   HCMV	   seropositive	   autologous	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stem-­‐cell	   transplant	   recipients,	   HCMV	   specific	   T	   cell	   responses	   were	   sufficient	   for	  
controlling	   HCMV	   infection	   (Reusser	   et	   al.,	   1997;	   Rauser	   et	   al.,	   2004).	   	   There	   is,	  
however,	   a	   study	   by	   Boeckh	   (2003)	   that	   argues	   that,	   after	   allogeneic	   stem	   cell	  
transplantation,	   recipients	  who	   lack	  HCMV	  specific	  CD4+	  and	  CD8+	  T	  cells	  are	  at	  a	  
greater	   risk	   of	   developing	   infection	   (Boeckh	   et	   al.,	   2003).	   	   In	   the	   animal	   model,	  
though,	   there	   is	  more	  direct	  evidence	  because	   it	   is	  possible	   to	  deplete	  T	   cells	   and	  
infect	  mice	  with	  mCMV.	  	  CD8+	  T	  cells	  protect	  a	  mCMV	  infected	  mouse	  from	  disease,	  
as	  it	  has	  been	  shown	  that	  depletion	  of	  CD8+	  T	  cells	  is	  associated	  with	  a	  remarkable	  
increase	  in	  morbidity	  after	  mCMV	  infection.	  	  Therefore,	  CD8+	  T	  cells	  are	  important	  in	  
immunity	   against	   mCMV	   (Reddehase	   et	   al.,	   1985).	   	   This	   evidence	   led	   to	   the	  
development	   of	   protocols	   for	   reconstituting	   HCMV-­‐specific	   CTL	   immunity	   in	  
transplant	  recipients	  by	  means	  of	  adoptive	  transfer	  of	  cloned	  CTL	  against	  the	  HCMV	  
structural	  protein	  pp65	  (Wills	  et	  al.,	  1996b).	  	  	  
Research	  on	   the	  specificity,	  phenotype	  and	   function	  of	  HCMV	  specific	  CD8+	  T	  cells	  
have	   been	   going	   on	   for	   over	   three	   decades.	   	   The	   immediate	   early	   protein	   (IE)	  
(Borysiewicz	  et	  al.,	  1988)	  and	  the	  tegument	  protein	  pp65	  (UL83)	  (McLaughlin-­‐Taylor	  
et	  al.,	  1994)	  were	  among	  the	  first	  viral	  proteins	  recognised	  as	  targets	  of	  the	  CD8+	  T	  
cell	   response	   to	   HCMV.	   	   Then,	  many	   studies	   have	   concluded	   that	   T	   cell	   reactivity	  
against	  pp65,	  pp50	  and	  IE1	  appears	  to	  constitute	  an	  important	  part	  of	  CMV-­‐specific	  
cytotoxic	  T	  lymphocyte	  (CTL)	  responses	  in	  the	  healthy	  population	  carrying	  the	  virus	  
(Elkington	  et	  al.,	  2003;	  Kern	  et	  al.,	  1999;	  Khan	  et	  al.,	  2002a;	  Khan	  et	  al.,	  2004).	  	  There	  
is	   conflicting	   evidence	   regarding	   the	   role	   of	   pp65	   responses	   as	   marker	   of	   clinical	  
importance.	   	   Some	   research	   has	   suggested	   the	   importance	   of	   pp65-­‐specific	   CTL	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responses	   (Riddell	   et	   al.,	   1992;	   Lacey	   et	   al.,	   2006);	   other	   studies	   have	   shown	   that	  
IE1-­‐specific	  CTL	  responses	  are	  important,	  while	  pp65-­‐specific	  CTLs	  are	  not	  (Bunde	  et	  
al.,	   2005).	   	   Apparently,	   pp65-­‐specific	   and	   IE1-­‐specific	   T	   cell	   responses	   are	   of	  
advantage	   throughout	   different	   phases	   of	   viral	   activity;	   perhaps	   the	   former	   is	  
important	   in	   identifying	   freshly	   infected	   cells,	   as	   virion-­‐derived	   pp65	   is	   readily	  
available	   for	  processing	  before	   IE1	  can	  be	  expressed.	   	  While	  virus	   reactivates	   from	  
latency,	  IE1	  responses	  could	  be	  important,	  as	  the	  processing	  and	  presentation	  of	  IE1	  
antigen	  would	  be	  expected	  to	  occur	  sooner	  than	  that	  of	  pp65.	   	   In	   fact,	   IE1-­‐specific	  
responses	   would	   likely	   increase	   progressively	   over	   time	   after	   primary	   HCMV	  
infection,	   while	   pp65	   responses	   would	   peak	   near	   the	   beginning	   and	   gradually	  
diminish	   thereafter	   (Khan	   et	   al.,	   2007).	   	   It	   also	   has	   been	   reported	   that	   successful	  
CMV-­‐specific	   immune	   responses	   in	  healthy	   carriers	  would	  depend	  on	  a	   strong	  CTL	  
response	  to	  a	  broad	  antigenic	  repertoire	  (Elkington	  et	  al.,	  2003).	  
Role	  of	  CD4+	  T	  cells	  in	  herpes	  virus	  infection	  and	  HCMV	  
Experiments	  with	   an	   animal	  model	   have	   also	   been	   done	   for	   HCMV-­‐specific	   CD4	   T	  
helper	  cells,	  the	  result	  being	  that	  depletion,	  and/or	  dysfunction,	  of	  CD4+	  T	  cells	  and	  
antibodies	   can	   result	   in	   HCMV-­‐associated	   disease	   (Waisman	   et	   al.,	   2008).	   	   The	  
triggering	  of	   killing	  potential	   of	   these	  CD4+	  T	   cells	   can	  be	   via	  direct	   recognition	  of	  
endogenous	  antigen	   in	  addition	  to	  exogenous	  antigens,	  as	  shown	  by	  studies	  of	  the	  
HCMV	   Glycoprotein	   B	   (gB),	   which	   is	   processed	   and	   expressed	   efficiently	   by	   MHC	  
class	  II	  of	  infected	  cells	  (Hegde	  et	  al.,	  2005).	  	  Although	  the	  response	  of	  CD4+	  T	  cells	  
can	  be	  demonstrated	  against	  a	  wide	   range	  of	  HCMV	  antigens,	   the	  main	   responses	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are	  found	  to	  be	  against	  pp65	  and	  gB,	  which	  are	  also	  strong	  antigens	  for	  CD8+	  T	  cells.	  	  
IE1,	  though	  a	  strong	  antigen	  for	  CD8+	  T	  cells,	  is	  less	  stimulatory	  than	  pp65	  and	  gB	  for	  
CD4+	  T	  cells	  (Sylwester	  et	  al.,	  2005).	  	  This	  may	  be	  because	  IE-­‐1	  does	  not	  access	  the	  
class	   II	   processing	   pathway	   as	   readily	   as	   pp65	   and	   gB,	   which	   are	   both	   structural	  
components	   of	   the	   virus	   particle	   and	   more	   classical	   exogenous	   antigens.	   Recent	  
studies	   on	   normal	   asymptomatic	   seropositive	   individuals	   and	   women	   throughout	  
pregnancy	   showed	   that	   CD4+	   cytotoxic	   T	   lymphocyte	   responses	   were	   mainly	  
directed	  towards	  the	  gB	  antigen	  (Hopkins	  et	  al.,	  1996).	  	  	  
1.8.3	  The	  adaptive	  immune	  response	  to	  HHV6	  	  
However,	   mutual	   development	   of	   adaptive	   immune	   responses	   by	   the	   host,	   as	  
reviewed	  for	  HCMV	  (Basta	  and	  Bennink,	  2003),	  has	  not	  been	  investigated	  for	  HHV6.	  	  
Regarding	   immune	   modulation,	   HHV6	   can	   infect	   a	   number	   of	   immune	   cells	  
implicated	   in	   the	   production	   of	   both	   cellular	   and	   humoral	   adaptive	   immune	  
responses.	  	  The	  adaptive	  immune	  response	  against	  herpes	  viruses	  is	  very	  important	  
in	  the	  control	  of	  viral	   replication	   in	  primary	   infections	  or	  during	  reactivations.	   	  The	  
characterisation	  of	   these	  responses	   in	  EBV	  and	  HCMV	  allowed	  the	  development	  of	  
immunotherapies	   (Leen	   et	   al.,	   2007;	   Leen	   et	   al.,	   2009).	   	   The	   specific	   adaptive	  
immune	  response	  to	  HHV6	  is	  very	  little	  known.	  	  The	  characterisation	  of	  the	  response	  
to	  HHV6	   is	  complicated	  due	  to	   its	   tropism	  for	  CD4+	  T	  cells	   (Takahashi	  et	  al.,	  1989)	  
and	  cytopathic	  effects	  following	  infection	  (Flamand	  et	  al.,	  1995;	  Gupta	  et	  al.,	  2009;	  Li	  
et	   al.,	   2011).	   	   In	   addition,	   owing	   to	   the	   fact	   that	   almost	   all	   of	   the	   population	   is	  
infected	  with	  HHV6	   (De	  Bolle	   et	   al.,	   2005),	   access	   to	  non-­‐infected	   individuals	  who	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could	   provide	   information	   on	   the	   basal	   level	   of	   immune	   responses	   remains	   very	  
difficult.	  Although	   the	  narrow	  host	   range	  of	  HHV6	  has	   limited	   the	  utility	  of	   animal	  
models,	  severe	  combined	  immunodeficiency	  (SCID)	  mice	  implanted	  with	  human	  fetal	  
thymus	  and	  liver	  (huSCID	  Thy/Liv	  mice)	  have	  provided	  a	  first	  useful	  model	  of	  HHV6	  
infection	   (Gobbi	   et	   al.,	   1999).	   	   In	   this	  model,	   HHV6	   subgroup	   6A	   or	   6B,	   efficiently	  
infected	   the	   human	   thymic	   tissue	   implanted	   in	   SCID-­‐hu	   Thy/Liv	   mice,	   leading	   to	  
thymocyte	  depletion	  and	  reduced	  thymic	  output.	  	  However,	  data	  on	  T	  cell	  responses	  
are	   limited	  regarding	  HHV6	  because	   it	   is	  restricted	  to	  primates	  (Lusso	  et	  al.,	  1990).	  	  
Therefore,	  there	  is	  so	  far	  no	  good	  animal	  model	  for	  infection	  and	  although	  the	  virus	  
is	  able	  to	  penetrate	  rodent	  cells,	  it	  is	  not	  capable	  of	  replication	  (Santoro	  et	  al.,	  1999;	  
Mock	  et	  al.,	  2006).	   	  The	  primary	  target	  cells	  for	  both	  HHV6A	  and	  6B	  are	  CD4+	  cells	  
(Lusso	   et	   al.,	   1988;	   Takahashi	   et	   al.,	   1989),	   although	   the	   A	   strains	   are	   capable	   of	  
broader	  tropism,	  including	  natural-­‐killer	  cells,	  γδ	  T	  cells	  and	  CD8+	  cells	  (Lusso	  et	  al.,	  
1991;	  Lusso	  et	  al.,	  1993;	  Lusso	  et	  al.,	  1995).	  	  HHV6	  infection	  enhances	  production	  of	  
inflammatory	  cytokines	  and	  chemokines,	  including	  IFN-­‐α,	  interleukin	  [IL]-­‐1β,	  IL-­‐6,	  IL-­‐
15,	   IL-­‐21	   and	   RANTES	   (Wang	   and	   Pellett,	   2007).	   	   Among	   them,	   regulated	   upon	  
activation,	  a	  normal	  T	  cell	  expressed	  and	  secreted	   (RANTES),	  a	  proinflammatory	  β-­‐
chemokine,	   is	   known	   for	   inducing	   local	   responses	   by	   selectively	   attracting	  
monocytes	  (the	  target	  for	  HHV6	  latency)	  and	  lymphocytes	  (a	  vehicle	  for	  virus	  spread;	  
Figure	   1.9).	   	   Interleukin-­‐1β	   (IL-­‐1β)	   enhances	   inflammatory	   and	   interferon-­‐γ	   (IFN-­‐γ)	  
responses,	   and	   is	   needed	   for	   IL-­‐6-­‐dependent,	   B-­‐lymphocyte	   immune	   responses.	  	  
Both	   IFN-­‐α	   and	   IFN-­‐β	   inhibit	   HHV6	   replication	   in-­‐vitro	   (Takahashi	   et	   al.,	   1992).	  	  
However,	   tumour	   necrosis	   factor-­‐α	   (TNF-­‐α),	   normally	   an	   antiviral	   cytokine,	   may	  
enhance	   release	   of	   extracellular	   HHV6	   by	   stimulating	   monocyte	   differentiation	  
	  	  P a g e |	  45	  
	  
(Arena	  et	  al.,	  1997).	  	  HCMV	  tegument	  and	  nucleo-­‐capsid	  proteins	  are	  better	  than	  the	  
glycoproteins	   at	   inducing	   T	   cells	   proliferation	   (Ljungman	   et	   al.,	   1985).	   	   Likewise,	  
neither	   HHV6A	   nor	   HHV6B	   glycoproteins	   induce	   T-­‐lymphocyte	   proliferation	   in	  
healthy	  adults;	  as	  an	  alternative,	  these	  antigens	  inhibit	  T-­‐lymphocyte	  proliferation	  to	  
antigens	  or	  mitogens	  (Horvat	  et	  al.,	  1993).	   	  Antigen	  preparations	  mainly	  composed	  
of	   the	   tegument	   and	   nucleocapsid	   proteins	   of	   HHV6A	   and	   HHV6B	   induce	   T-­‐cell	  
proliferation	   in	   healthy	   seropositive	   adults	   and	   children	   (Yakushijin	   et	   al.,	   1991;	  
Soldan	  et	  al.,	  2000).	  	  Studies	  were	  conducted	  in	  children	  infected	  by	  HHV6.	  	  Specific	  
T	  cell	  response	  to	  HHV6B	  is	  established	  in	  most	  children	  within	  two	  weeks	  after	  the	  
first	   symptoms	   (fever)	   (Kumagai	   et	   al.,	   2006).	   	   However,	   this	   anti-­‐HHV6	   response	  
appears	  to	  occur	  late	  compared	  to	  other	  human	  herpes	  viruses.	  	  The	  reasons	  for	  this	  
delay	  are	  not	  clear,	  but	  do	  not	  appear	  to	  be	  due	  to	  a	  dysfunction	  of	  T	  cells	  induced	  
by	  HHV6.	   	   In	  general,	   the	  memory	   immune	  responses	  seen	   in	  children	  seem	  to	  be	  
greatest	   between	   the	   ages	   of	   3	   and	   12	   (Koide	   et	   al.,	   1998).	   	   Analyses	   by	   flow	  
cytometry	   (FACS)	   on	   PBMC	   showed	   similar	   frequencies	   of	   CD4	   +	   T	   cells	   and	   CD8+	  
cells	   specific	   for	   HHV6	   in	   healthy	   adults	   and	   children	   post-­‐infection	   (Koide	   et	   al.,	  
1998;	  Haveman	   et	   al.,	   2010).	   	   Both	  MHC	  dependent	   and	   independent	   cytotoxicity	  
have	  been	  observed	  for	  HHV6-­‐specific	  CD4+	  T	  cell	  clones,	  suggesting	  heterogeneous	  
functions	  of	  CD4+	  T	  cells	  (Yakushijin	  et	  al.,	  1992).	  	  However,	  some	  T	  cell	  clones	  with	  
activity	   to	  HHV6	   also	   responded	   to	  HCMV	   and	  HHV-­‐7,	  which	  might	   indicate	   some	  
cross-­‐reactivity	  (Yasukawa	  et	  al.,	  1993).	  	  	  
Modulation	   of	   the	   host	   immune	   response	   represents	   an	   important	  mechanism	   of	  
evading	  the	  immune	  response	  or	  to	  make	  a	  good	  environment	  where	  the	  viruses	  can	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survive,	  grow	  and	  persist	  (Vossen	  et	  al.,	  2002),	  such	  as	  herpes	  viruses	  that	  persist	  for	  
the	  lifetime	  of	  the	  host	  (Hengel	  et	  al.,	  1998).	  	  HHV6	  has	  been	  characterised	  as	  having	  
immune	   modulatory	   properties	   mediated	   by	   direct	   effects	   in	   infected	   cells	   or	  
indirectly	   on	   uninfected	   cells.	   	   One	   of	   the	  most	   intriguing	   features	   of	   HHV6	   is	   its	  
ability	   to	   evade	   host	   immune	   defences.	   	   HHV6	   induces	   CD4+	   T-­‐lymphocyte	  
depletion.	  	  Interestingly,	  HHV6A	  and	  6B	  infection	  diverts	  Class	  I	  MHC	  molecules	  from	  
the	   cell	   surface	   into	   a	   lysosomal	   compartment	   via	   U21	   that	   binds	   and	   down	  
regulates	  MHC	  class	   I,	  which	  possibly	  aids	   the	  viruses	   to	  escape	   immune	  detection	  
(Glosson	   and	   Hudson,	   2007).	   As	   mentioned	   above,	   the	   HHV6	   receptor	   is	   CD46,	   a	  
molecule	   that	   is	   critically	   important	   in	   the	   immunological	   synapse,	   IL-­‐2	   and	   IFN-­‐γ	  
production.	   	   However,	   HHV6	   infection	   results	   in	   a	   dramatic	   down	   modulation	   of	  
CD46	   expression	   (Santoro	   et	   al.,	   1999).	   	   Another	   intriguing	   CD46-­‐mediated	  
mechanism	  that	  might	  operate	  is	   induction	  of	  a	  T-­‐regulatory	  cell	  1	  phenotype	  (Tr1)	  
(Kemper	  et	  al.,	  2003).	  	  Active	  suppression	  by	  (Tr1)	  cells	  has	  emerged	  as	  an	  essential	  
factor	   in	   the	   control	   of	   auto	   reactive	   cells	   (Shimon,	   2000).	   	   From	   studies	   of	   T-­‐cell	  
differentiation	   via	   specific	   monoclonal	   antibodies	   Kemper	   illustrated	   that	   co-­‐
engagement	   of	   CD3	   and	  CD46	   (the	   complement	   regulator)	   in	   the	   presence	  of	   IL-­‐2	  
induces	  a	  Tr1-­‐specific	  cytokine	  phenotype	  in	  CD4+	  T	  cells.	  	  Stimulation	  of	  CD3/CD46	  
induced	   IL-­‐10-­‐producing	  CD4+	  T	  cells	   to	  proliferate	   strongly,	   suppress	  activation	  of	  
bystander	  T	  cells	  and	  acquire	  a	  memory	  phenotype	  (Kemper	  et	  al.,	  2003).	  	  Wang	  et	  
al	   have	   reported	   the	   induction	   of	   IL-­‐10	   secreting	   CD4+	   T	   cells	   by	   HHV6	   infection	  
(Wang	  et	  al.,	  2006).	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HHV6	  reactivation	  from	  latency	  can	  lead	  to	  severe	  disease	  in	  immunocompromised	  
persons,	   such	   as	   T-­‐cell	   deficient	   transplant	   recipients.	   	   This	   suggests	   that	   host	  
immunity	  plays	  a	  key	  role	  in	  maintaining	  the	  normal	  disease-­‐free	  host-­‐virus	  balance.	  	  
Unlike	   for	  most	  other	  HHVs,	   there	   is	   very	   little	   information	  on	  T	   cell	   antigens	   and	  
epitopes	  encoded	  by	  HHV6;	  this	  will	  be	  addressed	  in	  this	  study.	  	  	  
	  
Figure	  1.9	  Immunobiological	  events	  of	  HHV6	  	  
This	  figure	  shows	  Immunobiological	  events	  during	  early	  primary	  HHV6	  infection	  (A),	  
and	  establishment	  of	  latency	  (B).	  	  (Wang	  and	  Pellett,	  2007)	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1.9	  Aims	  and	  objectives	  	  
At	  the	  start	  of	  this	  project	  very	  little	  was	  known	  about	  the	  T	  cell	  response	  to	  HHV6.	  	  
The	   immunogenic	  antigens	  had	  not	  been	   identified,	  and	   there	  was	  no	   information	  
on	   potential	   antigenic	   peptides,	   HLA	   restricting	   alleles	   and	   strength	   of	   responses.	  	  
However,	  based	  on	  the	  well-­‐characterised	  cellular	  immune	  response	  to	  other	  human	  
herpes	   viruses,	  particularly	  HCMV	  and	  EBV,	   it	  was	  hypothesised	   that	  HHV6	  will	   be	  
immunogenic	  for	  T	  cells.	  	  The	  aim	  of	  this	  thesis	  was	  to	  begin	  to	  characterise	  the	  T	  cell	  
response	  to	  HHV6.	  	  There	  were	  three	  main	  approaches:	  
1.	  	  To	  investigate	  if	  T	  cell	  responses	  to	  HHV6	  could	  be	  detected	  directly	  ex-­‐vivo	  in	  
healthy	  donors.	  
2.	  	  To	  In-­‐vitro	  expand	  and	  analyse	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  
and	  U90	  in	  a	  panel	  of	  healthy	  donors.	  	  	  
3.	  	  To	  Identify	  and	  Characterise	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11	  and	  
U90.	  
It	  was	  hoped	  that	  the	  data	  generated	  in	  this	  thesis	  would	  provide	  new	  information	  
and	   contribute	   to	   the	   existing	   information	   on	   the	   interaction	   between	   herpes	  
viruses/HHV6	   and	   the	   immune	   system	   as	   well	   as	   the	   potential	   to	   use	   this	  
information	   to	   develop	   adoptive	   T	   cell	   therapy	   for	   diseases	   linked	   to	   HHV6	  
proliferation.	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2.	  	  Materials	  and	  Methods	  	  
2.1	  Blood	  donors	  
Healthy	  adult	  volunteers	  (between	  20	  to	  60	  years	  old)	  were	  recruited	  for	  this	  study.	  	  
All	   blood	   samples	   were	   obtained	   after	   formal	   consent	   was	   taken	   from	   each	  
participating	  donor	  according	  to	  the	  Helsinki	  Declaration.	   	  The	  study	  was	  approved	  
by	   the	   Liverpool	   Adult	   Research	   Ethics	   Committee	   (RCE	   reference	   2K/175).	   	   All	  
donors	   were	   HLA	   typed	   using	   a	   PCR-­‐based	   protocol	   by	   the	   NHS	   Tissue	   Typing	  
laboratory	   based	   in	   the	   Clinical	   Immunology	   Department,	   Royal	   Liverpool	   and	  
Broadgreen	  University	  Hospital	  Trust.	  
2.2	  Peripheral	  blood	  mononuclear	  cells	  preparation	  
Human	   peripheral	   blood	   samples	   were	   obtained	   from	   healthy	   donors,	   ranging	   in	  
volume	   from	  10	   -­‐	   50	  ml.	   	   Blood	  was	   taken	  by	   venipuncture	   into	   preservative	   free	  
heparin,	   and	   peripheral	   blood	   mononuclear	   cells	   (PBMC)	   were	   isolated	   by	   Ficoll	  
Hypaque	   density	   gradient	   centrifugation	   using	   Ficoll-­‐PaqueTM	   Plus	   (GE	   Healthcare	  
Biosciences	   AB,	   UK).	   	   Blood	   was	   gently	   layered	   onto	   an	   equal	   volume	   of	   Ficoll-­‐
PaqueTM	  Plus	  and	  centrifuged	  at	  500	  x	  g	  for	  20	  minutes	  at	  room	  temperature	  (RT),	  
with	  the	  brake	  off.	  	  PBMC	  were	  harvested	  from	  the	  interface	  and	  washed	  twice	  with	  
20	  ml	   RPMI	   1640	  media	   (Sigma,	  UK),	   followed	  by	   centrifugation	   at	   500	   x	   g	   for	   10	  
minutes	  with	  brake	  on.	  	  Cell	  pellets	  were	  then	  re-­‐suspended	  in	  RPMI	  1640	  medium	  
supplemented	  with	  10%	  heat	   inactivated	  foetal	  calf	  serum	  [FCS],	  2	  mM	  Glutamine,	  
50	   IU/ml	  Penicillin	  and	  50	  μg/ml	  Streptomycin	   (R10	  growth	  medium).	   	  The	  yield	  of	  
PBMC	   was	   determined	   using	   a	   haemocytometer.	   	   PBMC	   were	   then	   either	   used	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immediately	  or	  cryo-­‐preserved	   in	   liquid	  nitrogen	   in	   freezing	  media	   (R10	  containing	  
10%	   DMSO	   and	   a	   further	   10%	   FCS).	   	   Cryo-­‐preserved	   PBMC	   were	   thawed	   and	  
washed,	  prior	  to	  use.	  
2.3	  Peptides	  
Single	  tube	  peptide	  mixes	  (pepmixes),	  containing	  15-­‐mer	  peptides	  overlapping	  by	  11	  
amino	  acids	   (aa)	  spanning	  the	  whole	  protein	  were	  obtained	  from	  JPT	  Technologies	  
(JPT	  Peptide	  Technologies	  GmbH,	  Berlin,	  Germany)	  for	  the	  following	  viral	  antigens:	  
HHV6B:	   	   U11,	  U39,	  U54	  and	  U90	  
HCMV:	  	   	   IE1,	  IE2,	  pp65	  and	  gB	  
Polyoma	  BK	  virus:	   VP1	  
JPT	  pepmixes	  were	  dissolved	  in	  dimethylsulphoxide	  (DMSO)	  at	  a	  concentration	  of	  5	  
mg/ml	  and	  stored	  at	  -­‐20°C.	  	  Individual	  15-­‐mer	  peptides,	  for	  HHV6B	  antigens	  U11	  and	  
U90	  (concentration	  of	  10	  mg/ml),	  again	  overlapping	  by	  11	  aa,	  were	  provided	  by	  Dr	  
Ann	  Leen	  (Baylor	  College	  of	  Medicine,	  Houston,	  USA).	  	  These	  individual	  U11	  and	  U90	  
15-­‐mer	  peptides	  were	  used	  to	  generate	  mini-­‐pools	  of	  16	  peptides,	   such	  that	   there	  
were	  30	  mini-­‐pools	  for	  U11	  and	  33	  for	  U90,	  with	  each	  15-­‐mer	  represented	  in	  2	  mini-­‐
pools.	   	  Peptide	  pools	  were	  prepared	  in	  RPMI	  1640	  medium,	  with	  each	  peptide	  at	  a	  
final	   working	   concentration	   of	   10	   μg/ml.	   	   Selected	   individual	   9-­‐mer	   peptides	   for	  
HHV6B	  U11	  and	  U90	  were	  purchased	  from	  Alta	  Bioscience	  Ltd	  (Birmingham,	  UK)	  and	  
reconstituted	  in	  DMSO	  to	  a	  final	  concentration	  of	  5	  mg/ml.	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2.4	  Cell	  lines	  
Phytohaemagglutinin	   (PHA)	  blasts	  were	  generated	   from	  donor	  PBMC.	   	  2x106	  PBMC	  
in	   2	  ml	   T	   cell	  media	   (RPMI	   1640	  medium	   supplemented	  with	   5%	   heat	   inactivated	  
Human	  AB	  Serum,	  2	  mM	  Glutamine,	  50	  IU/ml	  Penicillin	  and	  50	  μg/ml	  Streptomycin	  
were	  treated	  with	  5	  µg/ml	  PHA	  and	  maintained	  at	  37°C	   in	  a	  5%	  CO2	  .	   	  T	  cell	  media	  
was	  replenished	  every	  3	  days.	  	  PHA	  blasts	  were	  used	  in	  T	  cell	  assays	  from	  day	  3.	  
2.5	  Virus	  stocks	  	  
HHV6B	   virus	   strain	   Z29	   was	   generated	   as	   culture	   supernatant	   from	   HHV6B	   Z29	  
infected	   SupT1	   cells	   (Mayne	   et	   al.,	   2001),	   obtained	   from	   the	   HHV-­‐6	   Foundation	  
(Santa	   Barbara,	   CA	   93101	   USA).	   	   Briefly,	   HHV6B-­‐Z29	   infected	   SupT1	   cells	   were	  
maintained	  for	  6	  days	  in	  R10	  growth	  media.	  	  Virus-­‐containing	  supernatant	  was	  then	  
harvested,	  centrifuged	  at	  400	  x	  g	  for	  5	  minutes	  to	  remove	  cells,	  before	  being	  filtered	  
through	   a	   0.45	   µm	   Minisart®	   NML	   Syringe	   Filter	   (Sartorius	   UK	   Ltd,	   UK).	   	   Virus	  
containing	  supernatant	  was	  stored	  in	  single	  use	  aliquots	  at	  -­‐80°C.	  
Virus	  containing	  supernatant	  from	  HHV6B	  strain	  HST	   infected	  cells	  was	  provided	  by	  
Dr	  Andreas	  Moosmann,	  (Helmholtz	  Zentrum	  München,	  Munich,	  Germany).	  
2.6	  Flow	  Cytometry	  
Flow	   cytometric	   analysis	   in	   this	   project	   was	   carried	   out	   on	   BD	   FACS	   Calibur	   (BD	  
Biosciences).	   	  Different	  subsets	  of	   lymphocytes	  were	  defined	  using	  Forward	  Scatter	  
(FSC)	   and	   Side	   Scatter	   (SSC)	   based	   gating.	   	   Fluorescence	   emissions	   of	   different	  
fluorochromes	   were	   measured	   at	   different	   wavelengths	   as	   follows:	   fluorescein	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isothiocyanate	  (FITC)	  and	  Alexa	  fluor	  488	  in	  FL1	  at	  519nm,	  phycoerythrin	  (PE)	  in	  FL2	  
at	   578nm,	   peridinin	   chlorophyll	   protein–cyanine	   5.5.	   	   (PerCPCy5.5),	   phycoerythrin	  
with	  cyanin-­‐5	  (PECy5)	  and	  phycoerythrin	  with	  cyanin-­‐7	  	  (PECy7)	  in	  FL3	  at	  695nm,	  and	  
allophycocyanin	   (APC)	   and	   Alexa	   fluor	   660	   in	   FL4	   at	   660nm	   (Baumgarth	   and	  
Roederer,	   2000).	   	   Unstained	   cells	   were	   used	   to	   set	   the	   background	   levels	   of	  
fluorescence	   so	   that	   <1%	   of	   cells	   were	   determined	   as	   positive	   for	   any	   of	   the	  
fluorochromes	  used.	  	  Cells	  incubated	  with	  single	  fluorochromes	  were	  used	  to	  verify	  
detection	  of	  each	   individual	   fluorochromes.	   	   Colour	   compensation	  was	   carried	  out	  
when	  false	  positive	  results	  were	  obtained.	  	  For	  example,	  if	  FL4	  (APC)	  positive	  events	  
were	   also	   observed	   in	   samples	   stained	   with	   a	   PerCP-­‐Cy5.5	   -­‐conjugated	   antibody	  
only,	   the	   flow	   cytometer	   settings	   were	   corrected	   –	   i.e.	   	   compensated	   –	   to	   show	  
events	   as	   FL4	   (APC)	  negative.	   	   This	   compensation	  was	   applied	   for	   each	   channel	   in	  
order	   to	   avoid	   false	   positive	   results	   in	   the	   test	   samples,	   where	   dual	   staining	   was	  
employed.	   	   Data	   was	   acquired	   with	   CellQuest	   software	   (BD	   Biosciences)	   and	  
analysed	  with	  FlowJo	  software.	   	  The	  minimum	  number	  of	  events	  analysed	  for	  each	  
sample	  was	  105.	  
2.6.1	  Surface	  staining	  of	  stimulated	  PBMC	  	  
After	   stimulation	   of	   PBMCs	   with	   appropriate	   pepmix	   for	   10	   days,	   PBMC	   were	  
washed	  with	   4	  ml	   PBS	   containing	   0.1%	  Bovine	   serum	   albumin	   [BSA]	   (FACS	   buffer)	  
followed	  by	  centrifugation	  at	  400	  x	  g	  for	  5	  minutes.	  	  PBMC	  were	  then	  re-­‐suspended	  
in	   50	  µl	   FACS	   buffer,	   and	   transferred	   into	   5	  ml	   FACS	   tubes.	   	   Each	   tube	   contained	  
0.5×106	   PBMC	   in	   a	   total	   volume	   of	   50	   µl.	   	   After	   addition	   of	   appropriate	  
fluorochrome-­‐conjugated	  monoclonal	  antibodies	  (mAb),	  cells	  were	  incubated	  on	  ice	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for	  20-­‐30	  minutes.	   	  Cells	  were	  then	  washed	  with	  FACS	  buffer,	  resuspended	   in	  1	  ml	  
and	   analysed	   by	   flow	   cytometry.	   	   Control	   tubes	   were	   included	   in	   each	   immuno-­‐
staining	   experiment.	   	   These	   were	   an	   unstained	   sample	   control	   and	   appropriate	  
single-­‐colour	   compensation	   controls.	   	   The	   fluorochromes	   used	   were	   FITC,	   PE	   and	  
APC.	   	   Thus,	   three	   different	  monoclonal	   antibodies	  with	   the	   same	   specificity	   (anti-­‐
human	   CD8	   surface	   marker)	   were	   used,	   but	   labelled	   with	   the	   different	  
fluorochrome,	   as	   follows:	   (i)	   anti-­‐CD8-­‐FITC,	   (ii)	   anti-­‐CD8-­‐PE	   and	   (iii)	   anti-­‐CD8-­‐APC.	  	  
For	  more	  details	  see	  Table	  1.1.	  
Table	  2.1	  Details	  of	  antibody	  surface	  staining	  of	  stimulated	  PBMC	  
Tube	  no	   Tube	  Purpose	   FITC	   PE	   APC	  
1	   Unstained	   none	   none	   none	  
2	   FITC	  control	   CD8	  FITC	   none	   none	  
3	   PE	  control	   none	   CD8	  PE	   None	  
4	   APC	  control	   none	   none	   CD8	  APC	  
5	   T	  cell	  subsets	   CD8	  FITC	   CD3	  PE	   CD4	  APC	  	  
All	  antibodies	  are	  mouse	  anti-­‐human.	  
2.7	  Intracellular	  cytokine	  staining	  (ICS)	  
PBMC	  (0.5×106)	  in	  100	  µl	  were	  aliquoted	  into	  the	  required	  number	  of	  tubes	  and	  10	  
µl	   of	   individual	   peptide	   or	   2	  µl	   of	   pepmixes	   added	   (final	   peptide	   concentration	   2	  
µg/ml).	   	   A	   control	   unstimulated	   PBMC	   tube	   was	   included,	   where	   no	   antigen	   was	  
added	  to	   the	  cells.	   	  A	   further	  control	  was	  used	  where	  PBMC	  were	  stimulated	  with	  
either	  PHA	  at	  final	  concentration	  of	  10	  µg/ml	  or	  Concanavalin	  A	  (ConA)	  [5	  mg/ml]	  at	  
final	  concentration	  of	  5	  µg/ml.	  	  The	  samples	  were	  mixed	  and	  incubated	  at	  37°C,	  5%	  
CO2	  for	  90	  minutes.	  	  To	  prevent	  the	  export	  of	  cytokine,	  Brefeldin	  A	  (BFA)	  was	  added	  
to	   a	   final	   concentration	   of	   10	   μg/ml.	   	   Tubes	   were	   then	   returned	   to	   the	   37°C	  
incubator	  for	  a	  further	  14	  hours	  incubation.	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Cells	   were	   then	   harvested	   and	   washed	   with	   4	   ml	   FACS	   buffer,	   followed	   by	  
centrifugation	  at	  400	  x	  g	  for	  5	  minutes.	   	  The	  cells	  were	  re-­‐suspended	  in	  50	  μl	  FACS	  
buffer	   before	   addition	   1	   μl	   per	   test	   of	   mAbs	   against	   CD8.	   	   The	   cells	   were	   then	  
incubated	  on	  ice	  for	  20	  minutes.	  	  To	  fix	  the	  surface	  antibodies	  samples	  were	  washed	  
by	  addition	  of	  4	  ml	  FACS	  buffer,	  followed	  by	  centrifugation	  at	  400	  x	  g	  for	  5	  minutes,	  
before	   100	   μl	   fixation	   reagent	   BD	   Cytofix™	   (4%	   paraformaldehyde	   in	   PBS)	   was	  
added.	  	  Cells	  were	  then	  incubated	  in	  the	  dark	  for	  15	  minutes	  at	  RT.	  	  The	  cells	  were	  
then	   washed	   with	   4	   ml	   FACS	   buffer	   followed	   by	   centrifugation	   at	   400	   x	   g	   for	   5	  
minutes.	   	   Cells	   were	   then	   permeabilised	   by	   incubated	   for	   5	   minutes	   with	   100	   μl	  
permeabilisation	   buffer,	   (eBioscience,	   UK).	   	   Without	   washing	   away	   the	  
permeabilisation	   buffer,	   cells	   were	   incubated	   with	   anti	   fluorochrome-­‐conjugated	  
anti-­‐cytokine	  mAb	   (anti-­‐IFN-­‐γ	   and	   anti-­‐TNF-­‐α)	   or	   isotype	   control	   antibodies	   for	   30	  
minutes	  in	  the	  dark	  at	  RT	  (for	  more	  details	  of	  all	  mAbs	  used	  see	  Table	  2.2).	  	  Finally,	  
the	  cells	  were	  washed	  with	  4	  ml	  FACS	  buffer,	  centrifuged	  at	  400	  x	  g	  for	  5	  minutes,	  
and	   resuspended	   in	  400	  μl	  FACS	  buffer,	  before	  being	  analysed	  on	  BD	  FACS	  Calibur	  
flow	  cytometer.	  	  	  
Table	  2.2	  Details	  of	  antibody	  staining	  panel	  for	  ICS	  analysis	  of	  CD8	  T	  cells	  	  
Tube	  no	   Tube	  Purpose	   FITC	   PE	   PC5	  
1	   Unstained	   none	   none	   none	  
2	   FITC	  control	   CD8	  FITC	   none	   none	  
3	   PE	  control	   none	   CD8	  PE	   None	  
4	   PC5	  Control	   none	   none	   CD8	  PC5	  
5	   Isotype	  control	   Mouse	  IgG	  FITC	   Mouse	  IgG	  PE	   CD8	  PC5	  
6	   Test	  	  Ag	  specificity	   IFN-­‐γ	  FITC	   TNF-­‐α	  PE	   CD8	  PC5	  
7	   PHA	  control	   IFN-­‐γ	  FITC	   TNF-­‐α	  PE	   CD8	  PC5	  
8	   Unstimulated	  PBMC	   IFN-­‐γ	  FITC	   TNF-­‐α	  PE	   CD8	  PC5	  
All	  antibodies	  are	  mouse	  anti-­‐human.	  
	  	  P a g e |	  56	  
	  
2.8	  Carboxy-­‐Fluorescein	  Succinimidyl	  Ester	  (CFSE)	  proliferation	  assay	  	  
CellTraceTM	   CFSE	   Cell	   Proliferation	   Kit	   (Invitrogen)	   was	   used	   to	   perform	   the	   CFSE	  
labeling.	  	  Briefly,	  a	  stock	  solution	  of	  5	  mM	  CFSE	  was	  prepared	  by	  adding	  18	  μl	  DMSO	  
(Component	  B)	  to	  one	  vial	  of	  CFSE	  (Component	  A).	  	  Five	  µl	  of	  CFSE	  solution	  was	  then	  
added	   to	   2x106	  PBMC	   (at	   a	   concentration	   of	   1x106	  cells	   per	  ml),	  mixed	   gently	   and	  
incubated	  for	  10	  minutes	  at	  37°C.	  	  This	  was	  followed	  by	  washing	  three	  times	  with	  10	  
ml	  PBS,	  with	  a	  10	  minute	  centrifugation	  at	  400	  x	  g	  between	  each	  wash.	  	  Viable	  cells	  
were	   then	   recounted,	   and	   cells	   re-­‐suspended	   in	   R10	   growth	   media	   at	   a	  
concentration	   of	   1x106	   cells	   per	   ml	   in	   a	   well	   of	   24-­‐well	   plate.	   	   PBMC	   were	   then	  
stimulated	  with	  the	  HHV6B-­‐antigen	  Pepmixes	  (at	  final	  concentration	  of	  2	  µg/ml)	  or	  
PHA	   (at	   final	   concentration	   of	   10	   µg/ml).	   	   Unstimulated	   PBMC	   were	   used	   as	   a	  
negative	  control.	  	  Cells	  were	  then	  incubated	  for	  7	  days	  at	  37°C.	  
	  On	   day	   8,	   the	   cells	   were	   removed	   from	   the	   incubator	   and	   0.5x106	   cells	   were	  
aliquoted	   from	   the	   cell	   suspension	   into	   labelled	   FACS	   tubes.	   	   The	   cells	  were	   then	  
washed	   with	   4ml	   FACS	   buffer,	   and	   centrifuged	   at	   400	   x	   g	   for	   5	   minutes..	   	   The	  
supernatant	   was	   discarded	   and	   cells	   resuspended	   50	   µl	   of	   FACS	   buffer,	   before	  
addition	   of	   2.5	   µg/ml	   of	   anti-­‐CD8-­‐APC	  mAbs	   followed	   by	   incubation	   on	   ice	   for	   20	  
minutes.	  	  Unbound	  antibodies	  were	  removed	  by	  washing	  with	  4ml	  FACS	  buffer	  and	  
centrifuged	   at	   400	   x	   g	   for	   5	   minutes.	   	   Finally,	   cells	   were	   resuspended	   in	   400	   µl	  
fixation	   reagent	   and	   mixed	   thoroughly	   by	   vortexing	   for	   10-­‐15	   seconds.	   	   Flow	  
cytometric	   analysis	   was	   done	   using	   BD	   FACS	   Calibur	   flow	   cytometer.	   	   CFSE	   was	  
detected	  in	  the	  FL1	  channel	  and	  CD8	  in	  the	  FL4	  channel.	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2.9	  Short-­‐Term	  in-­‐vitro	  T	  cell	  reactivation	  
Peptide-­‐specific	   T	   cells	  were	   expanded	   in-­‐vitro	   by	   incubation	   of	   PBMC	  with	   either	  
pepmixes	   or	   individual	   peptides.	   	   PBMC	   (2×106)	   were	   pulsed	   with	   appropriate	  
peptides	  at	  a	  final	  concentration	  of	  10	  µg/ml	  in	  100	  µl	  RPMI	  for	  60	  minutes	  at	  37°C.	  	  
Cells	  were	   then	   resuspended	   in	  2	  ml	   T	   cell	  media	   and	   seeded	   into	  a	  24-­‐well	   plate	  
(2x106	  cells	   per	  well).	   	   Cultures	  were	   supplemented	   on	   day	   3	  with	   100	   IU/ml	   IL-­‐2	  
(Sigma,	  UK),	  which	  was	  replenished	  every	  3	  days.	  	  On	  day	  10	  T	  cells	  were	  harvested,	  
counted	  and	  characterised	  by	  both	  functional	  and	  phenotypic	  approaches.	  	  	  
2.10	  Enrichment	  of	  CD8+	  T	  cells	  
Epitope	  mapping	  was	  performed	  using	  either	  CD8-­‐enriched	  polyclonal	  T	  cell	  lines	  or	  
in	  some	  cases	  total	  polyclonal	  T	  cell	  populations.	  	  CD8	  enrichment	  was	  achieved	  by	  
depletion	  of	  CD4-­‐positive	  cells	  using	  an	  EasySep™	  Human	  CD4	  Positive	  Selection	  Kit	  
(STEMCELL,	  Manchester,	  U.K.)	  according	  to	  the	  manufacturer’s	  instructions.	  	  Briefly,	  
cells	  were	  labelled	  with	  10	  μl	  EasySep®	  CD4	  positive	  selection	  solution	  per	  107	  T	  cell	  
lines	   for	   15	   minutes	   at	   RT,	   before	   10	   μl	   EasySep®	   magnetic	   nanoparticles	   were	  
added	  and	  incubation	  continued	  for	  a	  further	  10	  minutes.	  	  The	  tube	  was	  then	  placed	  
in	  magnet	  for	  5	  minutes,	  and	  CD8+	  T	  cells	  collected	  by	  pouring	  off	  the	  supernatant	  
into	   a	   fresh	   tube,	  with	  CD4	   cells	   remain	   fixed	   in	   the	  original	   tube	   via	   the	  magnet.	  	  
The	  efficiency	  of	  CD8+	  T	  cell	  enrichment	  was	  analysed	  by	  flow	  cytometry	  staining	  the	  
isolated	  cells	  with	  anti-­‐	  CD4	  and	  anti-­‐CD8	  mAb.	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2.11	  Enzyme-­‐linked	  immunospot	  (ELISPOT)	  assay	  for	  single-­‐cell	  IFN-­‐γ	  release	  
Ninety-­‐six	  well	  polyvinylidene	  difluoride-­‐backed	  plates	  (Millipore,	  Bedford,	  MA)	  were	  
pre-­‐coated	  with	  15	  μg/ml	  anti-­‐IFN-­‐γ	  mAb,	  1-­‐DIK	  for	  3h	  in	  RT	  (MABTECH,	  Stockholm,	  
Sweden).	   	   Cells	   were	   added	   to	   the	   wells	   at	   known	   cell	   numbers	   in	   duplicate	   or	  
triplicate	  in	  the	  presence	  of	  pepmixes,	  peptide	  pools	  or	  individual	  peptides	  at	  a	  final	  
concentration	  of	  2	  µg/ml.	   	  The	  plates	  were	   incubated	  overnight	  at	  37°C	   in	  5%	  CO2.	  	  
The	  cells	  were	  then	  discarded	  and	  a	  biotinylated	  anti-­‐IFN-­‐γ	  mAb,	  7B6-­‐1	  (MABTECH),	  
was	  added	  at	  1	  μg/ml	  and	  the	  plated	  incubated	  for	  2-­‐4	  hours	  at	  RT.	  	  The	  wells	  were	  
then	  washed	   5	   times	  with	   PBS	   containing	   0.05%	   Tween	   20	   (PBS-­‐T).	   	   Streptavidin-­‐
conjugated	  alkaline	  phosphatase	  (MABTECH)	  (1	  mg/ml,	  diluted	  1:1000	  in	  PBS)	  50	  µl	  
was	   then	  added	   to	   the	  wells,	   followed	  by	   incubation	  at	  RT	   for	  2	  hours.	   	   The	  wells	  
were	   then	   washed	   5	   times	   with	   PBS-­‐T,	   and	   individual	   IFN-­‐γ-­‐producing	   cells	   were	  
detected	   as	   dark	   spots	   after	   addition	   of	   100	   µl	   5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indolyl	  
phosphate	  and	  nitroblue	  tetrazolium	  (10	  ul	  of	  each	  for	  every	  1	  ml	  of	  water	  at	  final	  
concentration	  of	  0.7	  mmol/L)	  using	  an	  alkaline	  phosphatase-­‐conjugated	  substrate	  kit	  
(Bio-­‐Rad,	   Richmond,	   CA).	   	   The	   numbers	   of	   spot	   forming	   cells	   (SFC)	   was	   then	  
determined	  manually	  by	  counting	  under	  a	  dissection	  microscope.	  
2.12	  IFN-­‐γ	  Enzyme-­‐Linked	  Immunosorbent	  Assay	  (ELISA)	  	  	  
Secretion	  of	  IFN-­‐γ into	  culture	  supernatants	  during	  T	  cell	  assays	  was	  measured	  with	  a	  
human	   IFN-­‐γ ELISA	   Ready-­‐Set-­‐Go®	   set	   (eBioscience,	   UK),	   following	   the	  
manufacturer’s	   instructions.	   	  Briefly,	  96-­‐well	  Costar	  plates	  were	  coated	  with	  100	  µl	  
capture	  antibody	  (anti-­‐human	  IFN-­‐γ	  MAb,	  diluted	  1:250	  with	  coating	  buffer)	  and	  the	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plates	   incubated	  overnight	  at	  4°C.	   	  The	  plate	  was	  then	  washed	  5	  times	  with	  PBS-­‐T,	  
and	  wells	  blocked	  for	  1	  hour	  with	  200	  μl	  assay	  diluent	  (10%	  bovine	  serum	  albumin	  in	  
PBS).	   	  The	  blocking	  buffer	  was	  then	  removed	  without	  wash,	  and	  the	  standards	  and	  
samples	  added	  to	  the	  plate	  at	  100	  μl/well.	  	  A	  total	  of	  7	  standards	  were	  prepared	  by	  
2-­‐fold	   serial	  dilutions	   from	   the	   top	   standard	  which	  was	  500	  pg/ml.	   	   The	  plate	  was	  
then	  incubated	  at	  RT	  for	  2	  hours,	  and	  then	  washed	  5	  times	  with	  PBS-­‐T.	   	  After	  that,	  
100	   μl	   of	   detection	   antibody	   (anti-­‐human	   IFN-­‐γ Biotin,	   diluted	   1:250	   with	   assay	  
diluent)	  was	   added	   to	   each	  well.	   	   The	   plate	  was	   then	   incubated	   at	   RT	   for	   1	   hour,	  
before	   being	  washed	   5	   times	  with	   PBS-­‐T.	   	   Next,	   100	   μl	   Avidin-­‐HRP	   (diluted	   1:250	  
with	   assay	   diluent)	   was	   added	   to	   each	  well	   and	   the	   plate	   incubated	   at	   RT	   for	   30	  
minutes.	  	  After	  washing	  5	  times	  with	  PBS-­‐T,	  100	  μl	  3,	  3',	  5,	  5'	  tetramethyl	  benzidine	  
(TMB)	   substrate	   solution	  was	   added	   to	   each	  well,	  with	   a	   further	   incubation	   of	   15	  
minutes	  at	  RT	  in	  dark.	  	  Then,	  50	  μl	  stop	  solution	  (1M	  H2SO4)	  was	  added	  to	  each	  well.	  	  
Finally,	  the	  absorbance	  was	  read	  at	  450	  nm	  using	  in	  Multiskan	  Spectrum	  microplate	  
reader	   (Thermo	   Scientific)	   using	   SkanIt	   software	   2.2.	   	   The	   concentration	   of	   IFN-­‐γ	  
(pg/ml)	  in	  each	  sample	  was	  calculated	  against	  the	  standard	  curve.	  
2.13	  Identification	  of	  HLA	  restriction	  element	  
To	  determine	  the	  HLA	  restricting	  alleles	  of	  newly	  identified	  HHV6B	  peptide	  epitopes,	  
autologous,	  partially	  HLA-­‐matched	  and	  HLA	  mis-­‐matched	  PBMC	  were	  used	  as	  targets	  
in	   T	   cell	   assays.	   	   Target	   cells	  were	   loaded	  with	   individual	   peptides	   (2	   μg/ml)	   for	   2	  
hours	  in	  volume	  of	  100	  µl	  RPMI	  at	  37°C,	  then	  washed	  3	  times	  with	  RPMI.	  	  Peptide-­‐
pulsed	  cells	  were	  then	  resuspended	  in	  R10	  growth	  media	  at	  1	  x	  105	  cells/ml	  and	  used	  
as	   targets	   in	   a	   T	   cell	   assay.	   	   100	   µl	   of	   target	   cells	   (1	   x	   104	   cells)	   were	   added	   in	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triplicate	   to	  wells	   of	   a	   96-­‐well	   V-­‐bottom	   plate	   and	   100	  µl	   of	   effector	   T	   cells	   from	  
short-­‐term	   in-­‐vitro	   reactivations	  were	   added	   at	   an	   Effector-­‐to-­‐Target	   (E:T)	   ratio	   of	  
10:1,	  5:1	  and	  2.5:1.	  	  	  
The	   effectors	   and	   targets	   were	   co-­‐cultured	   overnight	   at	   37°C,	   before	   100	   µl	   of	  
supernatant	  was	  harvested	  from	  each	  well	  and	  monitored	  for	  IFN-­‐γ 	  release	  using	  a	  
Human	  IFN	  gamma	  ELISA	  Ready-­‐SET-­‐Go®	  kit	  (see	  section	  2.13).	  
2.14	  T	  cell	  recognition	  of	  HHV6B	  infected	  cells	  
To	  prepare	  targets	  cells	  infected	  by	  HHV6B	  for	  T	  cells	  assays,	  2×106	  PHA	  blasts	  in	  500	  
µl	  T	  cell	  media	  were	  infected	  with	  230	  µl	  of	  HHV6B	  virus	  stocks	  HST	  or	  Z29	  (Martin	  et	  
al.,	  2012)	  (section	  2.5).	  	  Infections	  were	  incubated	  for	  90	  minutes	  at	  37°C.	  	  A	  further	  
1.5	  ml	  T	  cell	  media	  was	  then	  added.	   	  Six	  days	  after	   infection,	  the	  HHV6B	  wild-­‐type	  
virus-­‐infected	  PHA	  blasts	  were	  used	  as	  targets	   for	  HHV6B-­‐enriched	  antigen-­‐specific	  
T-­‐cells.	  	  Specific	  T-­‐cell	  recognition	  of	  targets	  was	  monitored	  by	  measuring	  release	  of	  
IFN-­‐γ	   in	   to	   the	   culture	   supernatant	   by	   ELISA.	   	   Infection	   by	   HHV6B	  was	  monitored	  
visually	  for	  cytopathic	  effects	  and	  by	  immunofluorescence.	   	  T	  cells	  specific	  for	  each	  
peptide	   to	   be	   tested	   were	   generated	   by	   stimulating	   PBMC	   with	   each	   individual	  
peptide,	  and	  cultures	  were	  maintained	  for	  10	  days	  at	  37°C,	  with	  IL2	  being	  added	  to	  
cultures	   from	   day	   3.	   	   Polyclonal	   cultures	   were	   then	   used	   as	   effectors	   in	   virus	  
recognition	   assays.	   	   Target	   cells	   incubated	   with	   effectors	   at	   an	   Effector-­‐to-­‐Target	  
(E:T)	  ratio	  of	  5:1	  or	  10:1.	   	  The	  effectors	  and	  targets	  were	  co-­‐cultured	  overnight	  for	  
16h,	  before	  target	  cell	  recognition	  was	  monitored	  by	  measuring	  release	  of	  IFN-­‐γ	  into	  
the	  culture	  supernatant	  by	  ELISA.	  	  At	  E:T	  ratio	  5:1,	  Virus	  infected	  PHA-­‐blasts	  or	  mock	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infected	  PHA-­‐blasts	  (1	  ×	  104	  cells	  in	  100ul	  media)	  were	  mixed	  with	  effector	  cells	  (5	  ×	  
104	   cells	   in	  100ul	  media)	   in	  96-­‐well	  V-­‐bottom	  plate	   in	   triplicate.	   	  At	  E:T	   ratio	  10:1,	  
Virus	  infected	  PHA-­‐blasts	  or	  mock	  infected	  PHA-­‐blasts	  (1	  ×	  104	  cells	  in	  100ul	  media)	  
were	  mixed	  with	   effector	   cells	   (1	   ×	   105	  cells	   in	   100ul	  media)	   in	   96-­‐well	   V-­‐bottom	  
plate	  in	  triplicate.	  	  At	  E:T	  ratio	  20:1,	  Virus	  infected	  PHA-­‐blasts	  or	  mock	  infected	  PHA-­‐
blasts	   (1	  ×	  104	  cells	   in	  100ul	  media)	  were	  mixed	  with	  effector	  cells	   (2	  ×	  105	  cells	   in	  
100ul	  media)	  in	  96-­‐well	  V-­‐bottom	  plate	  in	  triplicate.	  
For	   immunofluorescence	   monitoring	   of	   HHV6B-­‐infected	   PHA	   blasts,	   cells	   were	  
resuspended	  in	  1	  ml	  PBS	  at	  1	  x	  106	  cells/ml,	  5	  x104	  cells	  in	  50	  µl	  were	  then	  added	  to	  
defined	   areas	   on	   glass	   microscope	   slides	   (Shandon	   Cytospin	   4	   Cytocentrifuge;	  
Thermo	  Scientific).	  	  After	  drying	  at	  RT,	  cells	  were	  fixed	  in	  acetone	  for	  5	  minutes	  at	  -­‐
20°C.	  	  Slides	  were	  incubated	  in	  pre-­‐block	  (50	  µl	  5%	  normal	  goat	  serum	  in	  PBS)	  for	  30	  
minutes,	   followed	  by	  pouring	  off	  excess	  block	  without	  washing.	   	  This	  was	  followed	  
by	   incubation	   with	   50	   µl	   mouse-­‐anti–human	   HHV6B	   mAb	   (monoclonal	   antibody	  
MAB8535,	  clone	  C3108-­‐003;	  Chemicon)	  diluted	  1:50	  in	  PBS	  for	  1	  hour	  at	  37°C	  in	  5%	  
CO2.	   	  Slides	  were	  then	  washed	  5	  times	  in	  PBS	  for	  2	  minutes/wash,	  50	  µl	  secondary	  
antibody	   (goat	   anti-­‐mouse	   IgG-­‐FITC	   diluted	   1:200	   in	   PBS)	  was	   then	   added	   to	   each	  
cell	  spot	  and	  incubated	  for	  30	  minutes.	  	  The	  slide	  was	  then	  washed	  5	  times	  in	  PBS.	  	  
Finally,	   slides	   were	   mounted	   by	   Vectashield	   DAPI	   then	   analysed	   with	   a	   Nikon	  
fluorescence	   microscope.	   	   For	   each	   HHV6B-­‐infected	   PHA	   blasts	   stained	   by	   each	  
immunofluorescence	  two	  negative	  controls	  were	  added.	   	  Firstly,	  an	   isotype	  control	  
was	  used	  to	  ensure	  the	  specificity	  of	  binding	  of	  the	  primary	  antibody	  to	  the	  antigen.	  	  
A	  second	  negative	  control	  was	  used,	  where	  no	  primary	  antibody	  was	  added.	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2.15	  Statistical	  Analysis	  
Graphpad	  Prism	  version	  5	  software	  was	  used	  for	  all	  statistical	  tests.	  	  The	  Mann	  
Whitney	  non-­‐parametric	  test	  was	  used	  to	  compare	  differences	  between	  sample	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3.	  	  Ex-­‐vivo	  analysis	  of	  T	  cell	  responses	  to	  HHV6B	  in	  healthy	  
donors	  	  
When	  this	  project	  was	  initiated	  studies	  looking	  at	  the	  T	  cell	  responses	  to	  HHV6	  were	  
sparse.	  	  HHV6-­‐specific	  T	  cell	  lines	  and	  T	  cell	  clones	  had	  been	  established	  for	  CD4+	  T	  
cells,	  however	  there	  was	  no	  data	  on	  the	  CD8+	  T	  cell	  response	  to	  HHV6	  (Yakushijin	  et	  
al.,	  1991,	  1992;	  Yasukawa	  et	  al.,	  1993;	  Koide	  et	  al.,	  1998;	  Tejada-­‐Simon	  et	  al.,	  2002;	  
Kumagai	  et	  al.,	  2006).	   	  Thus,	   this	  was	  a	  neglected	  area	  of	  herpesvirus	   immunology	  
and,	   with	   the	   advances	   in	   technology	   available	   for	   analysing	   human	   immune	  
responses	   over	   the	   last	   15-­‐20	   years,	   warranted	   renewed	   investigation.	   	   The	   first	  
objective	  was	  to	  utilize	  a	  panel	  of	  healthy	  donors	  and	  investigate	  if	  T	  cell	  responses	  
to	  HHV6	   could	  be	  detected	   and	   characterised	  directly	  ex-­‐vivo,	   focusing	  on	  CD8+	  T	  
cell	  responses.	  	  	  
Previously	   a	   study	   had	   been	   carried	   out	   using	   putative	   HLA-­‐A2	   binding	   peptides	  
derived	   from	   the	   HHV6	   U90	   antigen,	   predicted	   using	   the	   SYFPEITHI	   epitope	  
prediction	  programme	  (Rammensee	  et	  al.,	  1999),	  and	  ELISpot,	  had	  failed	  to	  identify	  
any	   HHV6	   CD8+	   T	   cell	   responses	   in	   a	   group	   of	   14	   healthy	   donors	   [Naeem	   Khan,	  
personal	  communication].	  	  Thus,	  the	  approach	  to	  be	  employed	  in	  this	  thesis	  was	  to	  
focus	  on	  a	  wider	  panel	  of	  HHV6	  antigens,	  which	  are	  functionally	  equivalent	  to	  known	  
strongly	   immunogenic	   HCMV	   antigens,	   on	   the	   basis	   that	   these	   would	   also	   be	  
immunogenic	   in	  HHV6.	   	  The	  HHV6	  antigens	  to	  be	  investigated	  were	  U11,	  U39,	  U54	  
and	  U90,	  which	  are	  equivalent	  to	  the	  immunogenic	  HCMV	  antigens	  pp150,	  gB,	  pp65	  
and	  IE1	  (see	  Table	  3.1)	  (Efstathiou	  et	  al.,	  1988;	  Lawrence	  et	  al.,	  1990;	  Martin	  et	  al.,	  
1991;	   Nicholas,	   1994;	   Gompels	   et	   al.,	   1995;	   Khan,	   2007).	   	   A	   broad	   approach	   was	  
taken,	  whereby	   pepmixes,	   single	   tube	   libraries	   of	   15-­‐mer	   peptides	   overlapping	   by	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11aa	   (for	   a	   schematic	   representation	   see	   Figure	   3.1),	   representing	   the	   HHV6	  
antigens	  U11,	  U39,	  U54	  and	  U90	  were	  used	  to	  stimulate	  PBMC,	  before	  analysis	  of	  T	  
cell	   responses.	   	   Using	   single	   tube	   libraries	   of	   overlapping	   15-­‐mer	   peptides	   is	   a	  
powerful	   tool	   for	   an	   unbiased	   screen	   for	   global	   CD8+T	   cells	   responses	   in	   a	   single	  
reaction	  (Kern	  et	  al.,	  2000).	  	  As	  HHV6B	  is	  the	  most	  common	  virus	  subtype,	  present	  in	  
more	  than	  90%	  of	  HHV6-­‐infected	  individuals	  (Levy	  et	  al.,	  1990),	  pepmixes	  used	  were	  
based	  on	  the	  amino	  acid	  sequence	  of	  this	  strain	  of	  the	  virus.	  	  HHV6B	  antigen-­‐specific	  
T	  cell	  responses	  were	  monitored	  by	  two	  different	  approaches,	  (i)	  ICS	  for	  both	  IFN-­‐γ	  
and	  TNF-­‐α	  and	  (ii)	  CFSE	  proliferation	  assays,	  as	  outlined	  in	  Figure	  3.2.	  	  	  
Table	  3.1	  HHV6B	  proteins	  analysed	  in	  this	  thesis,	  their	  equivalent	  HCMV	  protein	  
and	  their	  properties*	  
 
HHV6B	  Protein	   HCMV	  Protein	  	   Properties	  
U11	   pp150	  (UL32)	   Antigenic	  tegument	  protein	  
U39	   gB	  (UL55)	   Major	  glycoprotein	  
U54	   pp65	  (UL83)	   Tegument	  protein	  virion	  transactivator	  
U90	   IE1	  (UL123)	   Immediately	  early	  transactivator	  
*For	   HHV6B	   the	   open	   reading	   frame	   nomenclature	   is	   used,	   for	   HCMV	   the	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A	  total	  of	  30	  healthy	  donors	  were	  analysed	  by	  these	  approaches.	  	  The	  HHV6	  status	  of	  
the	  donors	  was	  not	  known,	  however	  based	  on	  the	  estimated	  worldwide	  prevalence	  
of	  HHV6	  of	  greater	  than	  90%,	  it	  was	  assumed	  that	  the	  majority	  of	  donors	  would	  be	  
positive	  (Okuno	  et	  al.,	  1989;	  Levy	  et	  al.,	  1990;	  Braun	  et	  al.,	  1997;	  Zerr	  et	  al.,	  2005).	  	  
The	  HCMV	  status	  of	  donors	  was	  confirmed	  by	  ELISA.	  	  The	  HLA	  type	  was	  available	  for	  
the	   majority	   of	   donors.	   	   Full	   details	   of	   donors	   used	   throughout	   this	   thesis	   are	  
presented	  in	  the	  Appendix	  (Appendix	  Table	  8.1).	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Figure	   3.1	   Schematic	   representation	   of	   a	   whole	   protein	   spanning	   pepmix	   for	  
HHV6B	  U90.	  
The	  U90	  protein	  is	  1078	  aa	  in	  length,	  and	  the	  single	  tube	  pepmix	  contains	  a	  total	  of	  
267	   15-­‐mer	   peptides,	   overlapping	   by	   11	   amino	   acids,	   spanning	   the	   entire	   protein	  
sequence.	   	   The	   peptides	   are	   represented	   by	   black	   arrows,	   and	   the	   first	   three	  
peptides	  (P1-­‐P3)	  are	  shown	  in	  full	  to	  demonstrate	  the	  overlaps.	  
	   	  
P1  MESAKDTTSTSMFIL 
P2      KDTTSTSMFILGKPS 



















Figure	   3.2	   Flowchart	   showing	   the	   approaches	   used	   for	   ex-­‐vivo	   analysis	   of	   T	   cell	  
responses	  to	  HHV6B	  antigens. 
PBMC	  were	  either	  (A)	  incubated	  directly	  with	  HHV6B	  antigen	  pepmixes	  before	  being	  
stained	  for	  CD8+	  T	  cells,	  and	  either	  IFN-­‐γ	  or	  TNF-­‐α	  then	  analysed	  by	  flow	  cytometry,	  
or	   (B)	   labelled	   with	   CFSE,	   before	   being	   incubated	   with	   HHV6B	   antigen	   pepmixes,	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3.1	  Analysis	  of	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  
U90	  	  
In	  an	   initial	  attempt	   to	  determine	   the	   frequency	  of	  HHV6B	  antigen-­‐specific	  CD8+	  T	  
cells	  directly	  in	  PBMC,	  ICS	  was	  used	  to	  investigate	  production	  of	  both	  IFN-­‐γ	  and	  TNF-­‐
α	   after	   stimulation	   with	   HHV6B	   pepmixes	   for	   U11,	   U39,	   U54	   and	   U90.	   	   All	  
experiments	  were	   carried	   out	   using	   fresh	   PBMC,	  which	  were	   stimulated	   overnight	  
with	   individual	   pepmixes	   before	   being	   stained	  with	   fluorescently	   labelled	   anti-­‐CD8	  
and	  either	  anti-­‐IFN-­‐γ	  or	  anti-­‐TNF-­‐α mAbs.	   	   In	  addition,	  HCMV+ve	  donors	  were	  also	  
stimulated	  with	  pepmixes	  representing	  HCMV	  antigens	  pp65,	  gB,	  IE1	  and	  IE2,	  to	  give	  
an	  indication	  of	  the	  ability	  of	  T	  cells	  to	  respond	  to	  antigenic	  stimuli.	  	  ConA	  stimulated	  
PBMC	   was	   used	   as	   positive	   control	   throughout,	   and	   unstimulated	   PBMC	   as	   the	  
negative	  control.	  	  Subsequently,	  the	  ability	  of	  HHV6B	  antigen	  pepmixes	  to	  stimulate	  
CD8+	   T	   cell	   proliferation	   was	   investigated	   by	   CSFE	   proliferation	   assays	   (Lyons	   and	  
Parish,	  1994).	  	   
3.1.1	  Detection	  of	  HHV6B	  antigen-­‐specific	  IFN-­‐γ	  positive,	  CD8+	  T	  cells	  by	  
intracellular	  cytokine	  staining	  
Thirty	   healthy	  donors	  were	   analysed	   for	   IFN-­‐γ+ve,	   CD8+	   responses	   to	  HHV6B	  U11,	  
U39,	   U54	   and	   U90,	   and	   data	   presented	   as	   percentage	   of	   antigen-­‐specific	   CD8+	  
IFNγ−producing	  T	  cells	  in	  total	  CD8+	  lymphocytes.	  	  A	  positive	  result	  in	  this	  study	  was	  
considered	  as	  a	  value	  of	  at	  least	  0.02%	  above	  the	  negative	  control	  value	  (Mesa	  et	  al.,	  
2010;	   Gómez	   et	   al.,	   2011).	   	   Representative	   examples	   of	   the	   CD8+	   T	   cell	   staining	  
profiles	   are	   shown	   for	   donors	   HD01	   and	  HD05	   in	   Figure	   3.3.	   	   The	   flow	   cytometry	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plots	  of	  ICS	  in	  the	  left	  hand	  panel	  shows	  the	  CD8+	  T	  cell	  response	  from	  healthy	  donor	  
HD01.	  	  Overall	  responses	  detected	  in	  donor	  HD01	  were	  very	  low,	  ranging	  from	  0%	  for	  
U11,	   0.01%	   for	   U90,	   0.02%	   for	   U39	   to	   0.04%	   for	  U54.	   	   The	   background	   level	   for	  
unstimulated	   PBMC	   was	   0.01%,	   and	   based	   on	   the	   criteria	   stated	   above	   only	   the	  
response	   to	   U54	   was	   considered	   positive.	   	   In	   the	   same	   donor	   responses	   to	   the	  
immunogenic	   HCMV	   antigens	   pp65	   and	   IE1	   were	   0.12%	   and	   1.54%	   respectively,	  
suggesting	  that	  the	  equivalent	  antigens	  in	  HHV6	  were	  much	  less	  immunogenic.	   	   ICS	  
analysis	  for	  PBMC	  from	  donor	  HD05	  stimulated	  with	  the	  same	  antigens	  is	  shown	  in	  
the	  right	  hand	  panels	  (Figure	  3.3).	  	  Again,	  overall	  responses	  detected	  against	  HHV6B	  
antigens	   in	  this	  donor	  were	  very	   low,	  ranging	  from	  0.03%	  for	  U11,	  U39	  and	  U54	  to	  
0.16%	  for	  U90.	  	  The	  response	  present	  in	  unstimulated	  cells	  was	  0.03%,	  indicated	  that	  
this	  donor	  has	  a	  CD8+	  T	  cell	   response	  to	  HHV6B	  U90.	   	  HD05	  was	  shown	  to	  contain	  
strong	  responses	  to	  HCMV	  pp65	  (0.83%)	  and	  IE1	  (1.54%)	  (Figure	  3.3),	  reinforcing	  the	  
observation	   from	   donor	   HD01	   that	   HHV6	   is	   significantly	   less	   immunogenic	   than	  
HCMV.	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Figure	  3.3	  Analysis	  of	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  
U90	  in	  donor	  HD01	  and	  HD05	  ex-­‐vivo	  by	  intracellular	  cytokine	  staining	  for	  IFN-­‐γ  
PBMC	   (5x10
5
)	   from	   donors	   HD01	   and	   HD05	   were	   stimulated	   with	   HHV6B	   whole	  
antigen	  pepmixes	  for	  U11,	  U39,	  U54	  and	  U90,	  for	  16	  hours	  before	  being	  analysed	  for	  
production	  of	  IFN-­‐γ	  by	  ICS.	  	  PBMC	  were	  stimulated	  with	  Concanavalin	  A	  (Con	  A)	  as	  a	  
positive	   control,	   and	   also	   with	   pepmixes	   representing	   HCMV	   pp65	   and	   IE1.	  	  
Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	  Values	   indicated	   in	   upper	   right	  
quadrants	  denote	  the	  percentage	  of	  CD8+	   IFN-­‐γ	  producing	  cells	  out	  of	  total	  CD8+	  T	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A	   further	  28	  donors	  were	  analysed	   in	  this	  way,	  and	  the	  percentages	  of	  CD8+	   IFN-­‐γ	  
producing	   T	   cells	   specific	   for	   the	   HHV6B	   antigens	   tested	   are	   shown	   in	   Table	   3.2.	  	  
Overall,	   using	   the	   0.02%	   cut	   off	   criteria	   13	   donors	  were	   found	   to	   have	   responses	  
directed	   against	   HHV6B	   antigens.	   	   However,	   in	   general,	   as	   seen	   in	   Figure	   3.3	   for	  
donors	   HD01	   and	   HD05,	   responses	   were	   very	   low.	   	   For	   example,	   donor	   HD02	  
responded	   U54	   and	   U90	   (0.04%	   and	   0.08%	   respectively,	   with	   a	   background	   of	  
0.02%),	   and	   donor	  HD20	   responded	   to	  U90	   (0.18%,	  with	   a	   background	   of	   0.02%).	  	  
The	  mean	  frequency	  of	  CD8+	  T	  cells	  producing	  IFN-­‐γ	  in	  response	  to	  U11	  was	  0.006%	  
of	   total	   CD8+	   T	   cells	   in	   peripheral	   blood,	  with	  maximum	   response	   of	   0.04%	   (after	  
subtraction	   of	   the	   background	   for	   the	   negative	   control).	   	   The	   mean	   frequency	  
against	  U39	  was	  0.006%	  of	  total	  CD8+	  T	  cells,	  with	  a	  maximum	  response	  of	  0.03%.	  	  
The	  mean	  frequency	  against	  U54	  was	  0.01%	  of	  total	  CD8+	  T	  cells,	  with	  a	  maximum	  
response	   of	   0.04%.	   	   Finally,	   the	   mean	   frequency	   against	   U90	   was	   0.03%	   of	   total	  
CD8+	   T	   cells,	  with	   a	  maximum	   response	   of	   0.20%	   (Figure	   3.4).	   	   This	  was	   in	   direct	  
contrast	   to	   responses	   detectable	   against	   HCMV,	   for	   example	   individual	   responses	  
detected	  against	   IE1	   ranged	   from	  0.02	   to	  8.74	  %	   (Full	   data	   for	   all	   donors	   tested	   is	  
shown	   in	  Appendix	  Table	  8.2).	   	  The	  means	   frequencies	  detected	  against	   the	  HCMV	  
antigens	  are	  shown	   in	  Figure	  3.4.	   	  Overall,	  as	  analysed	  by	   ICS	   for	   IFN-­‐γ production,	  
13%	  of	  donors	  responded	  to	  HHV6B	  U11,	  	  10%	  to	  	  U39,	  30%	  to	  U54	  and	  33%	  to	  U90	  
(Figure	  3.9	  and	  Table	  3.5).	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Table	  3.2	  Total	  data	  for	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  
and	  U90	  in	  30	  donors	  analysed	  ex-­‐vivo	  by	  intracellular	  cytokine	  staining	  for	  IFN-­‐γ*	  
Donor	   U11	   U39	   U54	   U90	   Neg**	   Pos***	  
HD01	   0.00	   0.02	   0.04	   0.01	   0.01	   2.09	  
HD02	   0.01	   0.02	   0.04	   0.08	   0.02	   4.03	  
HD03	   0.03	   0.02	   0.04	   0.04	   0.03	   11.18	  
HD04	   0.00	   0.02	   0.02	   0.01	   0.02	   1.26	  
HD05	   0.03	   0.03	   0.03	   0.16	   0.03	   5.56	  
HD06	   0.01	   0.02	   0.02	   0.00	   0.02	   0.05	  
HD07	   0.04	   0.03	   0.05	   0.05	   0.04	   0.14	  
HD08	   0.06	   0.06	   0.04	   0.10	   0.05	   0.30	  
HD09	   0.02	   0.03	   0.05	   0.21	   0.02	   1.27	  
HD10	   0.03	   0.03	   0.03	   0.03	   0.01	   2.68	  
HD11	   0.04	   0.04	   0.04	   0.04	   0.02	   3.54	  
HD12	   0.04	   0.05	   0.08	   0.03	   0.04	   4.36	  
HD13	   0.08	   0.04	   0.07	   0.19	   0.05	   2.73	  
HD14	   0.05	   0.04	   0.03	   0.06	   0.01	   3.07	  
HD15	   0.02	   0.03	   0.03	   0.01	   0.03	   2.62	  
HD16	   0.02	   0.01	   0.01	   0.02	   0.01	   0.72	  
HD17	   0.15	   0.09	   0.06	   0.05	   0.18	   0.47	  
HD18	   0.10	   0.09	   0.10	   0.09	   0.10	   0.97	  
HD19	   0.00	   0.02	   0.02	   0.01	   0.03	   0.20	  
HD20	   0.04	   0.05	   0.01	   0.18	   0.04	   0.63	  
HD21	   0.04	   0.02	   0.02	   0.03	   0.06	   1.99	  
HD22	   0.01	   0.02	   0.00	   0.02	   0.01	   0.22	  
HD23	   0.03	   0.02	   0.02	   0.02	   0.02	   0.85	  
HD24	   0.02	   0.02	   0.00	   0.02	   0.01	   0.92	  
HD25	   0.00	   0.00	   0.00	   0.01	   0.00	   0.44	  
HD26	   0.00	   0.01	   0.02	   0.01	   0.00	   0.11	  
HD27	   0.00	   0.00	   0.00	   0.00	   0.01	   0.38	  
HD28	   0.01	   0.00	   0.00	   0.00	   0.02	   2.59	  
HD29	   0.00	   0.00	   0.01	   0.01	   0.00	   2.17	  
HD30	   0.00	   0.00	   0.01	   0.12	   0.00	   2.38	  
Total	  =	  13	   4	   3	   9	   10	   	   	  
 
*Values	  indicated	  are	  the	  percentage	  of	  CD8+	  T	  cells	  producing	  IFN-­‐γ.	  	  
**Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	   ***Stimulated	  
with	  Concanavalin	  A	  served	  as	  a	  positive	  control.	  	  Numbers	  in	  the	  final	  
row	  indicate	  numbers	  of	  positive	  donors.	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Figure	  3.4	  Overall	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  
and	  HCMV	  antigens	  IE1,	  IE2,	  pp65	  and	  gB	  analysed	  ex-­‐vivo	  by	  intracellular	  cytokine	  
staining	  for	  IFN-­‐γ 	  
(A)	   Summary	   of	   the	   donor	   data	   for	   the	   ICS	   analysis	   of	   CD8+	   IFN-­‐γ	   responses	   to	  
HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  (n=30),	  HCMV	  antigens	   IE1,	   IE2,	  pp65	  and	  
gB	  (n=17)	  and	  –ve	  control	  (n=30).	  	  The	  results	  are	  expressed	  as	  mean	  value	  of	  CD8+	  
cells	  producing	  IFN-­‐γ	  ±	  SEM.	  	  Unstimulated	  PBMC	  were	  used	  as	  a	  negative	  control	  (-­‐
ve).	   	   (B)	   The	   data	   presented	   in	   part	   (A)	   for	   HHV6B	   is	   shown	   here	   on	   its	   own	   to	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3.1.2	  Detection	  of	  intracellular	  TNF-­‐α	  positive,	  CD8+	  T	  cells	  by	  intracellular	  
cytokine	  staining.	  
As	  the	  CD8+	  T	  responses	  to	  HHV6B	  antigens	  as	  detected	  by	  ICS	  for	   IFN-­‐γ	  were	  very	  
low,	  it	  was	  possible	  that	  analysing	  for	  another	  effector	  cytokine	  might	  reveal	  stronger	  
responses,	  as	  measuring	  of	  one	  cytokine	  may	  not	  reflect	  the	  actual	  level	  of	  the	  T	  cell	  
responses	  (Nebbia	  et	  al.,	  2008).	  	  Thus,	  the	  same	  group	  of	  donors	  were	  analysed	  for	  
TNF-­‐α	   positive	   CD8+	   T	   cells	   after	   stimulation	   with	   the	   same	   HHV6B	   antigen	  
pepmixes,	   and	   HCMV	   controls	   (pp65	   and	   gB).	   	   A	   representative	   example	   of	   ICS	  
staining	  for	  HHV6B-­‐specific	  TNF-­‐α 	  positive	  CD8+	  T	  cells	  for	  donor	  HD05	  is	  shown	  in	  
Figure	   3.5	   (left	   hand	   panel).	   	   Similar	   to	   IFN-­‐γ	   responses,	   TNF-­‐α +ve	   CD8+	   T	   cells	  
against	  the	  HHV6B	  antigens	  were	  detected	  at	  a	  very	  low	  frequency.	  	  For	  donor	  HD05	  
responses	  ranged	  from	  0.03%	  for	  U11,	  to	  0.04%	  for	  U54,	  to	  0.05%	  for	  U39	  and	  0.22%	  
for	   U90.	   	  With	   a	   background	   level	   of	   0.03%,	   it	   was	   determined	   that	   HD05	   had	  
detectable	  TNF-­‐α +ve	  CD8+	  T	  cell	   responses	  against	  HHV6B	  antigens	  U39	  and	  U90.	  	  
In	   comparison,	   the	   frequency	   of	   TNF-­‐α +ve	   CD8+	   T	   cells	   against	   HCMV	   pp65	   was	  
0.86%	  and	  gB	  3.91%.	  	  	  
Another	  example	  is	  shown	  for	  donor	  HD16	  in	  Figure	  3.5	  (right	  hand	  panel)	  for	  TNF-­‐α	  
against	  the	  HHV6B	  antigens	  and	  control	  antigens	  (HCMV	  pp65	  and	  gB).	  	  HD16	  did	  not	  
have	  any	  detectable	  CD8+	  T	  cell	  response	  for	  TNF-­‐α	  against	  the	  HHV6B	  antigens.	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Figure	  3.5	  Analysis	  of	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  
U90	  in	  donor	  HD05	  ex-­‐vivo	  by	  intracellular	  cytokine	  staining	  for	  TNF-­‐α	  
PBMC	   (5x105)	   from	   donors	   HD05	   were	   stimulated	   with	   HHV6B	   whole	   antigen	  
pepmixes	   for	   U11,	   U39,	   U54	   and	   U90	   for	   16	   hours,	   before	   being	   analysed	   for	  
production	  of	  TNF-­‐α	  by	  ICS.	  	  PBMC	  were	  stimulated	  with	  Concanavalin	  A	  (Con	  A)	  as	  a	  
positive	   control,	   and	   also	   with	   pepmixes	   representing	   HCMV	   pp65,	   IE1	   or	   gB.	  	  
Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	   Values	   indicated	   in	   upper	   right	  
quadrants	  denote	  the	  percentage	  of	  CD8+	  TNF-­‐α	  producing	  cells	  out	  of	  total	  CD8+	  T	  
cells.	   	  Data	  was	  collected	  on	  a	  BD	  FACSCalibur	  and	  analysed	  using	  FlowJo	  software	  
(Treestar).	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PBMC$ (5x105)$ from$ donors$ HD05$ and$ HD16$ were$ s/mulated$ with$ HHV6B$ whole$
an/gen$ pep/de$ mixes$ for$ U11,$ U39,$ U54$ and$ U90$ for$ 16$ hours,$ before$ being$
analysed$for$produc/on$of$TNFFα$by$ICS.$PBMC$were$s/mulated$with$Concanavalin$
A$ (Con$ A)$ as$ a$ posi/ve$ control,$ and$ also$ with$ pep/de$mixes$ represen/ng$ HCMV$
pp65,$IE1$or$gB.$Uns/mulated$PBMC$served$as$a$nega/ve$control.$Values$indicated$
in$upper$ right$quadrants$denote$ the$percentage$of$CD8+$TNFFα$ producing$ cells$of$
total$ CD8+$ T$ cells.$ Data$ was$ collected$ on$ a$ BD$ FACSCalibur$ and$ analysed$ using$
FlowJo$so[ware$(Treestar).$
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The	   percentages	   of	   CD8+	   TNF-­‐α	   producing	   T	   cells	   specific	   for	   the	  HHV6B	   antigens	  
tested	   in	   all	   donors	   analysed	   are	   shown	   in	   Table	   3.3.	   	   Again,	   as	   seen	   for	   IFN-­‐γ,	  
responses	  were	  very	   low	   in	  all	  donors.	   	  Overall,	  using	   the	  0.02%	  cut	  off	  criteria	  20	  
donors	   were	   found	   to	   have	   responses	   directed	   against	   HHV6B	   antigens.	   	   For	  
example,	   donor	   HD02	   responded	   to	   U54	   and	   U90	   (0.06%	   and	   0.12%	   respectively,	  
with	   a	   background	   of	   0.02%),	   and	   donor	   HD13	   responded	   U90	   (0.14%,	   with	   a	  
background	   of	   0.08%).	   	   The	   mean	   frequency	   of	   CD8+	   T	   cells	   producing	   TNF-­‐α	   in	  
response	  to	  U11	  was	  0.007%	  of	  total	  CD8+	  T	  cells	  in	  peripheral	  blood,	  with	  maximum	  
response	   of	   0.04%.	   	   The	  mean	   frequency	   against	   U39	  was	   0.01%	   of	   total	   CD8+	   T	  
cells,	   with	   a	  maximum	   response	   of	   0.07%.	   	   The	  mean	   frequency	   against	   U54	  was	  
0.02%	  of	  total	  CD8+	  T	  cells,	  with	  a	  maximum	  response	  of	  0.08%.	  	  Finally,	  the	  mean	  
frequency	  against	  U90	  was	  0.04%	  of	  total	  CD8+	  T	  cells,	  with	  a	  maximum	  response	  of	  
0.19%	   (Figure	   3.6).	   	   Although	   U90	   was	   the	   highest	   response	   of	   HHV6B	   antigen,	  
however	  the	  difference	  for	  both	  U90	  and	  U54	  were	  significant	  when	  compared	  with	  
the	   negative	   control	   (Figure	   3.6B).	   	   This	   was	   in	   direct	   contrast	   to	   responses	  
detectable	   against	   HCMV,	   for	   example	   against	   IE1	   responses	   ranged	   from	   0.03	   to	  
8%.	   	   (Full	   data	   for	   all	   donors	   tested	   is	   shown	   in	   Appendix	   Table	  8.3).	   	   The	  means	  
frequencies	  detected	  against	  the	  HCMV	  antigens	  are	  shown	  in	  Figure	  3.6.	  	  Overall,	  as	  
analysed	  by	  ICS	  for	  TNF-­‐α	  production,	  20%	  of	  donors	  responded	  to	  HHV6B	  U11,	  	  40%	  
to	  	  U39,	  30%	  to	  U54	  and	  50%	  to	  U90	  (Figure	  3.9	  and	  Table	  3.5).	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Table	  3.3	  Total	  data	  for	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  
and	  U90	  in	  30	  donors	  analysed	  ex-­‐vivo	  by	  intracellular	  cytokine	  staining	  for	  TNF-­‐α*	  
 
Donor	   U11	   U39	   U54	   U90	   Neg**	   Pos***	  
HD01	   0.04	   0.05	   0.09	   0.04	   0.03	   4.48	  
HD02	   0.02	   0.02	   0.06	   0.12	   0.02	   2.68	  
HD03	   0.06	   0.05	   0.11	   0.12	   0.03	   6.65	  
HD04	   0.04	   0.04	   0.09	   0.02	   0.06	   2.75	  
HD05	   0.03	   0.05	   0.04	   0.22	   0.03	   5.14	  
HD06	   0.06	   0.11	   0.03	   0.09	   0.06	   4.86	  
HD07	   0.09	   0.12	   0.13	   0.12	   0.06	   3.77	  
HD08	   0.07	   0.05	   0.10	   0.11	   0.07	   3.37	  
HD09	   0.02	   0.05	   0.06	   0.16	   0.02	   0.73	  
HD10	   0.05	   0.05	   0.05	   0.04	   0.05	   1.50	  
HD11	   0.06	   0.04	   0.02	   0.11	   0.02	   1.14	  
HD12	   0.03	   0.02	   0.06	   0.04	   0.03	   4.25	  
HD13	   0.08	   0.08	   0.08	   0.14	   0.08	   1.64	  
HD14	   0.08	   0.08	   0.06	   0.09	   0.05	   1.21	  
HD15	   0.06	   0.06	   0.08	   0.07	   0.06	   1.56	  
HD16	   0.01	   0.02	   0.02	   0.01	   0.03	   0.35	  
HD17	   0.07	   0.02	   0.05	   0.00	   0.09	   0.28	  
HD18	   0.03	   0.06	   0.07	   0.20	   0.07	   2.70	  
HD19	   0.02	   0.01	   0.02	   0.04	   0.02	   1.57	  
HD20	   0.02	   0.08	   0.10	   0.12	   0.07	   3.85	  
HD21	   0.02	   0.02	   0.03	   0.03	   0.03	   1.33	  
HD22	   0.02	   0.03	   0.03	   0.02	   0.01	   1.25	  
HD23	   0.02	   0.01	   0.02	   0.02	   0.02	   0.19	  
HD24	   0.04	   0.04	   0.00	   0.04	   0.02	   0.86	  
HD25	   0.03	   0.02	   0.01	   0.02	   0.03	   2.20	  
HD26	   0.03	   0.04	   0.03	   0.02	   0.02	   0.16	  
HD27	   0.02	   0.03	   0.01	   0.00	   0.04	   0.29	  
HD28	   0.02	   0.04	   0.01	   0.02	   0.03	   2.17	  
HD29	   0.02	   0.01	   0.02	   0.02	   0.02	   2.45	  
HD30	   0.03	   0.02	   0.04	   0.03	   0.00	   1.48	  
Total	  =	  20	   6	   9	   12	   15	   	   	  
*Values	  indicated	  are	  the	  percentage	  of	  CD8+	  T	  cells	  producing	  TNF-­‐α.	  	  
**Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	   ***Stimulated	  
with	  Concanavalin	  A	  served	  as	  a	  positive	  control.	  	  Numbers	  in	  the	  final	  
row	  indicate	  numbers	  of	  positive	  donors.	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Figure	  3.6	  Overall	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  
and	  HCMV	  antigens	  IE1,	  IE2,	  pp65	  and	  gB	  analysed	  ex-­‐vivo	  by	  intracellular	  cytokine	  
staining	  for	  TNF-­‐α 	  
(A)	  Summary	  of	  the	  donor	  data	  for	  ICS	  analysis	  of	  CD8+	  TNF-­‐α+	  responses	  to	  HHV6B	  
antigens	  U11,	  U39,	  U54	  and	  U90	  (n=30),	  HCMV	  antigens	  IE1,	  IE2,	  pp65	  and	  gB	  (n=17)	  
and	   –ve	   control	   (n=30).	   	   The	   results	   are	   expressed	   as	   mean	   value	   of	   CD8+	   cells	  
producing	  TNF-­‐α ±	  SEM	   (error	  bars).	   	  Unstimulated	  PBMC	  were	  used	  as	  a	  negative	  
control	  (-­‐ve)	  and	  stimulated	  with	  Concanavalin	  A	  as	  a	  positive	  control	  (+ve).	  	  (B)	  The	  
data	  presented	  in	  figure	  A	  for	  HHV6B	  is	  shown	  here	  on	  its	  own	  to	  expand	  the	  y-­‐axis.	  	  
Statistical	   differences	   (**p<0.008	   and	   *p<0.05)	   between	   different	   groups	   were	  
calculated	  by	  Wilcoxon	  test.	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3.1.3	  Detection	  of	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  
by	  CFSE	  proliferation	  assays	  
Since	  it	  was	  clear	  that	  the	  responses	  detected	  by	  ICS	  for	  both	  IFN-­‐γ	  and	  TNF-­‐α	  were	  
very	   weak,	   CFSE	   proliferation	   assays	   were	   used	   to	   investigate	   if	   HHV6B	   antigen	  
induced	  cell	  proliferation	  was	  more	  readily	  detectable.	   	  Eleven	  donors	  were	  tested	  
for	  CD8+	  proliferation	   in	  response	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90.	   	  An	  
example	  of	  a	  CSFE	  proliferation	  assay	  for	  donor	  HD09	  is	  shown	  in	  Figure	  3.7.	  	  Values	  
indicated	  in	  upper	  left	  quadrants	  denote	  the	  percentage	  of	  proliferated	  CD8+	  T	  cells	  
out	  of	  total	  CD8+	  T	  cells.	  	  A	  positive	  result	  in	  this	  study	  was	  considered	  as	  a	  value	  of	  
at	   least	   0.5%	   above	   the	   negative	   control	   value	   (ProImmune,	   2014).	   	   Overall	  
responses	  detected	  in	  donor	  HD09	  were	  very	  low,	  ranging	  from	  0.65%	  for	  U11,	  0.7%	  
for	  U39,	   0.82%	   for	  U54	   to	   2.47%	   for	  U90.	   	   The	  background	   level	   for	   unstimulated	  
PBMC	  was	  0.47%,	  and	  based	  on	  the	  criteria	  stated	  above	  only	  the	  response	  to	  U90	  
was	  considered	  positive.	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Figure	  3.7	  Analysis	  of	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  
U90	  in	  donor	  HD09	  ex-­‐vivo	  by	  CFSE	  proliferation	  assay 
PBMC	  were	  isolated	  from	  donor	  HD09	  and	  2x10
6
	  were	  labelled	  with	  5µM	  of	  CFSE	  for	  
10	  minutes	   at	   37°C	   then	   stimulated	  with	  HHV6B	  whole	   antigen	  pepmixes	   for	  U11,	  
U39,	  U54	  and	  U90	  for	  7	  days	  then	  labelled	  with	  anti-­‐CD8+	  for	  20	  minutes	  on	  ice	  and	  
analysed	  on	  a	  flow	  cytometry.	   	  PBMC	  were	  stimulated	  with	  Concanavalin	  A	  (Con	  A)	  
as	   a	   positive	   control.	   	   Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	   Values	  
indicated	  in	  upper	  left	  quadrants	  denote	  the	  percentage	  of	  proliferated	  CD8+	  T	  cells	  
out	  of	  total	  CD8+	  T	  cells.	  	  Data	  was	  collected	  on	  a	  BD	  FACSCalibur	  and	  analysed	  using	  
FlowJo	  software	  (Treestar). 
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A	  further	  10	  donors	  were	  analysed	   in	  this	  way,	  and	  the	  percentages	  of	  CD8+	  T	  cell	  
proliferation	  responses	  to	  HHV6B	  antigens	  tested	  in	  all	  donors	  analysed	  are	  shown	  in	  
Table	   3.4.	   	   Overall,	   using	   the	   0.5%	   cut	   off	   criteria	   5	   donors	   were	   found	   to	   have	  
responses	  directed	  against	  HHV6B	  antigens.	  	  Table	  3.5	  in	  section	  3.1.4	  shows	  which	  
donors	  were	  positive	  and	  what	  antigens	  they	  responded	  to.	  	  However,	  in	  general,	  as	  
seen	   in	   Figure	  3.7	   for	  donor	  HD09,	   responses	  were	   very	   low.	   	   For	  example,	  donor	  
HD02	  responded	  U54	  and	  U90	  (2.36%	  and	  3.59%	  respectively,	  with	  a	  background	  of	  
1.7%).	  	  The	  mean	  frequency	  of	  proliferated	  CD8+	  T	  cells	  in	  response	  to	  HHV6B	  U11	  
was	   0.09%	   of	   total	   CD8+	   T	   cells	   in	   peripheral	   blood,	   with	   maximum	   response	   of	  
0.51%.	   	   The	  mean	   frequency	   against	   U39	  was	   0.09%	   of	   total	   CD8+	   T	   cells,	   with	   a	  
maximum	  response	  of	  1.3%.	   	   The	  mean	   frequency	  against	  U54	  was	  0.36%	  of	   total	  
CD8+	   T	   cells,	   with	   a	   maximum	   response	   of	   0.66%.	   	   Finally,	   the	   mean	   frequency	  
against	  U90	  was	  0.45%	  %	  of	  total	  CD8+	  T	  cells,	  with	  a	  maximum	  response	  of	  1.89%.	  	  
(Figure	   3.8A).	   	   This	   was	   in	   direct	   contrast	   to	   responses	   detectable	   against	   the	  
positeve	   control,	  which	   ranged	   from	   37.3	   to	   80.9%.	   	   Overall,	   as	   analysed	   by	   CFSE	  
proliferation	  assay,	  9%	  of	  donors	  responded	  to	  HHV6B	  U11,	  	  9%	  to	  	  U39,	  36%	  to	  U54	  
and	  27%	  to	  U90	  (Figure	  3.9).	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Table	  3.4	  Total	  data	  for	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  
and	  U90	  in	  11	  donors	  analysed	  ex-­‐vivo	  by	  CFSE	  proliferation	  assay*	  
 
Donor	   U11	   U39	   U54	   U90	   Neg**	   Pos***	  
HD01	   1.55	   2.80	   2.00	   1.94	   1.5	   60.5	  
HD02	   1.33	   1.49	   2.36	   3.59	   1.7	   70.7	  
HD03	   2.18	   2.07	   2.19	   2.37	   1.67	   78.8	  
HD07	   0.06	   0.08	   0.11	   0.11	   0.09	   73.30	  
HD09	   0.65	   0.70	   0.82	   2.47	   0.47	   62.50	  
HD14	   1.03	   0.95	   1.19	   1.08	   0.75	   80.90	  
HD16	   2.75	   2.32	   3.06	   2.29	   2.45	   45.1	  
HD17	   0.59	   1.05	   1.43	   0.65	   1.17	   54.7	  
HD18	   0.63	   0.60	   0.65	   0.51	   0.99	   45.7	  
HD19	   1.08	   1.49	   1.30	   1.38	   1.28	   37.3	  
HD21	   4.62	   4.31	   4.25	   4.77	   4.99	   61.4	  
Total	  =	  5	   1	   1	   4	   3	   	   	  
*Values	   indicated	   are	   the	   percentage	   of	   proliferated	   CD8+	   T	   cells.	  	  
**Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	   ***Stimulated	  
with	  Concanavalin	  A	  served	  as	  a	  positive	  control.	  	  Numbers	  in	  the	  final	  
row	  indicate	  numbers	  of	  positive	  donors.	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Figure	  3.8	  Summary	  of	  CD8+	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  
U90	  in	  11	  donors	  analysed	  ex-­‐vivo	  by	  CFSE	  proliferation	  assay	  
 
A	  total	  of	  11	  donors	  were	  analysed	  by	  CFSE	  proliferation	  assay	  for:	  HHV6B	  antigens	  
U11,	  U39,	  U54	   and	  U90.	   	  The	   results	   are	   expressed	   as	  mean	   value	   of	   proliferated	  
CD8+	  T	  cells	  ±	  SEM	  after	  subtract	   the	  negative	  control	   from	  the	   individual	   reading.	  	  
Unstimulated	  PBMC	  were	  used	  as	  a	  negative	  control.	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were$ used$ as$ a$ nega2ve$ control$ (Zve)$ and$ s2mulated$ with$ Concanavalin$ A$ as$ a$
posi2ve$ control$ (+ve).$ (B)$ The$ pie$ chart$ illustrates$ the$ percentage$ of$ donors$
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3.1.4	  Summary	  of	  CD8+	  T	  cell	  responses	  to	  HHV6B	  detected	  ex-­‐vivo	  in	  PBMC	  
A	  complete	  summary	  of	  the	  ex-­‐vivo	  CD8+	  responses	  against	  U11,	  U39,	  U54	  and	  U90	  
as	  detected	  by	  ICS	  (for	  IFN-­‐γ	  and	  TNF-­‐α)	  and	  CSFE	  staining	  are	  shown	  in	  Table	  3.5.	  	  As	  
stated,	  ex-­‐vivo	  responses	  detected	  against	  the	  HHV6B	  antigens	  tested	  in	  this	  chapter	  
were	   very	  weak.	   	  Despite	   this,	   the	   following	   conclusion	   could	  be	  made.	   	  Using	   ICS	  
and	   detection	   of	   IFN-­‐γ	   production,	   a	   total	   of	   thirteen	   donors	   (43%)	   responded	   to	  
HHV6B	  antigens,	  as	  follows:	  	  four	  donors	  (HD10,	  HD11,	  HD13	  and	  HD14)	  responded	  
to	  U11;	  three	  donors	  (HD10,	  HD11	  and	  HD14)	  responded	  to	  U39;	  nine	  donors	  (HD01,	  
HD02,	  HD09,	  HD10,	  HD11,	  HD12,	  HD13,	  HD14	  and	  HD26)	  responded	  to	  U54	  and	  ten	  
donors	   (HD02,	   HD05,	   HD08,	   HD09,	   HD10,	   HD11,	   HD12,	   HD13,	   HD14,	   HD20	   and	  
HD30)	   responded	   to	  U90.	   	  Using	   ICS	   and	  detection	  of	   TNF-­‐α production	   a	   total	   of	  
twenty	   donors	   (67%)	   responded	   to	   HHV6B	   antigens	   as	   follows:	   six	   donors	   (HD03,	  
HD07,	  HD11,	  HD14,	  HD24	  and	  HD30).	  	  responded	  to	  U11;	  nine	  donors	  (HD01,	  HD03,	  
HD05,	  HD06,	  HD07,	  HD09,	  HD11,	  HD14	  and	  HD28)	  responded	  to	  U39;	  twelve	  donors	  
(HD01,	  HD02,	  HD03,	  HD04,	  HD07,	  HD08,	  HD09,	  HD12,	  HD15,	  HD20,	  HD29	  and	  HD30)	  
respond	  to	  U54	  and	  fifteen	  donors	   (HD02,	  HD03,	  HD05,	  HD06,	  HD07,	  HD08,	  HD09,	  
HD11,	  HD13,	  HD14,	  HD18,	  HD19,	  HD20,	  HD29	  and	  HD30)	  responding	  to	  U90.	  	  When	  
the	  percentage	  of	  donors	  responding	  via	  IFN-­‐γ	  or	  TNF-­‐α	  is	  compared,	  although	  more	  
donors	  responded	  based	  on	  TNF-­‐α	  measurement,	  the	  overall	  hierarchy	   is	  generally	  
similar.	   	  Based	  on	  IFN-­‐γ	  production,	  33%	  of	  donors	  responded	  to	  U90,	  30%	  to	  U54,	  
13%	  to	  U11	  and	  10%	  to	  U39.	   	  Whereas,	  based	  on	  TNF-­‐α production	  50%	  of	  donors	  
responded	  to	  U90,	  40%	  to	  U54,	  30%	  to	  U39	  and	  20%	  to	  U11	  (Figure	  3.9).	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With	   U90	   being	   the	   most	   immunogenic	   for	   both	   secretion	   of	   IFN-­‐γ	   and	   TNF-­‐α,	  
followed	  by	  U54.	  	  For	  IFN-­‐γ,	  this	  is	  followed	  by	  U11	  and	  U39,	  whereas	  this	  is	  reversed	  
for	  TNF-­‐α.	  	  	  
Using	   CFSE	   proliferation	   assay	   five	   out	   of	   eleven	   donors	   (45%)	   responded	   to	   the	  
antignens	  tested,	  generally	  agreeing	  with	  the	  data	  for	  ICS.	  	  Although	  the	  number	  of	  
donors	  tested	  was	  small,	  using	  this	  assay	  U54	  was	  the	  most	  immunogenic	  with	  four	  
donors	   (36%)	   responding	   (HD01,	  HD02,	  HD03	  and	  HD16),	  with	   three	  donors	   (27%)	  
responding	  to	  U90	  (HD02,	  HD03	  and	  HD09),	  and	  one	  donor	  (9%)	  responding	  to	  U11	  
(HD03)	  and	  one	  donor	  (9%)	  to	  U39	  (HD01).	   	   In	  general	  agreeing	  with	  the	  hierarchy	  
determined	  using	  ICS	  (Figure	  3.9).	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Table	  3.5	  Summary	  of	  24	  positive	  CD8+	  T	  cell	  responses	  to	  HHV6B	  detected	  ex-­‐vivo	  
in	  PBMC	  
 
Donor	   IFN-­‐γ 	  	   TNF-­‐α 	   Proliferation	  
HD01	   U54	   U39	  and	  U54	   U39	  and	  U54	  
HD02	   U54	  and	  U90	   U54	  and	  U90	   U54	  and	  U90	  
HD03	   NR*	   All	  antigens	   U11,	  U54	  and	  U90	  
HD04	   NR	   U54	   NT**	  
HD05	   U90	   U39	  and	  U90	   NT	  
HD06	   NR	   U39	  and	  U90	   NT	  
HD07	   NR	   All	  antigens	   NR	  
HD08	   U90	   U54	  and	  U90	   NT	  
HD09	   U54	  and	  U90	   U39,	  U54	  and	  U90	   U90	  
HD10	   All	  antigens	   NR	   NT	  
HD11	   All	  antigens	   U11,	  U39	  and	  U90	   NT	  
HD12	   U54	   U54	   NT	  
HD13	   U11,	  U54	  and	  U90	   U90	   NT	  
HD14	   All	  antigens	   U11,	  U39	  and	  U90	   NR	  
HD15	   NR	   U54	   NT	  
HD16	   NR	   NR	   U54	  
HD17	   NR	   NR	   NR	  
HD18	   NR	   U90	   NR	  
HD19	   NR	   U90	   NR	  
HD20	   U90	   U54	  and	  U90	   NT	  
HD21	   NR	   NR	   NR	  
HD22	   NR	   NR	   NT	  
HD23	   NR	   NR	   NT	  
HD24	   NR	   U11	   NT	  
HD25	   NR	   NR	   NT	  
HD26	   U54	   NR	   NT	  
HD27	   NR	   NR	   NT	  
HD28	   NR	   U39	   NT	  
HD29	   NR	   U54	  and	  U90	   NT	  
HD30	   U90	   U11,	  U54	  and	  U90	   NT	  
Total	   13/30	   20/30	   5/11	  








Figure	  3.9	  Percentage	  of	  donors	  responding	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  
U90	  analysed	  ex-­‐vivo	  by	  intracellular	  cytokine	  staining	  for	  CD8+	   IFN-­‐γ+ 	  or	  TNF-­‐α+	  
cells	  and	  by	  CFSE	  proliferation	  assay 
	   
A	  total	  of	  30	  donors	  were	  analysed	  ex-­‐vivo	  by	  ICS	  for	  HHV6B	  antigens	  U11,	  U39,	  U54	  
and	   U90	   and	   11	   donors	   analysed	   ex-­‐vivo	   by	   CFSE	   proliferation	   assay.	   	   The	   chart	  
illustrates	   the	   percentage	   of	   donors	   responding	   to	   each	   HHV6B	   antigen	   tested	   for	  
CD8+	  IFN-­‐γ+,	  TNF-­‐α+	  or	  reduced	  CFSE	  staining.	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3.2	  Summary	  	  
These	  studies	  to	  detect	  HHV6B	  T	  cell	  responses	  ex-­‐vivo	  revealed	  that,	  in	  comparison	  
to	  HCMV,	  responses	  were	  in	  general	  very	  weak	  or	  undetectable.	  	  Using	  ICS	  (for	  both	  
IFN-­‐γ	  and	  TNF-­‐α)	  and	  CSFE	  proliferation	  assays	  values	   for	  HHV6B-­‐specific	  T	   cells	   in	  
PBMC	  ranged	  from	  0.02-­‐0.2%.	  	  CD8+	  T	  cell	  responses	  were	  detected	  against	  all	  the	  
antigens	  tested,	  with	  U54	  and	  U90	  being	  the	  most	  immunogenic.	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4.	  	  In-­‐vitro	  expansion	  and	  analysis	  of	  T	  cell	  responses	  to	  
HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  in	  a	  panel	  of	  healthy	  
donors	  	  	  
Attempts	   to	   characterise	   CD8+	   T	   cell	   responses	   specific	   for	   HHV6B	   antigens	   U11,	  
U39,	   U54	   and	   U90	   directly	   ex-­‐vivo	   using	   both	   ICS	   and	   CSFE	   staining	   showed	   that	  
responses	  were	  present,	  but	  that	  they	  were	  at	  a	  very	  low	  frequency	  (less	  than	  0.2%	  
of	  CD8	  T	  cells).	  	  Therefore,	  to	  maximise	  the	  ability	  to	  detect	  HHV6B	  antigen-­‐specific	  T	  
cells	   and	   obtain	   a	   better	   understanding	   of	   the	   immunogenicity	   of	   the	   4	   antigens	  
being	  studied,	  a	  short-­‐term	   in-­‐vitro	  reactivation	  protocol	  was	  utilised	  to	  generate	  a	  
polyclonal	  culture	  enriched	  with	  HHV6B-­‐specific	  T	  cells.	  	  The	  experimental	  approach	  
is	  outlined	  in	  Figure	  4.1.	  	  PBMC	  were	  stimulated	  with	  pepmixes	  representing	  either	  
U11,	  U39,	  U54	  and	  U90,	  and	  cultures	  were	  maintained	  for	  10	  days	  at	  37°C,	  with	  IL2	  
being	  added	  to	  cultures	  from	  day	  3.	  	  Polyclonal	  cultures	  were	  then	  analysed	  in	  two	  
ways.	  	  Firstly,	  T	  cell	  responses	  to	  individual	  HHV6B	  antigens	  were	  analysed	  by	  IFN-­‐γ	  
ELISpot.	   	   Secondly,	   the	   expanded	  HHV6B-­‐specific	   T	   cell	   culture	  were	   characterised	  
for	  the	  percentage	  of	  CD4+	  and	  CD8+	  T	  cells	  by	  flow	  cytometry.	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Figure	   4.1	   Flowchart	   showing	   the	   approach	   used	   for	   short-­‐term	   in-­‐vitro	  
reactivation	  of	  HHV6B-­‐specific	  T	  cells.	  
PBMC	  were	   stimulated	  with	  pepmixes	   representing	  HHV6B	  U11,	  U39,	  U54	  or	  U90,	  
and	  cultured	  for	  10	  days	  at	  37°C,	  with	  addition	  of	  IL2	  after	  day	  3.	  	  After	  10	  days	  the	  
polyclonal	   HHV6B	  enriched	   antigen-­‐specific	   T	   cells	  were	   (A)	   analysed	   for	   HHV6B	   T	  
cells	  responses	  by	  IFN-­‐γ	  ELISpot	  after	  simulation	  with	  the	  individual	  U11,	  U39,	  U54	  or	  
U90	  pepmixes,	  or	  (B)	  or	  anaylsed	  by	  flow	  cytometry	  to	  determine	  the	  percentage	  of	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4.1	   IFN-­‐γ	   ELISpot	   analysis	   of	   T	   cell	   responses	   after	   short-­‐term	   	   in-­‐vitro	  
stimulation	  of	  donor	  PBMC	  with	  individual	  antigen	  pepmixes	  	  
The	  work	  in	  this	  section	  has	  focused	  on	  utilising	  a	  short-­‐term	  in-­‐vitro	  stimulation	  step	  
to	   attempt	   to	   enhance	   detection	   of	   HHV6B	   T	   cell	   responses.	   	  After	   stimulation	   of	  
PBMC	  for	  10	  days	  with	  individual	  pepmixes,	  polyclonal	  cultures	  were	  then	  stimulated	  
overnight	  with	  the	  same	  individual	  pepmixes	  before	  being	  analysed	  by	  IFN-­‐γ	  ELISpot.	  	  
Throughout	  this	  chapter	  data	   is	  presented	  as	   IFN-­‐γ	  spot	   forming	  cells	   (SFC)	  per	  105	  
cells.	   	   In	   the	   ELISpot	   ConA	   stimulated	   PBMC	   was	   used	   as	   a	   positive	   control	  
throughout,	   and	   as	   a	   negative	   control	   cells	   were	   stimulated	   with	   an	   irrelevant	  
pepmix	   corresponding	   to	   the	  VP1	  antigen	   from	  BK	   virus.	   	  A	   positive	   ELISpot	   result	  
was	  considered	  as	  a	  value	  equal	  to	  or	  greater	  than	  10	  SFCs	  per	  105	  cells	  above	  the	  
negative	  control	  value	  (Boritz	  et	  al.,	  2004).	   	  Before	  using	  this	  method	  to	  investigate	  
HHV6B	  responses,	  to	  validate	  the	  approach	  similar	  experiments	  were	  undertaken	  to	  
analyse	  responses	  to	  known	  HCMV	  immunogenic	  antigens.	  	  	  
4.1.1	  Analysis	  of	  HCMV-­‐specific	  T	  cell	  responses	  by	  ELISpot	  after	  10-­‐day	  in-­‐vitro	  
stimulation.	  
These	   validation	   experiments	  were	   carried	   out	   using	   both	   sero-­‐positive	   and	   sero–
negative	   HCMV	   donors,	   and	   pepmixes	   representing	   four	   immunogenenic	   HCMV	  
antigens,	  namely	  IE1,	   IE2,	  pp65	  and	  gB	  (Khan,	  2007).	   	  The	  first	  donor	  analysed	  was	  
HD15,	  an	  HCMV	  sero-­‐positive	  donor	  with	  an	  HLA	  type	  A1,	  A2,	  B7,	  and	  B44,	  so	  would	  
be	   expected	   to	   have	   T	   cells	   specific	   to	   the	   pp65	   HLA-­‐A2	   restricted	   peptide	  
NLVPMVATV	   (NLV,	   aa495-­‐503)	   and	   pp65	   HLA-­‐B7	   restricted	   peptide	   TPRVTGGGAM	  
(TPR,	  aa417-­‐426)	  (Wills	  et	  al.,	  1996a).	  	  The	  base	  line	  level	  of	  T	  cells	  specific	  for	  NLV	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and	  TPR	  peptides	  were	  measured	  by	  IFN-­‐γ	  ELISpot.	  	  HD15	  had	  a	  low,	  but	  detectable	  
response	  to	  NLV	  and	  TPR	  of	  4	  and	  8	  SFC/105	  PBMC,	  respectively	  (Figure	  4.2A).	  	  PBMC	  
from	  this	  donor	  where	  then	  stimulated	  with	  pp65	  pepmix	  for	  10	  days,	  with	  addition	  
of	  IL2	  from	  day	  3.	  	  The	  expanded	  pool	  of	  polyclonal	  T	  cells	  were	  then	  assayed	  by	  IFN-­‐
γ	  ELISpot,	  using	  the	  NLV	  and	  TPR	  peptides	  as	  the	  stimulatory.	  	  There	  was	  a	  significant	  
enrichment	   of	   NLV	   and	   TPR	   -­‐specific	   T	   cells	   to	   120	   and	   147	   SFCs/105	   T	   cells,	  
respectively	  and	  DMSO	  gave	  62	  SFCs/105	  T	  cells	  (Figure	  4.2B).	  
This	  donor	  was	  also	  shown	  to	  have	  a	  weak	  but	  detectable	  response	  to	  IE2	  of	  0.02%	  
of	  both	  CD4	  and	  CD8	  T	  cells,	  as	  measured	  previously	  using	  IFN-­‐γ	   ICS.	  	  The	  base	  line	  
levels	  of	  T	  cells	  specific	  for	  HCMV	  IE2	  were	  measured	  by	  IFN-­‐γ	  ELISpot,	  using	  an	  IE2	  
pepmix	  as	  the	  stimulatory	  peptides.	  	  The	  results	  in	  Figure	  4.3A,	  show	  that	  HD15	  has	  
a	  low,	  but	  detectable	  response	  to	  IE2	  of	  13	  SFC/105	  PBMC,	  generally	  corresponding	  
to	   the	   levels	   of	   IE2-­‐specific	   T	   cells	   measured	   previously	   using	   IFN-­‐γ	   ICS	   (0.02%).	  	  
PBMC	   from	   this	   donor	   where	   then	   stimulated	   with	   IE2	   pepmix	   for	   10	   days,	   with	  
addition	  of	  IL2	  from	  day	  3.	  	  The	  expand	  pool	  of	  polyclonal	  T	  cells	  were	  then	  assayed	  
by	   IFN-­‐γ	   ELISpot,	   using	   the	   IE2	   pepmix	   as	   the	   stimulatory	   peptides.	   	   There	   was	   a	  
significant	  enrichment	  of	  IE2-­‐specific	  T	  cells	  to	  400	  SFCs/105	  input	  cells,	  which	  after	  
subtraction	   of	   the	   DMSO	   negative	   controls	   reflected	   a	   26-­‐fold	   expansion	   in	   IE2-­‐
specific	  IFNγ-­‐positive	  T	  cells	  	  (Figure	  4.3B).	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Figure	   4.2	   An	   in-­‐vitro	   stimulation	   step	   can	   successfully	   expanded	   HCMV-­‐pp65	  
specific	  T	  cells	  in	  CMV	  positive	  donor	  HD15	  
	  
(A)	  The	  chart	  illustrates	  the	  base	  level	  of	  T	  cell	  responses,	  PBMC	  were	  isolated	  from	  
donor	  HD15	   and	   1x105	  were	   stimulated	  with	  HCMV-­‐NLV	   and	   -­‐TPR	   peptides	   for	   16	  
hours,	  before	  being	  analysed	  for	  production	  of	   IFN-­‐γ	  by	  ELISpot	  (B)	  PBMC	  from	  the	  
same	  donor	  were	  cultured	  for	  10	  days	  in	  the	  presence	  of	  HCMV-­‐pp65	  antigen	  and	  T	  
cells	  expression	  of	  IFN-­‐γ	  were	  determined	  by	  ELISpot	  using	  the	  NLV	  and	  TPR	  peptides	  
as	  the	  stimulatory.	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Figure	  4.3	  An	  in-­‐vitro	  stimulation	  step	  can	  successfully	  expanded	  HCMV-­‐IE2	  specific	  
T	  cells	  in	  HCMV	  sero-­‐positive	  donor	  HD15	  
 
(A)	  The	  base	  line	  levels	  of	  T	  cell	  responses	  to	  IE2	  were	  measured	  by	  direct	  analysis	  of	  
PBMC	  via	   IFN-­‐γ ELISpot	  using	  HCMV	   IE2	  whole	  antigen	  pepmix.	   	  (B)	  PBMC	  from	  the	  
same	  donor	  were	   than	   cultured	   for	   10	  days	   in	   the	  presence	  of	  HCMV-­‐IE2	  antigen,	  
and	   IL2	   from	   day	   3,	   the	   ELISpot	   repeated	   using	   this	   HCMV	   IE2	   enriched	   T	   cell	  
population.	   	  PBMC	  and	  the	  enriched	  cell	  population	  were	  pulsed	  with	  DMSO	  as	  the	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To	  ensure	  that	  this	  approach	  was	  specific	  for	  reactivation	  of	  memory	  HCMV-­‐specific	  
T	   cells,	   these	   experiments	   were	   repeated	   using	   the	   four	   HCMV	   antigen	   pepmixes	  
(IE1,	   IE2,	  pp65	  and	  gB)	   and	   four	  HCMV	  sero-­‐negative	  donors,	   along	  with	  a	   further	  
two	  sero-­‐positive	  donors.	  	  After	  stimulation	  of	  PBMC	  for	  10	  days	  with	  HCMV	  IE1,	  IE2,	  
pp65	  and	  gB	  pepmixes,	  polyclonal	   cultures	  were	   then	  assayed	  by	   IFN-­‐γ	  ELISpot	   for	  
antigen-­‐specific	   T	   cells,	   using	   the	   pepmixes	   as	   stimulus.	   	   For	   both	   sero-­‐positive	  
donors	   (HD24	   &	   HD32),	   there	   were	   significant	   levels	   of	   HCMV-­‐specific	   T	   cells	  
detected	  against	  all	  four	  antigens.	   	  For	  donor	  HD24	  responses	  ranged	  from	  54	  SFCs	  
per	  105	  cells	  for	  IE2,	  to	  62	  SFCs	  per	  105	  cells	  for	  pp65,	  to	  68	  SFCs	  per	  105	  cells	  for	  gB	  
and	  330	  SFCs	  per	  105	  cells	  for	  IE1.	  	  HD32	  had	  a	  detectable	  responses	  as	  follows:	  IE1	  
58	  SFCs	  per	  105	  cells,	  IE2	  246	  SFCs	  per	  105	  cells,	  pp65	  244	  SFCs	  per	  105	  cells,	  and	  gB	  
46	  SFCs	  per	  105	  cells	  (Figure	  4.4).	  	  The	  base	  line	  level	  of	  HCMV	  antigen-­‐specific	  T	  cells	  
was	  not	  measured	  by	  ELISpot	  for	  these	  donors.	  	  Data	  was	  available	  from	  ICS	  staining	  
(see	  Appendix	  Table	  8.2),	  which	  indicated	  that	  donor	  HD24	  had	  detectable	  responses	  
to	  IE1	  (0.31%)	  and	  pp65	  (1.92%).	  	  Whereas,	  donor	  HD32	  had	  detectable	  responses	  to	  
pp65	  (0.28%)	  and	  IE2	  (0.57%).	  	  Thus,	  again	  there	  was	  significant	  expansion	  of	  HCMV-­‐
specific	   T	   cells	   in	   these	   donors	   after	   the	   short-­‐term	   stimulation	   with	   individual	  
pepmixes.	   	   A	   total	   of	   4	   HCMV	   sero-­‐negative	   donors	   were	   screened,	   and	  
representative	   examples	   from	   donors	   HD18	   and	   HD56	   are	   shown	   in	   Figure	   4.4.	  	  
Importantly,	   no	  HCMV-­‐specific	   T	   cells	  were	   detectable	   in	   any	   of	   the	   sero-­‐negative	  
donors	  tested	  (Table	  4.1).	  	  Thus,	  this	  approach	  was	  thought	  to	  be	  suitable	  to	  expand	  
T	   cells	   specific	   for	  HHV6B,	   and	   that	   this	  would	   represent	  memory	   response	   rather	  
than	  primary	  responses.	  




Figure	  4.4	  ELISpot	  analysis	  of	  the	  frequency	  of	  T	  cell	  response	  to	  HCMV	  antigens	  in	  
HCMV-­‐sero-­‐positive	   and	   sero-­‐negative	   donors	   after	   a	   short	   term	   in-­‐vitro	  
reactivation	  
 
PBMC	  were	  cultured	  for	  10	  days	  in	  the	  presence	  of	  either	  HCMV	  IE1,	  IE2,	  pp65	  and	  
gB	  pepmixes,	  with	  IL2	  added	  from	  day	  3,	  and	  the	  frequency	  of	  antigen	  specific	  T	  cells	  
expressing	   IFN-­‐γ	  were	   determined	   by	  ELISpot.	   	  Donors	  HD24	  and	  HD32	  are	  HCMV	  
sero-­‐positive,	   whereas	   donors	   HD18	   and	   HD56	   are	   HCMV	   sero-­‐negative.	   	   Cells	  
stimulated	  with	  an	  irrelevant	  pepmix	  corresponding	  to	  the	  VP1	  antigen	  from	  BK	  virus	  
served	  as	  a	  negative	  control	  in	  ELISpots.	  	  	  
	  



































































































































































PBMC"were" cultured" for" 10" days" in" the" presence" of" HCMV" IE1," IE2," pp65" and" gB"
anIgens"and"T"cells"expression"of" IFN2γ"were"determined"by"ELISpot."Both"healthy"
donors"HD24"and"HD32"are"CMV2seroposiIve"chart.""Both"healthy"donors"HD18"and"
HD56" are" CMV–seronegaIve" donors" chart." Cells" sImulated" with" VP1" (irrelevant"
pepmix"form"BK"Virus)"served"as"2ve"control.""
"
HD24 HD32 HD18 HD56 
HCMV"+ve HCMV"2ve 
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Table	  4.1	  Summary	  of	  T	  cell	  responses	  to	  HCMV	  antigens	  IE1,	  IE2,	  pp65	  and	  gB	  in	  8	  
donors	  analysed	  in-­‐vitro	  by	  ELIspot	  for	  IFN-­‐γ 	   
 
Donor	   CMV	  
Status	  
IE1	   IE2	   pp65	   gB	  
HD10	   -­‐	   -­‐	   NT	   -­‐	   NT	  	  
HD15	   +	   +	   +	   +	   NT	  	  
HD18	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
HD24	   +	   +	   +	   +	   +	  
HD32	   +	   +	   +	   +	   +	  
HD44	   +	   +	   +	   +	   +	  
HD53	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
HD56	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
	  	  NT=	  not	  tested	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4.1.2	  Analysis	  of	  the	  breadth	  of	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  
and	  U90	  in	  healthy	  carriers	   	  
In	  the	  previous	  section,	  a	  short	  in-­‐vitro	  stimulation	  step	  was	  shown	  to	  expand	  HCMV-­‐
specific	  T	  cell	  responses	  in	  HCMV	  sero-­‐positive	  but	  not	  sero-­‐negative	  donors.	  	  Thus,	  
this	   approach	   was	   now	   utilised	   to	   attempt	   to	   expand	   HHV6B-­‐specific	   T	   cell	  
responses,	  with	  the	  overall	  aim	  of	  determining	  the	  breadth	  of	  T	  cell	  responses	  to	  the	  
four	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90.	   	  PBMC	  were	  stimulated	   in-­‐vitro	  with	  
individual	  pepmixes	  for	  10	  days,	  with	  IL2	  being	  added	  after	  day	  3.	  	  The	  frequency	  of	  
HHV6	  antigen-­‐specific	  T	  cells	  in	  the	  expanded	  polyclonal	  T	  cell	  populations	  was	  then	  
measured	  by	   IFNγ	  ELISpot.	   	  The	   first	  donor	  analysed	  was	  HD27.	   	  PBMC	   from	  HD27	  
were	  stimulated	  with	  HHV6B	  U11,	  U39,	  U54	  and	  U90	  pepmixes	  cultured	  for	  10	  days	  
and	  the	  number	  of	  expanded	  T	  cells	  specific	  for	  the	  stimulatory	  pepmix	  determined	  
by	  IFN-­‐γ	  ELISpot	  (Figure	  4.5).	   	   IFNγ+ve	  T	  cells	  were	  detected	  against	  all	  four	  HHV6B	  
antigens,	  at	  frequencies	  ranging	  from	  94	  SFCs	  per	  105	  cells	  for	  U54	  and	  104	  SFCs	  per	  
105	  cells	  for	  U39,	  up	  to	  260	  SFCs	  per	  105	  cells	  for	  U11	  and	  286	  SFCs	  per	  105	  cells	  for	  
U90.	   	  Responses	  detected	  against	   the	   irrelevant	  VP1	  pepmix	  were	   low,	   less	   than	  5	  
SFCs	  per	  105	  cells.	  	  Based	  on	  the	  ex-­‐vivo	  analysis	  of	  PBMC	  chapter	  3,	  this	  donor	  was	  
not	   predicted	   to	   have	   any	   responses	   against	   HHV6B	   antigens	   tested	   	   (see	   earlier,	  
Table	  3.5)	  Thus,	   the	  additional	  step	  of	  a	  10-­‐day	   in-­‐vitro	  expansion	  provided	  a	  more	  
sensitive	   approach	   for	   determining	   the	   immunogenicity	   of	   the	   individual	   HHV6B	  
antigens.	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Figure	  4.5	  ELISpot	  analysis	  of	  the	  frequency	  of	  T	  cell	   response	  to	  HHV6B	  antigens	  
U11,	  U39,	  U54	  and	  U90	  in	  donor	  HD27	  after	  a	  short	  term	  in-­‐vitro	  reactivation	  
 
PBMC	  from	  donor	  HD27	  were	  stimulated	  with	  HHV6B	  pepmixes	  U11,	  U39,	  U54	  and	  
U90,	  and	  cultured	  for	  10	  days,	  in	  the	  presence	  of	  IL2	  after	  day	  3.	  	  The	  frequencies	  of	  
HHV6B	  -­‐specific	  T	  cell	  were	  then	  measured	  by	  IFN-­‐γ	  ELISpot.	   	  Results	  are	  presented	  
as	  spot-­‐forming	  cells	  (SCF)	  per	  10
5
	  T	  cells.	  	  The	  irrelevant	  pepmix,	  VP1,	  was	  used	  as	  a	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Data	  from	  three	  further	  donors,	  HD05,	  HD30	  and	  HD07,	  analysed	  by	  ELISpot	  after	  a	  
short-­‐term	  stimulation	  with	  each	  of	   the	  HHV6B	  pepmixes	  are	   shown	   in	  Figure	  4.6.	  	  
HD05	  had	  a	  detectable	  T	  cell	  response	  against	  all	  HHV6B	  antigens	  tested,	  with	  levels	  
of	  IFNγ-­‐postive	  antigen-­‐specifc	  T	  cells	  as	  follows:	  U11	  346	  SFCs	  per	  105	  cells,	  U39	  62	  
SFCs	  per	  105	  cells,	  U54	  372	  SFCs	  per	  105	  cells,	  and	  U90	  272	  SFCs	  per	  105	  cells.	  	  HD30	  
also	   had	   a	   detectable	   T	   cell	   response	   against	   all	   HHV6B	   antigens	   tested,	   although	  
generally	   lower	   than	   the	   two	   previous	   donors.	   	   Responses	   detected	  were	  U11	   98	  
SFCs	  per	  105	  cells,	  U39	  90	  SFCs	  per	  105	  cells,	  U54	  72	  SFCs	  per	  105	  cells,	  and	  U90	  96	  
SFCs	  per	  105	  cells,	  whereas,	  HD07	  had	  a	  detectable	  T	  cell	  response	  against	  only	  two	  
of	  the	  HHV6B	  antigens,	  U90	  (360	  SFCs	  per	  105	  cells)	  and	  U11	  (98	  SFCs	  per	  105	  cells).	  	  
The	   responses	   from	   elispots	   assays	   with	   these	   3	   donors	   were	   very	   high	   compare	  
with	  earlier	  data	  from	  intracellular	  staining	  and	  CFSE	  assays.	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Figure	  4.6	   Identification	  of	  T	   cell	   response	   to	  U11,	  U39,	  U54	  and	  U90	  after	   short	  
term	  in-­‐vitro	  reactivation	  
PBMC	  from	  donors	  HD05	   (A),	  HD30	   (B)	  and	  HD07	   (C)	  were	  stimulated	  with	  HHV6B	  
pepmix	  U11,	   U39,	   U54	   and	   U90,	   and	   cultured	   for	   10	   days	   in	   the	   presence	   of	   IL2.	  	  
HHV6B	  -­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	  IFN-­‐γ	  ELISpot.	  	  Results	  are	  
presented	  as	   spot-­‐forming	   cells	   (SCF)	  per	  105	  T	   cells.	   	  Pepmix	   representing	  BK-­‐VP1	  
was	  used	  as	  negative	  control.	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A	  total	  of	  25	  donors	  were	  analysed	  in	  this	  way.	  	  The	  overall	  results	  are	  shown	  in	  Table	  
4.2,	  which	   shows	   that	  all	   donors	   tested	   responded	   to	  at	   least	  one	  HHV6B	  antigen,	  
with	   15	   donors	   responding	   to	   all	   four	   antigens,	   2	   donors	   responding	   to	   three	  
antigens,	   6	   donors	   responding	   to	   two	   antigens	   and	   finally	   2	   donors	   responding	   to	  
only	  one	  antigen	   (Figure	  4.7).	   	  The	   individual	  magnitudes	  and	  mean	   frequencies	  of	  
the	  responses	  against	  each	  antigen	  are	  shown	  in	  Figure	  4.8.	  	  The	  mean	  frequency	  of	  
T	  cells	   responding	  to	  U11	  was	  93	  SFC	  per	  105	  of	   total	  T	  cells,	  with	  the	  range	  being	  
from	  14	  to	  372	  SFC	  per	  105.	  	  The	  mean	  frequency	  of	  T	  cells	  responding	  to	  U39	  was	  74	  
SFC	   per	   105	   of	   total	   T	   cells,	   with	   a	   range	   of	   10	   to	   186	   SFC	   per	   105).	   	   The	   mean	  
frequency	  of	  T	  cells	   responding	  to	  U54	  was	  121	  SFC	  per	  105	  of	   total	  T	  cells,	  with	  a	  
range	  of	  32	  to	  346	  SFC	  per	  105).	  	  Finally,	  the	  mean	  frequency	  of	  T	  cells	  responding	  to	  
U90	  was	  115	  SFC	  per	  105	  of	  total	  T	  cells,	  with	  a	  range	  from	  10	  to	  376	  SFC	  per	  105.	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Table	  4.2	  Summary	  of	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  
in	  25	  donors	  detected	  by	  IFN-­‐γ  ELIspot	  after	  a	  short-­‐term	  in-­‐vitro	  reactivation	  
 
Donor	   U11	   U39	   U54	   U90	  
HD02	   244	   186	   32	   252	  
HD05	   372	   62	   346	   272	  
HD07	   98	   0	   2	   360	  
HD10	   136	   120	   149	   93	  
HD11	   140	   188	   182	   192	  
HD18	   3	   77	   125	   144	  
HD24	   26	   28	   95	   15	  
HD27	   260	   104	   94	   286	  
HD30	   98	   90	   72	   96	  
HD31	   254	   162	   254	   376	  
HD32	   14	   4	   150	   0	  
HD44	   108	   38	   90	   10	  
HD45	   128	   130	   196	   134	  
HD46	   0	   172	   134	   146	  
HD47	   148	   92	   228	   166	  
HD48	   16	   102	   52	   152	  
HD49	   40	   116	   118	   44	  
HD50	   20	   0	   122	   2	  
HD51	   4	   2	   160	   0	  
HD52	   4	   4	   64	   0	  
HD53	   0	   0	   80	   10	  
HD54	   40	   10	   84	   10	  
HD55	   0	   50	   0	   60	  
HD57	   86	   120	   39	   44	  
HD58	   90	   0	   6	   154	  
Total	  out	  of	  25	   19	   18	   22	   21	  
*	   	   The	   results	   are	   expressed	   as	   SFC	   per	   105	   cells	   after	   subtract	   the	  
negative	  control	  from	  the	  individual	  reading.	  	  Numbers	  in	  the	  final	  row	  












Figure	   4.7	  Summary	  data	   from	  25	  donors	   screened	   against	  HHV6B	  antigens	  U11,	  
U39,	  U54	  and	  U90	  
The	  overall	  results	  of	  all	  donors	  tested	  against	  the	  HHV6B	  antigen	  are	  shown.	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Figure	  4.8	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  in	  25	  donors	  
analysed	  after	  in-­‐vitro	  reactivation	  by	  IFN-­‐γ  ELISpot	  
The	  results	  are	  expressed	  as	   IFN-­‐γ	  secreting	  T	  cells	  (SFC)	  against	  the	  HHV6B	  protein	  
from	  25	  donors,	  the	  mean	  value	  ±	  SEM	  are	  shown.	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Based	  on	  analysis	  of	  the	  mean	  frequency	  of	  SFC	  expanded	  by	  a	  10-­‐day	  culture,	  U54	  
was	   the	   most	   immunogenic,	   closely	   followed	   by	   U90,	   then	   U11	   and	   U39.	   	   To	  
determine	  the	  overall	  hierarchy	  of	  immune	  responses	  to	  the	  HHV6B	  antigens	  tested,	  
the	  number	  of	  donors	  responding	  to	  each	  of	  the	  four	  antigens	  test	  was	  determined.	  	  
Whilst	  all	  donors	  respond	  to	  a	  combination	  of	  the	  antigens	  (see	  earlier,	  Figure	  4.8),	  
HHV6B	  U54	  was	   the	  most	   immunodominant	  with	   22	  out	   of	   25	  donors	   responding	  
(88%),	  next	  was	  U90	  with	  21	  out	  of	  25	  donors	   responding	   (84%),	   followed	  by	  U11	  
with	  19	  of	  the	  25	  donors	  responding	  (76%)	  and	  then	  U39	  with	  18	  of	  the	  25	  donors	  
responding	  (72%)	  (Figure	  4.9).	  	  Thus,	  although	  all	  antigens	  were	  considered	  strongly	  
immunogenic,	  the	  overall	  hierarchy	  of	   iummunodominance	  detect	   in	  this	  cohort	  of	  
25	   donors	   showed	   that	   U54	  was	   the	  most	   immunogenic	   followed	   closely	   by	   U90,	  
then	  U11	  and	  finally	  U39.	  
Of	   the	  25	  donors	   analysed	  19	  were	  HCMV	  sero-­‐positive	  and	  6	  were	   sero-­‐negative.	  	  
Due	  to	   the	   level	  of	  similarity	  between	  the	  two	  β-­‐herpesviruses,	  HHV6B	  and	  HCMV,	  
there	  may	  be	  the	  potential	  of	  the	  HHV6B	  pepmixes	  to	  expand	  cross-­‐reactive	  HCMV	  T	  
cells.	  	  Thus,	  there	  was	  the	  possibility	  that	  data	  generated	  may	  not	  be	  truly	  reflective	  
of	  the	  frequency	  of	  HHV6B-­‐specific	  responses.	  	  When	  the	  level	  of	  responses	  against	  
HHV6B	  U11,	   U39,	   U54	   and	   U90	  were	   compared	   between	   the	   HCMV	   sero-­‐positive	  
and	  sero-­‐negative	  groups,	  the	  overall	  levels	  of	  responsive	  T	  cells	  were	  similar	  and	  the	  
hierarchy	  was	  identical	  (Figure	  4.10).	  	  	  
	  
	   	  




Figure	  4.9	  Percentage	  of	  donors	  eliciting	  T	  cell	   responses	  to	  HHV6B	  antigens	  U11,	  
U39,	  U54	  and	  U90	  in	  25	  donors	  analysed	  after	  in-­‐vitro	  reactivation	  by	  IFN-­‐γ 	  ELISpot	  
 
A	   total	   of	   25	   donors	  were	   analysed	   after	   in-­‐vitro	   reactivation	   by	   IFN-­‐γ	   ELISpot	   for	  
HHV6B	   antigens	   U11,	  U39,	   U54	   and	   U90.	   	   The	   highest	   number	   of	   donors	   (22/25)	  
responded	  to	  U54,	  followed	  by	  U90	  (21/25),	  U11	  (19/25)	  and	  response	  to	  U39	  was	  
the	  lowest	  (18/25)	  among	  them. 
 



























A$total$of$25$donors$were$a aly ed$a=er$in>vitro$r acAvaAon$by$IFN>g$ELISpot$for:$
HHV6B$anAgens$U11,$U39,$U54$and$U90$(n=25).$The$pie$chart$illustrates$the$
percentage$of$donors$responding$to$each$HHV6B$anAgen$tested.$$








Figure	  4.10	  T	  cell	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90	  in	  relation	  
to	  CMV	  sero-­‐positivity.	  
Figure	  showing	  similar	  pattern	  and	  magnitude	  of	  T	  cell	  responses	  in	  CMV	  positive	  
(left)	  and	  CMV	  negative	  donors	  (right).	  	  For	  each	  antigen,	  the	  negative	  control	  
(DMSO)	  is	  shown	  to	  the	  right	  of	  the	  pepmix.	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4.2	   Determination	   of	   the	   frequency	   of	   CD4+	   and	   CD8+	   T	   cells	   in	   the	  
expanded	  HHV6B-­‐specific	  polyclonal	  T	  populations	  	  
The	   previous	   section	   has	   shown	   that	   100%	   of	   donors	   tested	   had	   T	   cell	   responses	  
directed	  against	  HHV6B	  that	  could	  be	  expanded	   in-­‐vitro	  by	  short-­‐term	  reactivation	  
with	   antigen	  pepmixes.	   	   Further,	   all	   of	   the	   antigens	   tested	  were	   able	   to	   stimulate	  
expansion	  of	  HHV6B-­‐specific	  T	  cells.	   	  However,	   this	  analysis	  was	  carried	  out	  at	   the	  
level	  of	  total	  T	  cells,	  and	  gave	  no	  indication	  of	  the	  CD4+	  and	  CD8+	  T	  cell	  composition	  
of	  these	  expanded	  cultures	  and	  subsequently	  what	  type	  of	  HHV6B-­‐specific	  T	  cell	  was	  
being	   expanded.	   	   Thus,	   the	   frequencies	   of	   CD4+	   and	   CD8+	   T	   cells	   in	   10-­‐day	  
polyclonal	   cultures,	   stimulated	  with	   each	   HHV6B	   pepmix,	   were	  measured	   by	   flow	  
cytometry.	  	  	  
An	  example	  of	  this	  analysis	  for	  donor	  HD49	  is	  shown	  in	  Figure	  4.11.	  	  After	  a	  10-­‐day	  
expansion	  with	  each	  antigen	  pepmix,	  cells	  were	  stained	  with	  CD3	  and	  either	  CD4	  or	  
CD8,	  and	  the	  frequencies	  of	  CD3+CD4+	  and	  CD3+CD8+	  cells	  determined.	  	  As	  seen	  in	  
figure	   4.10,	   the	   frequency	   of	   CD3+CD4+	   cells	   present	   in	   the	   respective	   pepmix-­‐
expanded	   cultures	  were	   64.5%	   (U11),	   70.4%	   (U39),	   61.8%	   (U54)	   and	   68.3%	   (U90).	  	  
The	   corresponding	   levels	   of	   CD3+CD8+	   cells	   were	   27%	   (U11),	   22.7%	   (U39),	   28.7%	  
(U54)	  and	  25.4%	  (U90).	  	  Thus,	  for	  this	  donor	  the	  vast	  majority	  of	  expanded	  T	  cells	  for	  
each	  HHV6B	  antigen	  were	  CD4+.	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Figure	   4.11	  Phenotypic	   analysis	   of	   polyclonal	   culture	   of	  HHV6B-­‐specific	   T	   cells	   in	  
donor	  HD49	  after	  a	  short-­‐term	  in-­‐vitro	  reactivation 
PBMC	  were	  isolated	  from	  donor	  HD49	  and	  5x10
5
	  were	  stimulated	  with	  HHV6B	  whole	  
antigen	  pepmixes	   for	  either	  U11,	  U39,	  U54	  orU90	   for	  10	  days.	   	  Lymphocytes	  were	  
identified	   based	   on	   their	   forward-­‐	   and	   side-­‐scatter	   properties.	   	   Subsequently,	   CD3	  
was	  used	  to	  identify	  T	  cells	  among	  the	  previously	  selected	  lymphocytes.	  	  CD4+	  T	  cells	  
and	  CD8+	  T	  cells	  were	   identified	   for	  polyclonal	  culture	  of	  HHV6B-­‐enriched	  antigen-­‐
specific	  T	  cells.	  	  Values	  indicated	  denote	  the	  percentage	  of	  CD4+	  or	  CD8+	  cells.	  	  Data	  
was	  collected	  on	  a	  BD	  FACSCalibur	  and	  analysed	  using	  FlowJo	  software	  (Treestar).	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A	   total	  of	  10	  donors	  were	  analysed,	  and	   the	  percentage	  values	   for	  CD3+CD4+	  and	  
CD3+CD8+	  cells	  are	  shown	  in	  Table	  4.3.	  	  Overall,	  the	  pattern	  observed	  was	  similar	  to	  
that	   for	   donor	  HD49.	   	   However,	   interestingly	   donors	  HD32,	  HD50	   and	  HD51	  were	  
found	   to	   have	   significantly	   higher	   levels	   of	   CD3+CD8+	   cells	   (42%,	   41%	   and	   36%	  
respectively)	  in	  U54	  expanded	  T	  cell	  populations.	  	  As	  shown	  in	  the	  previous	  chapter,	  
U54	  was	   deemed	   to	   be	   immunogenic	   for	   CD8+	   responses,	   although	   these	   donors	  
were	  not	   included	   in	   that	  part	  of	   the	  study.	   	  A	  summary	  of	   the	  results	   is	  shown	   in	  
Figure	   4.12.	   	   The	   mean	   frequency	   of	   CD3+CD4+	   and	   CD3+CD8+	   T	   cells	   for	   each	  
antigen	   pepmix	   is	   shown	   in	   Figure	   4.12.	   	   Overall,	   the	   values	   for	   each	   antigen	   are	  
similar,	  with	  only	  a	  slight	  increase	  in	  the	  mean	  value	  of	  CD8+	  cells	  for	  U54	  over	  the	  
other	   antigens,	   reflecting	   the	   values	   highlighted	   above.	   	   The	   mean	   frequency	  
detected	   and	   range	   where	   as	   follows:	   CD3+CD4+	   cells	   for	   U11	   was	   66.6%	   (range	  
42.8%	   to	   77.3%);	   U39	   was	   67.9%	   (range	   37.7%	   to	   79.3%);	   U54	   was	   61.8%	   (range	  
42.6%	  to	  80%);	  U90	  was	  67.4%	  (range	  42.3%	  to	  83.9%).	  	  CD3+CD8+	  cells	  for	  in	  U11	  
was	   21.3%	   (range.7%	   to	   38.8%);	   U39	  was	   23.2%	   (range	   0.2%	   to	   27.6%);	   U54	  was	  
28.7%	  (range	  13.3%	  to	  41.8%);	  U90	  was	  24.4%	  (range	  1.3%	  to	  27.1%).	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Table	  4.3	  CD4	  and	  CD8	  phenotype	  and	  frequency	  of	  T	  cell	  lines	  after	  10-­‐day	  in-­‐vitro	  
stimulation	  with	  HHV6B	  antigens 
	  
Donor	   CD3+CD4+	  T	  cells	   CD3+CD8+	  T	  cells	  
	   U11	   U39	   U54	   U90	   U11	   U39	   U54	   U90	  
HD02	   77.1	   79.3	   80	   83.9	   13.9	   14.2	   13.3	   11.6	  
HD05	   66.3	   74.2	   73	   NT	   19.1	   21.2	   21.4	   NT	  	  
HD07	   66.8	   68.2	   68.1	   63.6	   23.5	   25.5	   24	   26	  
HD27	   NT	   NT	   NT	   71.2	   NT	   NT	   NT	   20	  
HD31	   68.7	   66.1	   64.2	   68.5	   23.9	   24.9	   25.2	   23.3	  
HD32	   52.4	   66.5	   45.2	   NT	   38.8	   27.6	   41.8	   NT	  	  
HD48	   69.6	   67.6	   58.1	   63	   16.7	   23.7	   31.1	   27.1	  
HD49	   64.5	   70.4	   61.8	   68.3	   27	   22.7	   28.7	   25.4	  
HD50	   NT	   NT	   46.9	   66.5	   NT	   NT	   40.8	   26.1	  
HD51	   42.8	   37.7	   42.6	   42.3	   0.713	   0.21	   36.2	   1.26	  
Mean	   58.4	   62.8	   61	   68.6	   19.3	   24.5	   29.8	   31.2	  
	  	  	  	  	  	  NT	  =	  not	  tested	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Figure	   4.12	   Phenotypic	   analysis	   of	   polyclonal	   cultures	   of	   HHV6B-­‐specific	   T	   cells	  
generated	  by	  short-­‐term	  in-­‐vitro	  reactivation	  with	  antigen	  pepmixes.	  
The	  mean	  percentage	  values,	  ±	   SEM,	  of	  CD3+CD4+	  and	  CD3+CD8+	   cells	  present	   in	  
polyclonal	  culture	  of	  HHV6B-­‐enriched	  antigen-­‐specific	  T	  cells.	  	  The	  number	  of	  donors	  
analysed	  for	  each	  antigen	  pepmix	  were	  as	  follows:	  U11	  n=8,	  U39	  n=8,	  U54	  n=9	  and	  
U90	  n=8. 
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4.3	   Summary	   of	   the	   analysis	   of	   pepmix	   expanded	   HHV6B-­‐specific	   T	   cell	  
populations	  
In	  conclusion,	  despite	  the	  very	  low	  levels	  of	  HHV6B-­‐specific	  T	  cells	  detected	  ex-­‐vivo	  
in	   chapter	   1,	   an	   in-­‐vitro	   stimulation	   step	   in	   the	   presence	   of	   IL-­‐2	   successfully	  
expanded	  HHV6B	  antigen-­‐specific	  T	  cells.	  	  T	  cell	  responses	  were	  detected	  against	  all	  
HHV6B	  antigens	  tested	  (U11,	  U39,	  U54	  and	  U90).	  	  All	  25	  donors	  analysed	  responded	  
to	   at	   least	   one	   of	   the	   HHV6B	   antigen.	   	   A	   hierarchy	   of	   immunodominance	   was	  
determined,	  with	  U54	  being	   the	  most	   immunogenic,	   followed	   closely	  by	  U90	   then	  
U11	  and	  U39.	  	  The	  expanded	  CD3+	  T	  cell	  population	  consisted	  mainly	  of	  CD4+	  T	  cells,	  
with	  a	  significantly	  lower	  percentage	  of	  CD8+	  T	  cells.	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5.	  	  Identification	  and	  characterisation	  of	  HLA	  Class	  I	  restricted	  
antigenic	  peptides	  in	  HHV6B	  U11	  and	  U90	  	  
The	  previous	  chapter	  has	  shown	  that	  T	  cells	  responses	  to	  HHV6B	  antigens	  U11,	  U39,	  
U54	   and	   U90	   can	   be	   successfully	   expanded	   in-­‐vitro.	   	   The	   next	   stage	   was	   to	  
characterise	   these	   responses	   in	   more	   detail,	   focusing	   specifically	   of	   HLA	   class	   I	  
restricted	  CD8+	  T	  cell	  responses,	  which	  will	  provide	  valuable	  information	  to	  support	  
any	  future	  application	  of	  T	  cell	  therapy	  against	  HHV6B	  driven	  disease.	  	  This	  chapter	  
will	   describe	   the	   mapping	   the	   minimal	   antigenic	   peptides,	   identifying	   the	   HLA	  
restriction	   elements	   and	   determining	  whether	   such	   T	   cells	  were	   capable	   of	   killing	  
HHV6B-­‐infected	  cells.	  	  Although	  U54	  was	  shown	  to	  be	  the	  most	  immunogenic	  of	  the	  
four	  tested,	  there	  was	  very	  little	  real	  difference	  between	  this	  antigen	  and	  U90,	  with	  
84%	  of	  donors	  tested	  responding	  to	  U90.	  	  U11	  was	  also	  recognised	  by	  the	  majority	  
of	   donors	   (76%).	   	   Importantly,	   peptide	   libraries	   of	   individual	   15-­‐mer	   peptides,	  
overlapping	   by	   11aa,	   were	   available	   for	   both	   antigens	   (provided	   by	   Dr	   Ann	   Leen,	  
Houston,	  USA).	   	  Thus,	   this	  chapter	  has	   focused	  on	  U11	  and	  U90	  and	  donors	  which	  
were	  shown	  to	  have	  CD8+	  T	  cell	  responses	  to	  these	  antigens	  that	  could	  be	  expanded	  
in-­‐vitro.	  
Briefly,	  using	  the	  same	  approach	  as	   in	  Chapter	  4	  PBMC	  from	  selected	  donors	  were	  
reactivated	  in-­‐vitro	  with	  U11	  or	  U90	  pepmixes.	  	  These	  U11	  or	  U90-­‐specific	  expanded	  
polyclonal	   T	   cell	   populations	   were	   then	   characterised	   in	   more	   detail.	   	   Initially,	   to	  
attempt	  to	  identify	  novel	  CD8+	  T	  cell	  epitopes	  in	  these	  antigens	  expanded	  polyclonal	  
cultures	  were	  screened	  by	  ELISpot	  using	  the	  15-­‐mer	  peptide	  libraries.	  	  These	  libraries	  
consisted	  of	  267	  15-­‐mers	  for	  U90	  and	  212	  15-­‐mers	  for	  U11.	  	  To	  maximise	  the	  use	  of	  
T	  cell	  cultures,	  these	  peptide	  libraries	  were	  arranged	  into	  mini-­‐pools	  such	  that	  each	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peptide	  was	  present	  in	  2	  pools.	  	  This	  generated	  33	  mini-­‐pools	  for	  U90	  and	  30	  mini-­‐
pools	   for	   U11.	   	   These	   peptide	  mini-­‐pools	  were	   organised	   in	   a	   2	   dimension	  matrix	  
that	   allowed	   for	   easy	   identification	   of	   individual	   target	   peptides,	   as	   described	  
previously	   (Kern	   et	   al.,	   2000)	   (see	   Figure	   5.1).	   	   T	   cell	   lines	   were	   exposed	   to	   the	  
relevant	  mini-­‐pools,	  and	  positive	  responses	  were	  detected	  by	   IFN-­‐γ	  ELISpot.	   	  These	  
responses,	   which	   could	   be	   mapped	   to	   individual	   15-­‐mers,	   were	   then	   analysed	   in	  
more	   detail	   using	   shorter	   peptides	   to	   map	   minimal	   epitopes.	   	   HLA	   restricting	  
elements	  were	  mapped	  using	  autologous	  and	  partially	  matched	  target	  cells.	  	  Finally,	  
The	   T	   cell	   lines	   were	   tested	   functionally	   for	   their	   ability	   to	   recognising	   HHV6B-­‐
infected	  target	  cells.	  	  An	  outline	  of	  the	  approaches	  used	  is	  shown	  in	  Figure	  5.2.	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Figure	   5.1	  Representation	  of	   the	  HHV6-­‐U90	  and	  U11	  mini-­‐pools	   of	   individual	  15-­‐
mer	  peptides	  
The	   two	   dimensional	   grids	   show	   the	  mini-­‐pools	   of	   individual	   15-­‐mer	   peptides	   for	  
U90	  (A)	  and	  U11	  (B).	   	  For	   the	  267	  15-­‐mer	  peptides	  representing	  U90,	   there	  are	  33	  
mini-­‐pools	  containing	  either	  15,	  16	  or	  17	  peptides.	   	  Each	  U90	  15-­‐mer	   is	  present	   in	  
two	  pools.	   	  For	  the	  212	  15-­‐mer	  peptides	  representing	  U11,	  there	  are	  30	  mini-­‐pools	  
containing	  either	  14,	  15	  or	  16	  peptides.	  	  Each	  U11	  15-­‐mer	  is	  present	  in	  two	  pools.	  
	  
	   	  
U90!$ 1$ 2$ 3$ 4$ 5$ 6$ 7$ 8$ 9$ 10$ 11$ 12$ 13$ 14$ 15$ 16$ 17$
18$ 1!! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12! 13! 14! 15! 16! 17!
19$ 18! 19! 20! 21! 22! 23! 24! 25! 26! 27! 28! 29! 30! 31! 32! 33! 34!
20$ 35!!! 36! 37! 38! 39! 40! 41! 42! 43! 44! 45! 46! 47! 48! 49! 50! 51!
21$ 52! 53! 54! 55! 56! 57! 58! 59! 60! 61! 62! 63! 64! 65! 66! 67! 68!
22$ 69! 70! 71! 72! 73! 74! 75! 76! 77! 78! 79! 80! 81! 82! 83! 84! 85!
23$ 86! 87! 88! 89! 90! 91! 92! 93! 94! 95! 96! 97! 98! 99! 100! 101! 102!
24$ 103! 104!105!106! 107! 108! 109! 110! 111! 112! 113! 114! 115! 116! 117! 118! 119!
25$ 120! 121!122!123! 124! 125! 126! 127! 128! 129! 130! 131! 132! 133! 134! 135! 136!
26$ 137! 138!139!140! 141! 142! 143! 144! 145! 146! 147! 148! 149! 150! 151! 152! 153!
27$ 154! 155!156!157! 158! 159! 160! 161! 162! 163! 164! 165! 166! 167! 168! 169! 170!
28$ 171! 172!173!174! 175! 176! 177! 178! 179! 180! 181! 182! 183! 184! 185! 186! 187!
29$ 188! 189!190!191! 192! 193! 194! 195! 196! 197! 198! 199! 200! 201! 202! 203! 204!
30$ 205! 206!207!208! 209! 210! 211! 212! 213! 214! 215! 216! 217! 218! 219! 220! 221!
31$ 222! 223!224!225! 226! 227! 228! 229! 230! 231! 232! 233! 234! 235! 236! 237! 238!
32$ 239! 240!241!242! 243! 244! 245! 246! 247! 248! 249! 250! 251! 252! 253! 254! 255!












U11$ 1$ 2$ 3$ 4$ 5$ 6$ 7$ 8$ 9$ 10$ 11$ 12$ 13$ 14$ 15$ 16$
17$ 1! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12! 13! 14! 15! 16!
18$ 17! 18! 19! 20! 21! 22! 23! 24! 25! 26! 27! 28! 29! 30! 31! 32!
19$ 33! 34! 35! 36! 37! 38! 39! 40! 41! 42! 43! 44! 45! 46! 47! 48!
20$ 49! 50! 51! 52! 53! 54! 55! 56! 57! 58! 59! 60! 61! 62! 63! 64!
21$ 65! 66! 67! 68! 69! 70! 71! 72! 73! 74! 75! 76! 77! 78! 79! 80!
22$ 81! 82! 83! 84! 85! 86! 87! 88! 89! 90! 91! 92! 93! 94! 95! 96!
23$ 97! 98! 99! 100! 101! 102! 103! 104! 105! 106! 107! 108! 109! 110! 111! 112!
24$ 113! 114! 115! 116! 117! 118! 119! 120! 121! 122! 123! 124! 125! 126! 127! 128!
25$ 129! 130! 131! 132! 133! 134! 135! 136! 137! 138! 139! 140! 141! 142! 143! 144!
26$ 145! 146! 147! 148! 149! 150! 151! 152! 153! 154! 155! 156! 157! 158! 159! 160!
27$ 161! 162! 163! 164! 165! 166! 167! 168! 169! 170! 171! 172! 173! 174! 175! 176!
28$ 177! 178! 179! 180! 181! 182! 183! 184! 185! 186! 187! 188! 189! 190! 191! 192!
29$ 193! 194! 195! 196! 197! 198! 199! 200! 201! 202! 203! 204! 205! 206! 207! 208!
30$ 209! 210! 211! 212! ! ! ! ! ! ! ! ! ! ! ! !
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  Figure	  5.2	  Overview	  of	  the	  process	  used	  to	  characterise	  CD8+	  T	  cells	  responses	  to	  
HHV6B	  U90	  and	  U11	  
PBMC	   are	   stimulated	  with	   pepmixes	   representing	   HHV6B	  U90	   or	   U11,	   or	   in	   some	  
cases	   individual	   peptides	  were	   used,	   and	   cultures	  were	  maintained	   for	   10	   days	   at	  
37°C,	   with	   IL2	   being	   added	   to	   cultures	   from	   day	   3.	   	   Either	   total	   polyclonal	   T	   cell	  
populations	  or	  populations	  enriched	  for	  CD8+	  T	  cells,	  are	  screened	  by	  IFN-­‐γ	  ELISpot	  
using	  15-­‐mer	  mini-­‐pools.	   	  Positive	  responses	  (T	  cell	   lines)	  are	  then	  analysed	  further	  
by	  mapping	  the	  minimal	  peptide	  epitope,	   identification	  of	  the	  HLA	  restriction	  allele	  
and	  investigating	  if	  they	  recognise	  HHV6B-­‐infected	  cells. 











PBMC% are% s'mulated% with% pep'de% mixes% represen'ng% HHV6B% U90% or% U11,% or% in%
some%cases%individual%U90%or%U11%pep'des,%and%cultured%for%10%days%in%the%presence%
of%IL2.%%Polyclonal%T%cell%popula'ons%enriched%for%U90%or%U11@specifc%T%cells%are%then%
enriched% for% CD8+% T% cells,% before% being% screened% for% pep'de@specific% responses%
using% IFN@γ% ELISpot% and% individual% pep'de% pools,% each% containing% three% 15mer%
pep'des% represen'ng% the%en're% sequence%of%U90%or%U11.% %Posi've% responses%are%
then%analysed%further%by%mapping%the%minimal%pep'de%epitope,%iden'fica'on%of%th %
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5.1	  Mapping	  of	  HLA	  Class	  I	  restricted	  T	  cell	  epitopes	  in	  HHV6B	  antigen	  U90	  	  
U90-­‐specific	  T	  cells	  were	   identified	   in	  expanded	  T	  cell	  populations	   in	  21	  (out	  of	  25)	  
donors	   (see	   section	  4.1.1).	   	   In	   this	   section,	  based	  on	  availability	  of	  donors,	   6	  were	  
selected	  for	  further	  analysis	  in	  this	  chapter.	  	  These	  were	  donors	  HD27,	  HD53,	  HD57,	  
HD49,	   HD10	   and	   HD24.	   	   All	   but	   HD53	   had	   been	   shown	   to	   responded	   to	   all	   four	  
HHV6B	  antigens	  tested.	  	  HD53	  was	  shown	  to	  respond	  to	  U90	  and	  U54.	  	  PBMC	  were	  
isolated,	   stimulated	   with	   U90	   pepmixes	   in	   the	   presence	   of	   IL2	   for	   10	   days,	   and	  
subsequently	   analysed	   with	   the	   15-­‐mer	   mini-­‐pools.	   	   In	   some	   cases,	   PBMC	   were	  
subsequently	   stimulated	   with	   individual	   15-­‐mers	   to	   allow	   for	   follow	   up	   mapping	  
experiments.	  	  For	  the	  first	  donor	  analysed	  (HD27),	  the	  initial	  ELISpot	  screen	  using	  the	  
mini-­‐pools	   was	   carried	   out	   with	   total	   T	   cell	   populations.	   	   However,	   using	   this	  
approach	  the	  majority	  of	  pools	  gave	  a	  positive	  ELIspot	  results,	  likely	  to	  be	  due	  in	  part	  
to	  CD4+	  T	  cell	  responses	  (see	  Figure	  5.3A).	  	  As	  the	  aim	  here	  was	  to	  identify	  and	  map	  
CD8+	  T	   cell	   epitopes,	   a	   CD4+	  T	   cell	   depletion	   step	  was	   incorporated,	   to	   enrich	   for	  
CD8+	  T	  cells	  prior	  to	  screening	  by	  ELIspot	  with	  the	  15-­‐mer	  mini-­‐pools.	  	  	  
5.1.1	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD27	  	  	  
Donor	  HD27	   (HLA	   type	  HLA-­‐A1,	  A2,	  B44)	  had	  strong	   responses	   to	  U90	  of	  286	  SFCs	  
per	  105	   cells	  after	  10-­‐day	   stimulation	  of	  PBMC	  with	  pepmix	   (Figure	  4.5).	   	   To	  begin	  
mapping	   CD8+	   T	   cell	   responses,	   a	   pepmix-­‐expanded	   total	   T	   cell	   population	   was	  
incubated	   with	   the	   U90	   mini-­‐pools	   and	   analysed	   by	   ELISpot	   for	   IFN-­‐γ	   secretion	  
(Figure	   5.3A).	   	   The	  U90	   pepmix	   positive	   control	   gave	   a	   high	   level	   of	   SFC,	   and	   the	  
pepmix	   representing	   the	   BK	   virus	   VP1	   negative	   control	   was	   below	   20	   SFCs.	   	   As	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mentioned	  above,	  when	  screening	  a	  total	  T	  cell	  population	  the	  majority	  of	  peptide	  
mini-­‐pools	  were	  above	  the	  cut	  off	  of	  2-­‐fold	  greater	  than	  the	  negative	  control.	   	  This	  
was	  unmanageable	  in	  terms	  of	  further	  analysis,	  and	  as	  stated	  was	  likely	  in	  part	  to	  be	  
due	  to	  the	  presence	  of	  CD4+	  T	  cells	  responding	  to	  U90	  peptides.	  	  Thus,	  CD4+	  T	  cells	  
were	  depleted	  leading	  to	  enrichment	  of	  CD8+	  cells	  from	  15%	  to	  67%	  (Figure	  5.3D).	  	  
This	   CD8-­‐enriched	   T	   cell	   population	  was	   then	   rescreened	   against	   the	   15-­‐mer	  mini	  
pools	   giving	   a	   much	   cleaner	   result	   (Figure	   5.3B).	   	   U90	   mini-­‐pools	   which	   were	  
considered	   positive	   for	   HD27	   were	   pools	   2,	   3,	   12,	   14,	   15,	   17,	   21,	   22,	   23	   and	   27.	  	  
Based	  on	  the	  strengths	  of	  the	  responses	  seen	  mini-­‐pools	  2,	  3,	  14,	  15,	  21	  and	  22	  were	  
selected	  for	  further	  analysis,	  and	  the	  overlap	  regions	  for	  these	  pools	  are	  highlighted	  
in	  the	  2	  dimension	  matrix	  below	  the	  bar	  chart	  (Figure	  5.3C).	  	  It	  is	  possible	  pools	  12,	  
17,	   23	   and	   27	   also	   contain	   responses	   but	   these	   were	   not	   selected	   for	   further	  
analysis.	  	  This	  highlighted	  individual	  15-­‐mer	  peptides	  53	  and	  54	  (overlap	  of	  2/3	  and	  
21),	  65	  and	  66	  (overlap	  of	  2/3	  and	  22),	  70	  and	  71	  (overlap	  of	  14/15	  and	  21),	  and	  82	  
and	  83	  (overlap	  of	  14/15	  and	  22).	  	  The	  CD8+	  enriched	  T	  cell	  line	  was	  then	  screened	  
by	   ELISpot	   against	   the	   individual	   15-­‐mers,	   including	   for	   thoroughness	   additional	  
peptides	   on	   either	   side	   of	   the	   overlaps,	   for	   example	   for	   15-­‐mers	   53	   and	   54	   also	  
peptides	  52	  and	  55.	   	  Responses	  where	  only	  seen	  against	  overlapping	  individual	  15-­‐
mers	   53	   and	   54,	   and	   82	   and	   83	   (Figure	   5.4),	   suggesting	   the	   other	  mini-­‐pools	   hits	  
were	   non-­‐specific	   background.	   	   The	   15-­‐mer	   peptide	   53	   corresponds	   to	   aa209-­‐223	  
(ASESRDLLMDLKANM)	   and	   54	   corresponds	   to	   aa213-­‐237	   (RDLLMDLKANMNNQF).	  	  
The	   15-­‐mer	   peptide	   82	   corresponds	   to	   aa325-­‐339	   (IHINCKNLITAAKNI)	   and	   83	  
corresponds	  to	  aa329-­‐343	   (CKNLITAAKNIGIAV).	   	  The	  overlap	  of	  peptides	  82	  and	  82	  
includes	  the	  sequences	  NLITAAKNI	  (aa331-­‐339)	  and	  the	  sequence	  ITAAKNIGI	  (aa333-­‐
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341)	  (Figure	  5.5).	   	  The	  9-­‐mer	  sequences	  had	  previously	  been	  identified	  as	  potential	  
HLA-­‐A2	  binding	  peptides	  using	  SYFPEITHI	  epitope	  prediction	  programme	  (N.	   	  Khan,	  
personal	   communication).	   	   Importantly,	   this	   donor	  was	   HLA-­‐A2	   positive.	   	   Thus,	   as	  
PBMC	   and	   expanded	   T	   cells	   populations	   were	   limiting	   from	   this	   donor,	   the	   next	  
experiments	   focused	   on	   investigating	   if	   responses	   mapped	   to	   these	   9-­‐mers.	   	   The	  
enriched	   T	   cells	   were	   screened	   by	   ELISpot	   against	   the	   15-­‐mer	   peptide	   85	  
CKNLITAAKNIGIAV	  and	  both	  putative	  HLA-­‐A2	  restricted	  9-­‐mers.	  	  Both	  NLITAAKNI	  and	  
ITAAKNIGI	   peptides	   were	   recognised	   in	   the	   ELISpot	   assay	   (Figure	   5.5),	   suggesting	  
that	   these	  are	   indeed	  HLA	  A2-­‐restricted	  T	  cells	  epitopes	   from	  HHV6B	  U90,	   termed	  
NLI	   and	   ITA	   (based	   on	   the	   first	   three	   amino	   acids).	   	   However,	   no	   addition	   fine	  
mapping	   was	   carried	   out.	   	   Further	   analysis	   of	   these	   epitopes	   (HLA	   mapping	   and	  
presentation	   in	   virus-­‐infected	   cells)	   is	   presented	   in	   section	   5.3	   and	   5.4	   (this	   is	   the	  
case	  for	  all	  epitopes	  identified	  and	  present	  in	  section	  5.2).	  	  The	  potential	  response	  to	  
the	   overlapping	   15-­‐mer	   peptides	   ASESRDLLMDLKANM	   and	   RDLLMDLKANMNNQF	  
was	  not	  followed	  up	  but	  may	  represent	  an	  additional	  U90	  T	  cell	  epitope	  recognised	  
by	  this	  donor.	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Figure	  5.3	  Screening	  by	  IFN-­‐γ 	  ELISpot	  of	  U90-­‐specifc	  T	  cells	  in	  donor	  HD27	  enriched	  
using	  short	  term	  in-­‐vitro	  reaction	  of	  PBMC	  with	  U90	  pepmix.	  	  	  
C U90!% 1% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15% 16% 17%
18% 1!! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12! 13! 14! 15! 16! 17!
19% 18! 19! 20! 21! 22! 23! 24! 25! 26! 27! 28! 29! 30! 31! 32! 33! 34!
20% 35!!! 36! 37! 38! 39! 40! 41! 42! 43! 44! 45! 46! 47! 48! 49! 50! 51!
21% 52! 53! 54! 55! 56! 57! 58! 59! 60! 61! 62! 63! 64! 65! 66! 67! 68!
22% 69! 70! 71! 72! 73! 74! 75! 76! 77! 78! 79! 80! 81! 82! 83! 84! 85!
23% 86! 87! 88! 89! 90! 91! 92! 93! 94! 95! 96! 97! 98! 99! 100! 101! 102!
24% 103! 104! 105! 106! 107! 108! 109! 110! 111! 112! 113! 114! 115! 116! 117! 118! 119!
25% 120! 121! 122! 123! 124! 125! 126! 127! 128! 129! 130! 131! 132! 133! 134! 135! 136!
26% 137! 138! 139! 140! 141! 142! 143! 144! 145! 146! 147! 148! 149! 150! 151! 152! 153!
27% 154! 155! 156! 157! 158! 159! 160! 161! 162! 163! 164! 165! 166! 167! 168! 169! 170!
28% 171! 172! 173! 174! 175! 176! 177! 178! 179! 180! 181! 182! 183! 184! 185! 186! 187!
29% 188! 189! 190! 191! 192! 193! 194! 195! 196! 197! 198! 199! 200! 201! 202! 203! 204!
30% 205! 206! 207! 208! 209! 210! 211! 212! 213! 214! 215! 216! 217! 218! 219! 220! 221!
31% 222! 223! 224! 225! 226! 227! 228! 229! 230! 231! 232! 233! 234! 235! 236! 237! 238!
32% 239! 240! 241! 242! 243! 244! 245! 246! 247! 248! 249! 250! 251! 252! 253! 254! 255!
33% 256! 257! 258! 259! 260! 261! 262! 263! 264! 265! 266! 267! ! ! ! ! !


























































































































































1 HD037 Positive Fraction
Event Count: 422550





















1 HD037 Positive Fraction
Event Count: 380079

















1 HD037 Positive Fraction
Event Count: 376517



















1 HD037 Negative Fraction
Event Count: 603900





















1 HD037 Negative Fraction
Event Count: 319935

















1 HD037 Negative Fraction
Event Count: 141614



















4 HD037 2nd -Ve Fraction
Event Count: 487500





















4 HD037 2nd -Ve Fraction
Event Count: 220909

















4 HD037 2nd -Ve Fraction
Event Count: 70832



















5 HD037 2nd -Ve Fraction
Event Count: 139350
Lymphocytes gate
5 HD037 2nd -Ve Fraction
Event Count: 75635
T cells gate









































































1 HD037 Positive Fraction
Event Count: 422550





















1 HD037 Positive Fraction
Event Count: 380079

















1 HD037 Positive Fraction
Event Count: 376517



















1 HD037 Negative Fraction
Event Count: 603900





















1 HD037 Negative Fraction
Event Count: 319935

















1 HD037 Negative Fraction
Event Count: 141614



















4 HD037 2nd -Ve Fraction
Event Count: 487500





















4 HD037 2nd -Ve Fraction
Event Count: 220909

















4 HD037 2nd -Ve Fraction
Event Count: 70832



















5 HD037 2nd -Ve Fracti n
Event Count: 139350
Lymphocytes gate
5 HD037 2nd -Ve Fraction
Event Count: 75635
T cells gate











U90 mini-pools  
U90 mini-pools  
	  	  P a g e |	  126	  
	  
PBMC	  from	  donor	  HD27	  were	  stimulated	  with	  U90	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U90-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U90	  protein,	  in	  
33	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	  Polyclonal	  T	   cells	  were	  
either	   screened	   directly	   (A)	   or	   after	   enrichment	   of	   CD8+	   T	   cells	   (B).	   	   Results	   are	  
presented	   as	   spot-­‐forming	   cells	   (SCF)	   per	   105	   T	   cells	   or	   CD8-­‐enriched	   T	   cells.	  	  
Pepmixes	  representing	  U90	  and	  BK-­‐VP1	  were	  used	  as	  positive	  and	  negative	  control	  
respectively.	  	  Cut	  off	  responses	  are	  indicated	  by	  dashed	  blue	  lines.	  (C)	  The	  lower	  grid	  
represents	  the	  33	  pools	  of	  U90	  15-­‐mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pools	  2,	  
3	  and	  21	  (based	  on	  cut	  off	  line)	  are	  highlighted	  (blue	  and	  red	  respectively),	  and	  the	  
15-­‐mer	  peptide	  present	   in	  both	   these	  pools,	  peptides	  53	  and	  54	  are	  highlighted	   in	  
yellow.	  	  Positive	  pools	  14,	  15	  and	  22	  (based	  on	  cut	  off	  line)	  are	  highlighted	  (blue	  and	  
red	  respectively),	  and	  the	  15-­‐mer	  peptide	  present	   in	  both	  these	  pools,	  peptides	  82	  
and	   83	   are	   highlighted	   in	   yellow.	   	   (D)	   Flow	   cytometry	   analysis	   of	   polyclonal	   T	   cell	  
populations	  (left	  hand	  panel)	  and	  CD8-­‐enriched	  populations	  (right	  hand	  panel)	  used	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Figure	   5.4	  Confirmation	   of	   U90-­‐specific	   T	   cell	   response	   to	   peptides	   53	   and	   82	   in	  
donor	  HD27 
(A)	   U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD27,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U90	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  
15-­‐mer	   peptides	   52,	   53,	   54	   and	   55	   (left	   side).	   	   DMSO	  pulsed	   cells	  were	   used	   as	   a	  
negative	   control.	   	   Results	   are	   presented	   as	   spot-­‐forming	   cells	   (SCF)	   per	   105	   CD8-­‐
enriched	  T	  cells.	  	  15-­‐mer	  peptides	  69,	  70,	  71	  and	  72	  (right	  side)	  screened	  for	  Pool	  2,	  3	  
and	   Pool	   22	   were	   negative.	   	   (B)	   U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD27,	  
enriched	  by	  10-­‐day	  in-­‐vitro	  reactivation	  using	  a	  U90	  pepmix,	  were	  then	  screened	  by	  
IFN-­‐γ	   ELISpot	   against	   U90	   15-­‐mer	   peptides	   81,	   82,	   83	   and	   84	   (right	   side).	   	  DMSO	  
pulsed	  cells	  were	  used	  as	  a	  negative	  control.	  	  Results	  are	  presented	  as	  spot-­‐forming	  
cells	  (SCF)	  per	  105	  CD8-­‐enriched	  T	  cells.	  	  15-­‐mer	  peptides	  64,	  65,	  66	  and	  67	  (left	  side)	  
screened	  for	  Pool	  14,	  15	  and	  Pool	  21	  were	  negative.	  
	   	  


















































Figure)5.4) )Confirma3on)of)U908specific)T)cell) response)to)pep3des)53)and)82) in)
donor)HD27.'
)
(A)' U901specific' polyclonal' T' cells' from' donor' HD27,' enriched' by' 101day' in#vitro(
reac$va$on'using'a'U90'pep$de'mix,'were'then'screened'by' IFN1γ'ELISpot'against'
U90'151mer'pep$des'52,'53,'54'and'55'(leT'side).''DMSO'pulsed'cells'were'used'as'a'
nega$ve' control.' Results' are' presented' as' spot1forming' cells' (SCF)' per' 105' CD81
enriched'T'cells.'151mer'pep$des'69,'70,'71'and'72'(right'side)'screened'for'Pool'2,3''
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Figure	   5.5	  Mapping	   of	   minimal	   peptide	   epitope	   to	   NLITAAKNI	   and	   ITAAKNIGI	   in	  
donor	  HD27 
(A)	  U90	  15-­‐mer	  peptide	  83	  -­‐specific	  polyclonal	  T	  cells	  from	  donor	  HD27,	  enriched	  by	  
10-­‐day	   in-­‐vitro	   reactivation	   using	   15-­‐mer	   peptide	   83,	   a	   CD4+	   T	   cell	   depletion	   step	  
was	   incorporated,	   to	   enrich	   for	   CD8+	   T	   cells	   prior	   to	   screening	   by	   ELIspot	   9-­‐mers	  
representing	   the	   15-­‐mer	   peptide	   83	   (CKNLITAAKNIGIAV).	   	   Using	   putative	   HLA-­‐A2	  
binding	  peptides	  derived	  from	  the	  HHV6	  U90	  antigen,	  predicted	  using	  the	  SYFPEITHI	  
epitope	  prediction	  programme,	  the	  minimal	  peptide	  epitope	  was	  mapped	  to	  the	  9-­‐
mer	  peptides	  NLITAAKNI	  and	  ITAAKNIGI.	  	  DMSO	  pulsed	  cells	  were	  used	  as	  a	  negative	  
control.	   	   Results	   are	   presented	   as	   spot-­‐forming	   cells	   (SCF)	   per	   105	  CD8-­‐enriched	   T	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5.1.2	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD53	  
Donor	  HD53	  (HLA-­‐A29,	  B44)	  also	  had	  strong	  response	  to	  U90	  in	  pepmix	  expanded	  T	  
cells	   (section	   4.1.2).	   	  PBMC	  were	   stimulated	  with	   U90	   pepmix,	   depleted	   of	   CD4	   T	  
cells	  and	  the	  CD8-­‐enriched	  population	  screened	  with	  the	  15-­‐mer	  mini-­‐pools	  (Figure	  
5.6).	  	  There	  were	  very	  strong	  responses	  direct	  against	  U90	  mini-­‐pools	  3	  and	  29,	  with	  
low	  levels	  seen	  against	  a	  small	  number	  of	  other	  pools	  (6,	  9,	  30,	  31	  and	  32).	  	  Initially,	  
responses	   to	   pools	   3	   and	   29	   were	   selected	   for	   further	   analysis.	   	   The	   intersect	  
between	  these	  pools	  is	  highlighted	  in	  the	  2-­‐dimensional	  grid	  was	  the	  15-­‐mer	  peptide	  
190	  (Figure	  5.6).	  	  The	  enriched	  T	  cells	  were	  then	  screened	  by	  ELISpot	  against	  this	  15-­‐
mer,	  and	  the	  15-­‐mers	  either	  side	  (peptides	  189,	  190	  and	  191).	   	  As	  shown	   in	  Figure	  
5.7A,	   T	   cells	   responded	  exclusively	   to	  peptide	  190	   (aa757–771,	  KPSKSKKIKLDRLPE),	  
agreeing	  with	  the	  mini-­‐pool	  screen	  data	  and	  implying	  that	  the	  minimal	  peptide	  was	  
contained	  within	  this	  15-­‐mer	  sequence.	  	  Individual	  overlapping	  9-­‐mer	  peptides	  were	  
then	   synthesised	   spanning	   the	   15-­‐mer	   sequence,	   and	   screened	   by	   ELIspot	   against	  
the	   CD4-­‐depleted	   polyclonal	   T	   cell	   line	   from	   donor	   HD53.	   	   Seven	   9-­‐mer	   peptides	  
were	   tested,	   and	   a	   response	   was	   detected	   against	   a	   single	   peptide	   aa758-­‐766,	  
PSKSKKIKL	  (Figure	  5.7B).	   	  This	  was	  deemed	  to	  be	  the	  minimal	  peptide	  epitope	  from	  
U90,	  termed	  PSK,	  recognised	  by	  T	  cells	  from	  donor	  HD53	  (this	  response	  is	  analysed	  
further	  in	  sections	  5.3	  and	  5.4).	  	  	  
CD8+	  enriched	  T	  cell	  populations	   from	  donor	  HD53	  were	  also	  screened	  against	   the	  
intersecting	   (and	   flanking)	   peptides	   for	   pools	   9	   and	   30,	   and	   6	   and	   31.	   	  As	   seen	   in	  
Figure	   5.8	   the	   15-­‐mer	   peptides	   213	   (aa849–863,	   IPIRSMPGTHDIRNK)	   and	   227	  
(aa905-­‐919,	  CFINHFVPIKTDDEE)	  were	  also	  identified	  as	  targets	  for	  T-­‐cells	  from	  donor	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HD57.	   	   Due	   to	   limited	   PBMC	   these	   were	   not	   followed	   up	   further,	   but	   the	   may	  
represent	  novel	  U90	  CD8+	  T	  cell	  epitopes.	  
As	  this	  epitope	  was	  shown	  to	  be	  presented	  by	  HLA-­‐A29	  (see	  section	  5.3,	  Figure	  5.27)	  
and	   a	   second	   donor	   was	   available	   carrying	   this	   allele	   (Donor	   HD33),	   a	   further	  
experiment	  was	  undertaken.	  	  PBMC	  from	  donor	  HD33	  were	  stimulated	  with	  the	  PSK	  
peptide	   for	   10	   days	   to	   determine	  whether	   this	   donor	   also	  mounted	   a	   response	   to	  
this	  peptide.	   	  ELISpot	  analysis	  of	  the	  expanded	  T	  cell	  culture	  is	  shown	  in	  Figure	  5.9.	  	  
Donor	  HD33	  was	  found	  to	  respond	  to	  PSK.	  This	  supports	  the	  conclusion	  that	  this	  is	  a	  
novel	  U90	  CD8+	  T	  cell	  epitope.	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Figure	   5.6	   U90-­‐specifc	   T	   cells	   in	   donor	   HD53	   enriched	   by	   short	   term	   in-­‐vitro	  
reaction	  of	  PBMC	  with	  U90	  pepmix 
PBMC	  from	  donor	  HD53	  were	  stimulated	  with	  U90	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U90-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U90	  protein,	  in	  
33	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	  Polyclonal	  T	   cells	  were	  
enriched	  for	  CD8+	  T	  cells.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  105	  
CD8-­‐enriched	  T	  cells.	  	  Pepmixes	  representing	  U90	  and	  BK-­‐VP1	  were	  used	  as	  positive	  
and	  negative	  control	  respectively.	  	  The	  lower	  grid	  represents	  the	  33	  pools	  of	  U90	  15-­‐
mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pools	  3	  and	  29	  (based	  on	  cut	  off	  line)	  are	  
highlighted	   (blue	   and	   red	   respectively),	   and	   the	   15-­‐mer	   peptide	   present	   in	   both	  
these	  pools,	  peptide	  190	  is	  highlighted	  in	  yellow.	  
	   	  
U90!$ 1$ 2$ 3$ 4$ 5$ 6$ 7$ 8$ 9$ 10$ 11$ 12$ 13$ 14$ 15$ 16$ 17$
18$ 1!! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12! 13! 14! 15! 16! 17!
19$ 18! 19! 20! 21! 22! 23! 24! 25! 26! 27! 28! 29! 30! 31! 32! 33! 34!
20$ 35!!! 36! 37! 38! 39! 40! 41! 42! 43! 44! 45! 46! 47! 48! 49! 50! 51!
21$ 52! 53! 54! 55! 56! 57! 58! 59! 60! 61! 62! 63! 64! 65! 66! 67! 68!
22$ 69! 70! 71! 72! 73! 74! 75! 76! 77! 78! 79! 80! 81! 82! 83! 84! 85!
23$ 86! 87! 88! 89! 90! 91! 92! 93! 94! 95! 96! 97! 98! 99! 100! 101! 102!
24$ 103! 104! 105! 106! 107! 108! 109! 110! 111! 112! 113! 114! 115! 116! 117! 118! 119!
25$ 120! 121! 122! 123! 124! 125! 126! 127! 128! 129! 130! 131! 132! 133! 134! 135! 136!
26$ 137! 138! 139! 140! 141! 142! 143! 144! 145! 146! 147! 148! 149! 150! 151! 152! 153!
27$ 154! 155! 156! 157! 158! 159! 160! 161! 162! 163! 164! 165! 166! 167! 168! 169! 170!
28$ 171! 172! 173! 174! 175! 176! 177! 178! 179! 180! 181! 182! 183! 184! 185! 186! 187!
29$ 188! 189! 190! 191! 192! 193! 194! 195! 196! 197! 198! 199! 200! 201! 202! 203! 204!
30$ 205! 206! 207! 208! 209! 210! 211! 212! 213! 214! 215! 216! 217! 218! 219! 220! 221!
31$ 222! 223! 224! 225! 226! 227! 228! 229! 230! 231! 232! 233! 234! 235! 236! 237! 238!
32$ 239! 240! 241! 242! 243! 244! 245! 246! 247! 248! 249! 250! 251! 252! 253! 254! 255!
33$ 256! 257! 258! 259! 260! 261! 262! 263! 264! 265! 266! 267! ! ! ! ! !



















































Figure	   5.7	   Confirmation	   of	   U90-­‐specific	   T	   cell	   response	   to	   peptide	   190	   in	   donor	  
HD53	  and	  mapping	  of	  minimal	  peptide	  epitope	  to	  PSKSKKIKL 
(A)	   U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD53,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U90	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  
15mer	   peptides	   189,	   190	   and	   191.	   	   DMSO	   pulsed	   cells	   were	   used	   as	   a	   negative	  
control.	   	   Results	   are	   presented	   as	   spot-­‐forming	   cells	   (SCF)	   per	   105	  CD8-­‐enriched	   T	  
cells.	   	   (B)	   Using	   overlapping	   9mers	   representing	   the	   15mer	   peptide	   190	  
(KPSKSKKIKLDRLPE),	   the	  minimal	   peptide	   epitope	  was	  mapped	   by	   IFN-­‐γ	  ELISpot	   to	  
the	  9mer	  peptide	  PSKSKKIKL.	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Figure)5.7) )Confirma3on)of)U908specific)T) cell) response) to)pep3de)190) in)donor)
HD53)and)mapping)of)minimal)pep3de)epitope)to)PSKSKKIKL.$
)
(A)$ U90-specific$ polyclonal$ T$ cells$ from$ donor$ HD53,$ enriched$ by$ 10-day$ in#vitro$
reac3va3on$using$a$U90$pep3de$mix,$were$then$screened$by$ IFN-γ$ELISpot$against$
U90$15-mer$pep3des$189,$190$and$191.$$DMSO$pulsed$cells$were$used$as$a$nega3ve$
control.$ Results$ are$ presented$ as$ spot-forming$ cells$ (SCF)$ per$ 105$ CD8-enriched$ T$
cells.$ $The$corresponding$wells,$plus$the$ConA$posi3ve$control,$are$also$shown.$(B)$$
Usi g$ verlapping$9-mers$represen3ng$the$15-mer$pep3de$190$(KPSKSKKIKLDRLPE),$
th $minimal$ pep3de$ epitope$ was$mapped$ by$ IFN-γ$ ELISpot$ to$ the$ 9-mer$ pep3de$
PSKSKKIKL.$$
Pool$3$overlap$with$Pool$29$




Figure	  5.8	  Confirmation	  of	  U90-­‐specific	  T	  cell	   response	  to	  peptide	  213	  and	  227	   in	  
donor	  HD53	  
 
U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD53,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U90	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  
15-­‐mer	  peptides	  212,	  213	  and	  214	  for	  Pool	  9	  and	  Pool	  30	  (left	  side).	  	  15-­‐mer	  peptides	  
226,	  227	  and	  228	  for	  Pool	  6	  and	  Pool	  31	  (right	  side).	  	  DMSO	  pulsed	  cells	  were	  used	  as	  
a	   negative	   control.	  Results	   are	   presented	   as	   spot-­‐forming	   cells	   (SCF)	   per	   105	  CD8-­‐

























































Figure	  5.9	  Confirmation	  of	  minimal	  peptide	  epitope	  to	  PSKSKKIKL	  in	  donor	  HD33	  	  
 
PBMC	  from	  donors	  HD33	  were	  stimulated	  with	  PSKSKKIKL,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	  IL2.	  	  HHV6B-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	  IFN-­‐γ	  
ELISpot.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SFC)	  per	  10
5
	  T	  cells.	  	  DMSO	  was	  
used	  as	  negative	  control.	  



























ELISpot." "Results"are"presented"as" spotKforming"cells" (SCF)"per"105"T" cells." "DMSO"
was"used"as"nega?ve"control.""
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5.1.3	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD57	  	  
PBMC	   from	   donor	   HD57	   (HLA-­‐A2,	   B40(60),	   B50)	   were	   reactivated	   with	   the	   U90	  
pepmix	  and	  a	  CD4-­‐depleted	  polyclonal	  T	  cell	  line	  subsequently	  screened	  with	  the	  15-­‐
mer	  mini-­‐pools.	   	  A	  number	  of	  pools	  were	  found	  to	  give	  a	  response	  at	   least	  2	  times	  
great	   than	   the	   BK-­‐VP1	   background,	   these	   were	   2,	   3,	   9,	   14,	   18,	   22	   and	   31	   (Figure	  
5.10).	  	  In	  the	  first	  instance,	  responses	  to	  pools	  9,	  14	  and	  18	  were	  selected	  for	  further	  
analysis.	   	  These	  were	  selected	  based	  on	  unpublished	  data	  provided	  by	  Dr	  Ann	  Leen	  
(Houston,	   USA)	   at	   the	   time	   that	   these	   experiments	   were	   been	   undertaken,	  	  
identifying	  B40	  restricted	  peptides	  corresponding	  to	  this	  region	  of	  U90	  (this	  data	  was	  
subsequently	   published,	   (Gerdemann	   et	   al.,	   2013)	   –	   see	   discussion).	   	   The	   overlap	  
regions	  for	  these	  pools,	  the	  15-­‐mer	  peptides	  9	  (overlap	  of	  9	  and	  18),	  and	  14,	  (overlap	  
of	  14	  and	  18)	  are	  highlighted	   in	  the	  2	  dimension	  matrix	   in	  Figure	  5.10.	   	  To	  confirm	  
these	  peptides	  contained	  a	  CD8+	  T	  cell	  epitope,	  the	  T	  cell	  line	  was	  then	  screened	  by	  
ELISpot	   against	   these	   15-­‐mer	   peptides,	   and	   the	   relevant	   flanking	   15-­‐mers.	   	   Data	  
shown	  in	  Figure	  5.11	  shows	  that	  the	  15-­‐mer	  peptide	  9	  (Figure	  5.11A,	  left	  hand	  panel)	  
and	   15-­‐mer	   peptides	   14	   and	   15	   (Figure	   5.11B,	   left	   hand	   panel)	   are	   recognised	   by	  
these	  T	  cells	  from	  donor	  HD57.	  	  Peptide	  9	  (aa33–47;	  YHPDPVVEESIKEIL)	  includes	  the	  
sequence	  VEESIKEIL	  (aa39-­‐47,	  VEE)	  identified	  by	  Leen	  and	  colleagues	  (Gerdemann	  et	  
al.,	  2013)	  as	  a	  HLA-­‐B40	  restricted	  peptide	  in	  HHV6B	  U90.	  	  The	  VEE	  peptide	  was	  thus	  
tested	   on	   Donor	   HD57	   T	   cells,	   and	   found	   to	   induce	   a	   response	   in	   ELISpot	   (Figure	  
5.11A,	   right	  hand	  panel).	  The	   lack	  of	   response	  to	  peptide	  10	  that	  also	   includes	   the	  
sequence	  VEESIKEIL	   is	  due	  to	  the	  processing	  deficiency	  that	  comes	  with	  using	  non-­‐
professional	  APCs	  as	  presenters	  (Gerdemann	  et	  al.,	  2013).	  	  
	  
The	   overlap	   of	   15-­‐mer	   peptides	   14	   (aa53-­‐67;	   CDVSFESLLFPELEA)	   and	   15	   (aa57-­‐71	  
(FESLLFPELEAFDLF)	   contained	   the	  peptide	   FESLLFPEL	   (aa57-­‐65,	   FES).	   	   This	  was	   also	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identified	  by	  Leen	  and	  colleagues	  as	  a	  HLA-­‐B40	  restricted	  peptide	  epitope	  in	  HHV6B	  
U90	  (Gerdemann	  et	  al.,	  2013).	   	  As	  before,	  expanded	  T	  cells	  from	  donor	  HD57	  were	  
tested	   against	   FES	   by	   Elispot	   and	   found	   to	   respond	   to	   this	   peptide	   (Figure	   5.11B,	  
right	   hand	   panel).	   	   Two	   additional	   HLA-­‐B40	   positive	   donors	   [HD05	   HLA-­‐A2,	   A24,	  
B40(60),	  B44	  and	  HD30	  HLA-­‐A2,	  A32,	  B7,	  B40(60)]	  were	  also	  screened	  for	  responses	  
to	  VEE	  and	  FES.	   	  PBMC	  were	  reactivated	  with	  each	  9-­‐mer,	  and	  after	  10	  day	  culture	  
tested	  by	  ELISpot.	  	  Both	  donor	  HD05	  and	  HD30	  were	  found	  to	  respond	  to	  these	  B40-­‐
restricted	  peptide	  in	  U90	  (Figure	  5.12).	  
	  
The	  other	  positive	  pools	  from	  the	  mini-­‐pool	  screen	  of	  HD57	  U90	  pepmix	  stimulated	  
cells,	  polls	  2,	  3,	  20,	  and	  31	  (Figure	  5.10)	  were	  not	  followed	  up	  but	  may	  represent	  an	  
additional	  U90	  T	  cell	  epitope	  recognised	  by	  this	  donor.	  	  	  
	  
	  




Figure	  5.10	  Screening	  of	  U90-­‐specifc	  T	  cells	  in	  donor	  HD57	  enriched	  by	  short	  term	  
in-­‐vitro	  reaction	  of	  PBMC	  with	  U90	  pepmix 
PBMC	  from	  donor	  HD57	  were	  stimulated	  with	  U90	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U90-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U90	  protein,	  in	  
33	  pools	  such	  that	  each	  15-­‐mer	  was	  present	  in	  two	  pools.	  	  Results	  are	  presented	  as	  
spot-­‐forming	   cells	   (SCF)	   per	   105	  CD8-­‐enriched	   T	   cells.	   	   Pepmixes	   representing	  U90	  
and	  BK-­‐VP1	  were	  used	  as	  positive	  and	  negative	  control	  respectively.	  	  The	  lower	  grid	  
represents	  the	  33	  pools	  of	  U90	  15-­‐mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pools	  9,	  
14,	   and	   18	   are	   highlighted	   in	   blue	   and	   red.	   	   The	   15-­‐mer	   peptide	   present	   in	  
overlapping	   pools	   9	   and	   18,	   peptide	   9,	   and	   pools	   14	   and	   18,	   peptide	   14	   are	  







days! in!the!presence!of! IL2.! !U90Gspecific!polyclonal!T!cells!were!then!screened!by!
IFNGγ! ELISpot! against! overlapping! 15Gmer! pep3des,! represe 3ng! the! en3re! U90!
prot in,! in!33!pools!such!that!each!15Gmer!w s!pr sent! in! two!pools.! !Results!are!
presented! as! spotGform ! cells! (SCF)! per! 105! CD8Genriched! T! cells.! ! Pepm xes!
represen3ng! U90! nd! BKGVP1! were! used! as! posi3ve! and! nega3ve! control!
respec3vely.!The!lower!grid!represents!the!33!pools!of!U90!15Gmer!pep3d s!used!in!
the!screen.!!Posi3ve!pools!9,!14,!and!18!are!highlighted!in!blue!and!red.!!The!15Gmer!
pep3de! present! in! overlapping! pools! 9! and! 18,! pep3de! 9,! and! pools! 14! and! 18,!
pep3de!14!are!highlighted!in!yellow.!!
U90!' 1' 2' 3' 4' 5' 6' 7' 8' 9' 10' 11' 12' 13' 14' 15' 16' 17'
18' 1!! 2! 3! 4! 5! 6! 7! 8! 9! 10! 11! 12! 13! 14! 15! 16! 17!
19' 18! 19! 20! 21! 22! 23! 24! 25! 26! 27! 28! 29! 30! 31! 32! 33! 34!
20' 35!!! 36! 37! 38! 39! 40! 41! 42! 43! 44! 45! 46! 47! 48! 49! 50! 51!
21' 52! 53! 54! 55! 56! 57! 58! 59! 60! 61! 62! 63! 64! 65! 66! 67! 68!
22' 69! 70! 71! 72! 73! 74! 75! 76! 77! 78! 79! 80! 81! 82! 83! 84! 85!
23' 86! 87! 88! 89! 90! 91! 92! 93! 94! 95! 96! 97! 98! 99! 100! 101! 102!
24' 103! 104! 105! 106! 107! 108! 109! 110! 111! 112! 113! 114! 115! 116! 117! 118! 119!
25' 120! 121! 122! 123! 124! 125! 126! 127! 128! 129! 130! 131! 132! 133! 134! 135! 136!
26' 137! 138! 139! 140! 141! 142! 143! 144! 145! 146! 147! 148! 149! 150! 151! 152! 153!
27' 154! 155! 156! 157! 158! 159! 160! 161! 162! 163! 164! 165! 166! 167! 168! 169! 170!
28' 171! 172! 173! 174! 175! 176! 177! 178! 179! 180! 181! 182! 183! 184! 185! 186! 187!
29' 188! 189! 190! 191! 192! 193! 194! 195! 196! 197! 198! 199! 200! 201! 202! 203! 204!
30' 205! 206! 207! 208! 209! 210! 211! 212! 213! 214! 215! 216! 217! 218! 219! 220! 221!
31' 222! 223! 224! 225! 226! 227! 228! 229! 230! 231! 232! 233! 234! 235! 236! 237! 238!
32' 239! 240! 241! 242! 243! 244! 245! 246! 247! 248! 249! 250! 251! 252! 253! 254! 255!
33' 256! 257! 258! 259! 260! 261! 262! 263! 264! 265! 266! 267! ! ! ! ! !
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Figure	   5.11	  Confirmation	   of	   U90-­‐specific	   T	   cell	   response	   to	   peptides	   9	   and	   14	   in	  
donor	  HD57	  and	  mapping	  of	  minimal	  peptide	  epitope	  to	  VEESIKEIL	  and	  FESLLFPEL 
(A)	   U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD53,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U90	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  
15-­‐mer	  peptides	  8,	  9	  and	  10	  (left	  side).	  	  Confirmation	  of	  the	  U90-­‐specific	  CD8+	  T	  cell	  
response	   to	   the	   individual	   9-­‐mer	   peptide	   VEESIKEIL	   (right	   side).	   	   (B)	   U90-­‐specific	  
polyclonal	  T	  cells	  from	  donor	  HD53,	  enriched	  by	  10-­‐day	   in-­‐vitro	  reactivation	  using	  a	  
U90	  pepmix,	  were	  then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  15-­‐mer	  peptides	  13,	  
14	  and	  15	   (left	   side).	   	  Confirmation	  of	   the	  U90-­‐specific	  CD8	  T	   cell	   response	   to	   the	  
individual	  9-­‐mer	  peptide	  FESLLFPEL	  (right	  side).	   	  DMSO	  pulsed	  cells	  were	  used	  as	  a	  
negative	   control.	   	   Results	   are	   presented	   as	   spot-­‐forming	   cells	   (SCF)	   per	   10
5
	   CD8-­‐
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Figure	  5.12	  Confirmation	  of	  minimal	  peptide	  epitope	  to	  VEESIKEIL	  and	  FESLLFPEL	  in	  
donors	  HD05	  and	  HD30	  
(A)	   PBMC	   from	   donors	   HD05	   were	   stimulated	   with	   VEESIKEIL	   (left	   side)	   and	  
FESLLFPEL	   (right	   side),	   then	   cultured	   for	   10	   days	   in	   the	   presence	   of	   IL2.	   	  HHV6B-­‐
specific	   polyclonal	   T	   cells	   were	   then	   screened	   by	   IFN-­‐γ	   ELISpot.	   	   Results	   are	  
presented	  as	   spot-­‐forming	   cells	   (SCF)	  per	  105	  T	   cells.	   	  DMSO	  was	  used	  as	  negative	  
control.	  	  (B)	  PBMC	  from	  donors	  HD30	  were	  stimulated	  with	  VEESIKEIL	  (left	  side)	  and	  
FESLLFPEL	   (right	   side),	   then	   cultured	   for	   10	   days	   in	   the	   presence	   of	   IL2.	   	  HHV6B-­‐
specific	   polyclonal	   T	   cells	   were	   then	   screened	   by	   IFN-­‐γ	   ELISpot.	   	   Results	   are	  
presented	  as	   spot-­‐forming	   cells	   (SCF)	  per	  105	  T	   cells.	   	  DMSO	  was	  used	  as	  negative	  






















(A)" PBMC" from" donors" " HD05" were" sEmulated" with" VVEESIKEL" (leL" side)" and"
FESLLFPEL" (right" side)," then" cultured" for" 10" days" in" the" presence" of" IL2." HHV6BR
specific" polyclonal" T" cells" were" then" screened" by" IFNRγ" ELISpot." " Results" are"
presented"as"spotRforming"cells" (SCF)"per"105"T"cells." "DMSO"was"used"as"negaEv "
control." " (B)"PBMC"from"donors" "HD30"were"sEmulated"with"VVEESIKEL" (leL"side)"
and"FESLLFPEL"(right"side),"then"cultured"for"10"days"in"the"presence"of"IL2."HHV6BR
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5.1.4	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD49	  
The	   fourth	   donor	   to	   be	   analysed	   was	   HD49	   (HLA-­‐A1,	   A2,	   B8,	   B44).	   	   PBMC	  were	  
reactivated	   with	   the	   U90	   pepmix	   and	   a	   CD4-­‐depleted	   polyclonal	   T	   cell	   line	  
subsequently	  screened	  with	  the	  15-­‐mer	  mini-­‐pools.	  	  The	  results	  are	  shown	  in	  Figure	  
5.13.	   	  There	  were	  a	   large	  number	  of	  U90	  mini-­‐pools	  above	   the	  cut-­‐off	   line.	   	  Those	  
considered	  positive	  were	  pools	  2,	  3,	  6,	  10,	  12,	  16,	  18,	  21,	  22,	  23	  and	  24.	   	   Initially,	  
responses	   to	   pools	   2,	   12	   and	   24	   were	   selected	   for	   further	   analysis.	   	   The	   overlap	  
regions	   for	   these	   pools	   are	   highlighted	   in	   the	   2	   dimension	   matrix,	   the	   15-­‐mer	  
peptides	  104	  and	  114	  (Figure	  5.13).	  	  Theses	  individual	  15-­‐mers	  and	  flanking	  peptides	  
were	   then	   tested	   in	   ELISpot	   against	   CD4-­‐depleted	   polyclonal	   T	   cell	   line.	   	   T	   cells	  
responded	   to	   peptides	   104	   (aa413–427	   SICDLNIDPSESILL) and	   114	   (aa453-­‐467	  
NVDYLKYMEVQSPTD)	   (Figure	   5.14A),	   agreeing	   with	   the	   mini	   pool	   screen	   data.	  	  
Individual	   overlapping	   9-­‐mer	  peptides	  were	   then	   synthesised	   spanning	   the	  15-­‐mer	  
peptide	  104	  (SICDLNIDPSESILL)	  sequence,	  and	  screened	  by	  ELIspot	  against	  the	  CD4-­‐
depleted	  polyclonal	  T	  cell	  line	  from	  donor	  HD49.	  	  A	  response	  was	  detected	  against	  a	  
single	  9-­‐mer	  peptide,	  aa417–425,	  LNIDPSESI	  	  (Figure	  5.14B).	  	  This	  was	  deemed	  to	  be	  
the	  a	  CD8+	  peptide	  from	  U90,	  termed	  LNI,	  recognised	  by	  T	  cells	   from	  donor	  HD49.	  	  
The	  response	  to	   the	   individual	  15-­‐mer	  peptide	  114	   (NVDYLKYMEVQSPTD)	  was	  very	  
weak	   (Figure	  5.14A),	   and	  due	   to	   limiting	   T	   cell	   numbers	   this	  was	  not	   followed	  up,	  
although	  it	  may	  represent	  a	  target	  epitope	  with	  U90.	  	  No	  responses	  were	  confirmed	  
to	  the	  other	  15-­‐mer	  mini-­‐pool	  hits.	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Figure	   5.13	   U90-­‐specifc	   T	   cells	   in	   donor	   HD49	   enriched	   by	   short	   term	   in-­‐vitro	  
reaction	  of	  PBMC	  with	  U90	  pepmix 
PBMC	  from	  donor	  HD49	  were	  stimulated	  with	  U90	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U90-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U90	  protein,	  in	  
33	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	   Polyclonal	  T	   cells	  were	  
enriched	  for	  CD8+	  T	  cells.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  105	  
CD8-­‐enriched	  T	  cells.	  	  Pepmixes	  representing	  U90	  and	  BK-­‐VP1	  were	  used	  as	  positive	  
and	  negative	  control	  respectively.	  	  The	  lower	  grid	  represents	  the	  33	  pools	  of	  U90	  15-­‐
mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pools	  2,	  12	  and	  24	  (based	  on	  cut	  off	  line)	  
are	  highlighted	  (blue	  and	  red	  respectively),	  and	  the	  15-­‐mer	  peptides	  present	  in	  these	  
pools,	  peptides	  104	  and	  114	  are	  highlighted	  in	  yellow. 
	   	  












































U90%" 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" 11" 12" 13" 14" 15" 16" 17"
18" 1%% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15% 16% 17%
19" 18% 19% 20% 21% 22% 23% 24% 25% 26% 27% 28% 29% 30% 31% 32% 33% 34%
20" 35%%% 36% 37% 38% 39% 40% 41% 42% 43% 44% 45% 46% 47% 48% 49% 50% 51%
21" 52% 53% 54% 55% 56% 57% 58% 59% 60% 61% 62% 63% 64% 65% 66% 67% 68%
22" 69% 70% 71% 72% 73% 74% 75% 76% 77% 78% 79% 80% 81% 82% 83% 84% 85%
23" 86% 87% 88% 89% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% 100% 101% 102%
24" 103% 104% 105% 106% 107% 108% 109% 110% 111% 112% 113% 114% 115% 116% 117% 118% 119%
25" 120% 121% 122% 123% 124% 125% 126% 127% 128% 129% 130% 131% 132% 133% 134% 135% 136%
26" 137% 138% 139% 140% 141% 142% 143% 144% 145% 146% 147% 148% 149% 150% 151% 152% 153%
27" 154% 155% 156% 157% 158% 159% 160% 161% 162% 163% 164% 165% 166% 167% 168% 169% 170%
28" 171% 172% 173% 174% 175% 176% 177% 178% 179% 180% 181% 182% 183% 184% 185% 186% 187%
29" 188% 189% 190% 191% 192% 193% 194% 195% 196% 197% 198% 199% 200% 201% 202% 203% 204%
30" 205% 206% 207% 208% 209% 210% 211% 212% 213% 214% 215% 216% 217% 218% 219% 220% 221%
31" 222% 223% 224% 225% 226% 227% 228% 229% 230% 231% 232% 233% 234% 235% 236% 237% 238%
32" 239% 240% 241% 242% 243% 244% 245% 246% 247% 248% 249% 250% 251% 252% 253% 254% 255%












highlighted% (blue% and% red% respec?vely),% and% the% 15(mer% pep?de% present% in% both%
these%pools,%pep?de%104%is%highlighted%in%yellow.%
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Figure	   5.14	  Confirmation	  of	  U90-­‐specific	   T	   cell	   response	   to	   peptide	   104	   in	   donor	  
HD49	  and	  mapping	  of	  minimal	  peptide	  epitope	  to	  LNIDPSESI 
(A)	   U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD49,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U90	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  
15-­‐mer	  peptides	  103,	  104	  and	  105	  for	  Pool	  2	  and	  Pool	  24	  (left	  side).	  	  15-­‐mer	  peptides	  
113,	  114	  and	  115	  for	  Pool	  12	  and	  Pool	  24	  (right	  side).	  DMSO	  pulsed	  cells	  were	  used	  
as	  a	  negative	  control.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  105	  CD8-­‐
enriched	  T	  cells	  (B)	  	  Using	  overlapping	  9-­‐mers	  representing	  the	  15-­‐mer	  peptide	  104	  
(SICDLNIDPSESILL),	  the	  minimal	  peptide	  epitope	  was	  mapped	  by	  IFN-­‐γ	  ELISpot	  to	  the	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5.1.5	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD10	  
The	  fifth	  donor	  to	  be	  analysed	  was	  HD10	  (HLA-­‐A1,	  A2,	  B8,	  B39).	  	  The	  results	  from	  the	  
15-­‐mer	  mini	  pools	  screen	  on	  a	  CD4-­‐depleted	  T	  cell	  line	  are	  shown	  in	  Figure	  5.15.	  	  A	  
large	   number	   of	  U90	  mini-­‐pools	   were	   above	   the	   cut-­‐off,	   and	   considered	   positive.	  	  
These	   were	   pools	   2,	   3,	   5,	   9,	   10,	   11,	   12,	   16,	   18,	   21,	   23,	   31,	   32	   and	   33.	   	   Initially,	  
responses	  to	  pools	  5	  and	  31	  were	  selected	  for	  further	  analysis,	  the	  intersect	  between	  
these	   pools	   is	   the	   15-­‐mer	   peptide	   226	   (Figure	   5.15).	   	   To	   confirm	   this	   peptide	  
contained	  a	  CD8+	  T	  cell	  epitope,	  the	  T	  cell	  line	  was	  then	  screened	  by	  ELISpot	  against	  
this	  15-­‐mer,	  and	  the	  15-­‐mers	  either	  side	  (i.e.	  	  peptides	  225,	  226	  and	  227).	  	  As	  shown	  
in	  Figure	  5.16A,	  the	  response	  to	  the	  individual	  15-­‐mers	  was	  weak,	  although	  peptide	  
226	   (aa901–915,	  EANHCFINHFVPIKT)	   gave	   the	   strongest	   response	   above	   the	   other	  
15-­‐mers	   and	   DMSO	   control.	   	   Although	   weak,	   this	   response	   was	   analysed	   further.	  	  
Individual	   overlapping	   peptides	   representing	   this	   sequence	  were	   synthesised	   and	  
screened	  by	  ELIspot	  against	  the	  CD4-­‐depleted	  polyclonal	  T	  cell	  line	  from	  donor	  HD10.	  	  
Seven	   peptides	   were	   tested,	   in	   general	   the	   response	   was	   low,	   but	   two	   peptides	  
(ANHCFINHFV	  and	  NHCFINHFV)	  were	  recognised	  at	  equivalent	  levels	  (Figure	  5.15B).	  	  
As	  loss	  of	  the	  alanine	  residue	  appeared	  to	  have	  little	  effect	  on	  recognition,	  whereas	  
loss	   of	   the	   asparagine	   and	   also	   the	   valine	   has	   a	   significant	   effect.	   	   Thus,	   it	   was	  
deemed	  to	  be	  the	  minimal	  peptide	  epitope	  from	  U90	  recognised	  by	  donor	  HD10	  was	  
the	   9-­‐mer	   peptide	   aa903–911,	   NHCFINHFV,	   termed	   NHC	   (Figure	   5.16B).	   	   From	  
representative	   experiments	   with	   donor	   HD10,	   two	   other	   15-­‐mer	   peptides	   were	  
identified	  as	  targets	  for	  T-­‐cell	  responses	  (Figure	  5.17).	  	  The	  potential	  response	  to	  the	  
15-­‐mer	   peptides	   231	   aa921–935	   (EKENVSYTYSKIQDS)	   and	   254	   aa1013-­‐1027	  
(GNNSPILNIINDTTC)	  was	  not	  followed	  up	  but	  may	  represent	  an	  additional	  U90	  T	  cell	  
epitope	  recognised	  by	  this	  donor.	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Figure	   5.15	   U90-­‐specifc	   T	   cells	   in	   donor	   HD10	   enriched	   by	   short	   term	   in-­‐vitro	  
reaction	  of	  PBMC	  with	  U90	  pepmix 
PBMC	  from	  donor	  HD10	  were	  stimulated	  with	  U90	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U90-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U90	  protein,	  in	  
33	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	   Polyclonal	  T	   cells	  were	  
enriched	  for	  CD8+	  T	  cells.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  105	  
CD8-­‐enriched	  T	  cells.	  	  Pepmixes	  representing	  U90	  and	  BK-­‐VP1	  were	  used	  as	  positive	  
and	  negative	  control	  respectively.	  	  The	  lower	  grid	  represents	  the	  33	  pools	  of	  U90	  15-­‐
mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pools	  5	  and	  31	  (based	  on	  cut	  off	  line)	  are	  
highlighted	   (blue	   and	   red	   respectively),	   and	   the	   15-­‐mer	   peptide	   present	   in	   both	  
these	  pools,	  peptide	  226	  is	  highlighted	  in	  yellow.	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18$ 1%% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15% 16% 17%
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20$ 35%%% 36% 37% 38% 39% 40% 41% 42% 43% 44% 45% 46% 47% 48% 49% 50% 51%
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25$ 120% 121% 122% 123% 124% 125% 126% 127% 128% 129% 130% 131% 132% 133% 134% 135% 136%
26$ 137% 138% 139% 140% 141% 142% 143% 144% 145% 146% 147% 148% 149% 150% 151% 152% 153%
27$ 154% 155% 156% 157% 158% 159% 160% 161% 162% 163% 164% 165% 166% 167% 168% 169% 170%
28$ 171% 172% 173% 174% 175% 176% 177% 178% 179% 180% 181% 182% 183% 184% 185% 186% 187%
29$ 188% 189% 190% 191% 192% 193% 194% 195% 196% 197% 198% 199% 200% 201% 202% 203% 204%
30$ 205% 206% 207% 208% 209% 210% 211% 212% 213% 214% 215% 216% 217% 218% 219% 220% 221%
31$ 222% 223% 224% 225% 226% 227% 228% 229% 230% 231% 232% 233% 234% 235% 236% 237% 238%
32$ 239% 240% 241% 242% 243% 244% 245% 246% 247% 248% 249% 250% 251% 252% 253% 254% 255%
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Figure	   5.16	  Confirmation	  of	  U90-­‐specific	   T	   cell	   response	   to	   peptide	   226	   in	   donor	  
HD10	  and	  mapping	  of	  minimal	  peptide	  epitope	  to	  NHCFINHFV 
(A)	   U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD10,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U90	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  
15-­‐mer	   peptides	   103,	   104	   and	   105.	   	   DMSO	   pulsed	   cells	   were	   used	   as	   a	   negative	  
control.	   	   Results	   are	   presented	   as	   spot-­‐forming	   cells	   (SCF)	   per	   105	  CD8-­‐enriched	   T	  
cells.	   	   (B)	   Using	   overlapping	   9-­‐mers	   representing	   the	   15-­‐mer	   peptide	   226	  
(EANHCFINHFVPIKT),	   the	  minimal	  peptide	  epitope	  was	  mapped	  by	   IFN-­‐γ	  ELISpot	   to	  
the	  9-­‐mer	  peptide	  NHCFINHFV.	  	  
	  































(A)$ U90-specific$ polyclonal$ T$ cells$ from$ donor$ HD10,$ enriched$ by$ 10-day$ in#vitro(
reac3va3on$using$a$U90$pep3de$mix,$were$then$screened$by$ IFN-γ$ELISpot$against$
U90$15-mer$pep3des$103,$104$and$105.$$DMSO$pulsed$cells$were$used$as$a$nega3ve$
control.$ Results$ are$ presented$ as$ spot-for ing$ cells$ ( )$ $ 5$ - i $ $
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Figure	  5.17	  Confirmation	  of	  U90-­‐specific	  T	  cell	  response	  to	  peptides	  231	  and	  254	  in	  
donor	  HD10 
U90-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD10,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U90	  peptmix,	  were	  then	  screened	  by	  IFN-­‐γ	  ELISpot	  against	  U90	  
15-­‐mer	   peptides	   230,	   231	   and	   232	   for	   Pool	   10	   and	   Pool	   31	   (left	   side).	   	   15-­‐mer	  
peptides	  253,	  254	  and	  255	  for	  Pool	  16	  and	  Pool	  32	  (right	  side).	   	  DMSO	  pulsed	  cells	  
were	  used	  as	  a	  negative	  control.	   	  Results	  are	  presented	  as	   spot-­‐forming	  cells	   (SCF)	  
per	  10
5
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5.1.6	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD24	  
The	   last	  donor	  to	  be	  analysed	  for	  responses	  to	  U90	  was	  HD24	  whose	  HLA	  type	  was	  
HLA-­‐A29,	  A74,	  B35,	  B50.	   	  The	  results	  from	  the	  15-­‐mer	  mini	  pools	  screen	  on	  a	  CD4-­‐
depleted	  T	  cell	  line	  are	  shown	  in	  Figure	  5.18.	  	  U90	  mini-­‐pools	  which	  were	  considered	  
positive	   for	  HD24	  were	  pools	  3,	  4,	  8,	  13,	  15,	  16	  and	  18,	  21,	  22,	  25,	  28,	  29,	  30,	  31.	  	  
Pools	  4	   and	  28	  had	   the	   strongest	   response	   and	  were	   selected	   for	   further	   analysis.	  	  
The	   intersect	   between	   these	   pools	  was	   the	   15-­‐mer	   peptide	   174	   (Figure	   5.18).	   	   To	  
confirm	   this	   peptide	   contained	   a	   CD8+	   T	   cell	   epitope,	   the	   T	   cell	   line	   was	   then	  
screened	  by	  ELISpot	  against	  peptides	  173,	  174	  and	  175.	  	  As	  shown	  in	  Figure	  5.18B,	  T	  
cells	  responded	  to	  peptide	  173	  (aa689–703	  YIADCDSTVRTNNIH	  and	  174	  (aa693–707	  
CDSTVRTNNIHMNNT),	  with	   the	   strongest	   response	   to	   peptide	   174,	   suggesting	   that	  
the	   minimal	   peptide	   was	   contained	   within	   this	   15-­‐mer	   sequence.	   	   However,	   this	  
donor	   was	   simultaneously	   analysed	   for	   U11	   response,	   and	   subsequently	  was	   not	  
possible	  to	  follow	  this	  donor	  up	  further.	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Figure	   5.18	   U90-­‐specifc	   T	   cells	   in	   donor	   HD24	   enriched	   by	   short	   term	   in-­‐vitro	  
reaction	  of	  PBMC	  with	  U90	  pepmix	  and	  confirmation	  peptide	  174	  response 
PBMC	  from	  donor	  HD24	  were	  stimulated	  with	  U90	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U90-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U90	  protein,	  in	  
33	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	  Polyclonal	  T	   cells	  were	  
enriched	  for	  CD8+	  T	  cells.	   	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  10
5
	  
CD8-­‐enriched	  T	  cells.	  	  Pepmixes	  representing	  U90	  and	  BK-­‐VP1	  were	  used	  as	  positive	  
and	  negative	  control	  respectively.	  	  The	  lower	  grid	  represents	  the	  33	  pools	  of	  U90	  15-­‐
mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pools	  4	  and	  28	  (based	  on	  cut	  off	  line)	  are	  
highlighted	   (blue	   and	   red	   respectively),	   and	   the	   15-­‐mer	   peptide	   present	   in	   both	  
these	  pools,	  peptide	  174	  is	  highlighted	  in	  yellow.	   	  (B)	  U90-­‐specific	  polyclonal	  T	  cells	  
from	  donor	  HD24,	  enriched	  by	  10-­‐day	  in-­‐vitro	  reactivation	  using	  a	  U90	  peptmix,	  were	  
then	   screened	  by	   IFN-­‐γ	  ELISpot	  against	  U90	  15-­‐mer	  peptides	  173,	  174	  and	  175	   for	  
Pool	  4	  and	  Pool	  28.	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18& 1%% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15% 16% 17%
19& 18% 19% 20% 21% 22% 23% 24% 25% 26% 27% 28% 29% 30% 31% 32% 33% 34%
20& 35%%% 36% 37% 38% 39% 40% 41% 42% 43% 44% 45% 46% 47% 48% 49% 50% 51%
21& 52% 53% 54% 55% 56% 57% 58% 59% 60% 61% 62% 63% 64% 65% 66% 67% 68%
22& 69% 70% 71% 72% 73% 74% 75% 76% 77% 78% 79% 80% 81% 82% 83% 84% 85%
23& 86% 87% 88% 89% 90% 91% 92% 93% 94% 95% 96% 97% 98% 99% 100% 101% 102%
24& 103% 104%105%106% 107% 108% 109% 110% 111% 112% 113% 114% 115% 116% 117% 118% 119%
25& 120% 121%122%123% 124% 125% 126% 127% 128% 129% 130% 131% 132% 133% 134% 135% 136%
26& 137% 138%139%140% 141% 142% 143% 144% 145% 146% 147% 148% 149% 150% 151% 152% 153%
27& 154% 155%156%157% 158% 159% 160% 161% 162% 163% 164% 165% 166% 167% 168% 169% 170%
28& 171% 172%173%174% 175% 176% 177% 178% 179% 180% 181% 182% 183% 184% 185% 186% 187%
29& 188% 189%190%191% 192% 193% 194% 195% 196% 197% 198% 199% 200% 201% 202% 203% 204%
30& 205% 206%207%208% 209% 210% 211% 212% 213% 214% 215% 216% 217% 218% 219% 220% 221%
31& 222% 223%224%225% 226% 227% 228% 229% 230% 231% 232% 233% 234% 235% 236% 237% 238%
32& 239% 240%241%242% 243% 244% 245% 246% 247% 248% 249% 250% 251% 252% 253% 254% 255%































highlighted% (blue% and% red% respecAvely),% and% the% 15(mer% pepAde% present% in% both%
these%pools,%pepAde%174%is%highlighted%in%yellow.%(B)%U90(specific%polyclonal%T%cells%
from% donor% HD24,% enriched% by% 10(day% in#vitro( reacAvaAon% using% a% U90% peptmix,%
were%then%screened%by%IFN(γ%ELISpot%against%U90%15(mer%pepAdes%173,%174%and%175%
for%Pool%4%and%Pool%28.%%
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5.2	  Mapping	  of	  HLA	  Class	  I	  restricted	  T	  cell	  epitopes	  in	  HHV6B	  antigen	  U11	  	  
U11-­‐specific	  T	  cells	  were	   identified	   in	  expanded	  T	  cell	  populations	   in	  19	  (out	  of	  25)	  
donors	  (see	  section	  4.1.1).	  	  In	  this	  section,	  3	  were	  selected	  for	  further	  analysis	  in	  this	  
chapter.	   	   These	   were	   donors	   HD32,	   HD24,	   and	   HD57.	   	   Both	   HD24	   and	   HD57	  
responded	   	   to	   all	   four	   HHV6B	   antigens	   tested.	   	   Whereas,	   HD32	   was	   shown	   to	  
respond	  to	  U11	  and	  U54.	  	  PBMC	  were	  isolated,	  stimulated	  with	  U11	  pepmixes	  in	  the	  
presence	  of	  IL2	  for	  10	  days,	  and	  subsequently	  analysed	  with	  the	  15-­‐mer	  mini-­‐pools.	  	  
In	  some	  cases,	  PBMC	  were	  subsequently	  stimulated	  with	  individual	  15-­‐mers	  to	  allow	  
for	  follow	  up	  mapping	  experiments. 
5.2.1	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD32	  
HD32	  (HLA-­‐A1,	  A33,	  B37,	  B58)	  was	  the	  first	  donor	  analysed	  for	  U11	  responses.	  	  The	  
results	  from	  the	  15-­‐mer	  mini	  pools	  screen	  on	  a	  CD4-­‐depleted	  T	  cell	  line	  are	  shown	  in	  
Figure	  5.19.	  	  U11	  mini-­‐pools	  which	  were	  considered	  positive	  were	  pools	  5,	  6,	  11,	  12,	  
20	   and	   22.	   	   Responses	   to	   pools	   5	   and	   22	   were	   selected	   for	   further	   analysis,	   the	  
intersect	  between	  these	  pools	  was	  the	  15-­‐mer	  peptide	  85	  (Figure	  5.19).	  	  To	  confirm	  
this	  peptide	   contained	  a	  CD8+	  T	   cell	   epitope,	   the	  T	   cell	   line	  was	   then	   screened	  by	  
ELISpot	  against	  this	  15-­‐mer,	  and	  the	  15-­‐mers	  either	  side	  (i.e.	  peptides	  84,	  85	  and	  86).	  	  
As	   shown	   in	   Figure	   5.20,	   T	   cells	   responded	   to	   peptide	   85	   (aa337–351;	  
PLKTQRRHKFPESDS).	   	   Individual	  overlapping	  9-­‐mer	  peptides	  were	   then	   synthesised	  
spanning	   the	  15-­‐mer	   sequence,	   and	   screened	  by	  ELIspot	  against	   the	  CD4-­‐depleted	  
polyclonal	  T	  cell	  line	  from	  donor	  HD32.	  	  Seven	  9-­‐mer	  peptides	  were	  tested,	  and	  the	  
highest	   response	   was	   detected	   against	   a	   9-­‐mer	   peptide	   aa338-­‐346,	   LKTQRRHKF	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(Figure	   5.20B).	   	   This	   was	   deemed	   to	   be	   the	   minimal	   peptide	   epitope	   from	   U11,	  
termed	  LKT	  after	  the	  first	  three	  amino	  acids,	  recognised	  by	  T	  cells	  from	  donor	  HD32.	  	  	  
From	   same	   representative	   experiment	   with	   donor	   HD32,	   the	   15-­‐mer	   peptides	   59	  
(aa233–247	  RKNENFNAVYSQRVL)	  and	  88	   (aa349-­‐363	  SDSVDNAGGKILIKK)	  were	  also	  
identify	  as	  target	  for	  T-­‐cell	  response	  (Figure	  5.21A).	  	  As	  shown	  in	  Figure	  5.21B,	  T	  cells	  
responded	   to	  peptide	  59	  aa233–247	   (RKNENFNAVYSQRVL),	   agreeing	  with	   the	  mini	  
pool	   screen	  data	  and	   implying	   that	   the	  minimal	  peptide	  was	   contained	  within	   this	  
15-­‐mer	   sequence.	   	   Individual	   overlapping	   9-­‐mer	   peptides	   were	   then	   synthesised	  
spanning	   the	  15-­‐mer	   sequence,	   and	   screened	  by	  ELIspot	  against	   the	  CD4-­‐depleted	  
polyclonal	  T	  cell	  line	  from	  donor	  HD32.	  	  Seven	  9-­‐mer	  peptides	  were	  tested,	  and	  the	  
highest	   response	   was	   detected	   against	   a	   9-­‐mer	   peptide	   aa238-­‐246	   FNAVYSQRV	  
(Figure	   5.21B).	   	   This	   was	   deemed	   to	   be	   the	   minimal	   peptide	   epitope	   from	   U11,	  
termed	  FNA	  after	  the	  first	  three	  amino	  acids,	  recognised	  by	  T	  cells	  from	  donor	  HD32.	  	  
However,	   the	   potential	   T	   cells	   response	   to	   the	   15-­‐mer	   peptide	   88	   aa349-­‐363	  
(SDSVDNAGGKILIKK)	  was	  not	  followed	  up.	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Figure	   5.19	   U11-­‐specifc	   T	   cells	   in	   donor	   HD32	   enriched	   by	   short	   term	   in-­‐vitro	  
reaction	  of	  PBMC	  with	  U11	  pepmix 
PBMC	  from	  donor	  HD32	  were	  stimulated	  with	  U11	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U11-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U11	  protein,	  in	  
30	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	   Polyclonal	  T	   cells	  were	  
enriched	  for	  CD8+	  T	  cells.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  105	  
CD8-­‐enriched	  T	  cells.	  	  Pepmixes	  representing	  U11	  and	  BK-­‐VP1	  were	  used	  as	  positive	  
and	  negative	  control	  respectively.	  	  The	  lower	  grid	  represents	  the	  30	  pools	  of	  U11	  15-­‐
mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pools	  5	  and	  22	  (based	  on	  cut	  off	  line)	  are	  
highlighted	   (blue	   and	   red	   respectively),	   and	   the	   15-­‐mer	   peptide	   present	   in	   both	  
these	  pools,	  peptide	  85	  is	  highlighted	  in	  yellow.	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Figure	   5.20	   Confirmation	   of	   U11-­‐specific	   T	   cell	   response	   to	   peptide	   85	   in	   donor	  
HD32	  and	  mapping	  of	  minimal	  peptide	  epitope	  to	  LKTQRRHKF 
(A)	   U11-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD32,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U11	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U11	  
15-­‐mer	  peptides	  84,	  85	  and	  86.	  	  DMSO	  pulsed	  cells	  were	  used	  as	  a	  negative	  control.	  	  
Results	  are	  presented	  as	   spot-­‐forming	  cells	   (SCF)	  per	  10
5
	  CD8-­‐enriched	  T	  cells.	   	   (B)	  
Using	  overlapping	  9-­‐mers	  representing	  the	  15-­‐mer	  peptide	  85	  (PLKTQRRHKFPESDS),	  
the	   minimal	   peptide	   epitope	   was	   mapped	   by	   IFN-­‐γ	   ELISpot	   to	   the	   9-­‐mer	   peptide	  
LKTQRRHKF.	  	  Note,	  there	  may	  be	  responses	  to	  two	  minimal	  epitopes	  identified	  here.	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Figure)5.19) )Confirma4on)of)U117specific)T) cell) response) to)pep4de)85) in)donor)
HD32)and)mapping)of)minimal)pep4de)epitope)to)LKTQRRHKF!
)
(A)! U11'specific! polyclonal! T! cells! from! donor! HD32,! enriched! by! 10'day! in#vitro(
reac@va@on!using!a!U11!pepmix,!were!then!screened!by!IFN'γ!ELISpot!against!U11!
15'mer!pep@des!84,!85!and!86.!!DMSO!pulsed! ells!were!used!as!a!nega@ve!control.!
Results!are!presented!as! spot'forming! cells! (SCF)!per!105!CD8'enriched!T! cells.! (B)!!
Using!overlapping!9'mers!represen@ng!the!15'mer!pep@de!85!(PLKTQRRHKFPESDS),!
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Figure	  5.21	  Confirmation	  of	  U11-­‐specific	  T	  cell	   response	   to	  peptides	  59	  and	  88	   in	  
donor	  HD32	  and	  mapping	  of	  minimal	  peptide	  epitope	  to	  FNAVYSQRV 
(A)	   U11-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD32,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U11	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U11	  
15-­‐mer	  peptides	  58,	  59	  and	  60	  for	  Pool	  11	  and	  Pool	  20	  (left	  side).	  	  15-­‐mer	  peptides	  
87,	  88	  and	  89	  for	  Pool	  8	  and	  Pool	  22	  are	  (right	  side).	  	  DMSO	  pulsed	  cells	  were	  used	  as	  
a	  negative	   control.	   	   Results	   are	  presented	  as	   spot-­‐forming	   cells	   (SCF)	  per	   105	  CD8-­‐
enriched	  T	  cells.	   	   (B)	  Using	  overlapping	  9-­‐mers	  representing	  the	  15-­‐mer	  peptide	  59	  
(RKNENFNAVYSQRVL),	  the	  minimal	  peptide	  epitope	  was	  mapped	  by	  IFN-­‐ 	  ELISpot	  to	  












































0 20 40 60 80 100
DMSO
RKNENFNAVYSQRVL
   U11
peptide






























































	  	  P a g e |	  154	  
	  
5.2.2	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD24	  
The	  second	  donor	  to	  be	  analysed	  was	  HD24	  (HLA-­‐A29,	  A74,	  B35,	  B50).	   	  The	  results	  
from	  the	  15-­‐mer	  mini	  pools	  screen	  on	  a	  CD4-­‐depleted	  T	  cell	  line	  are	  shown	  in	  Figure	  
5.22.	  	  U11	  mini-­‐pools	  which	  were	  considered	  positive	  for	  HD24	  were	  pools	  1,	  2,	  5,	  6,	  
9,	  11,	  12,	  18,	  20,	  21,	  22	  and	  26.	  	  There	  were	  very	  strong	  responses	  directed	  against	  
pools	  5,	  6	  and	  21	  and	  these	  were	  selected	  for	  initial	  further	  analysis.	   	  The	  intersect	  
between	  these	  pools	  were	  the	  15-­‐mer	  peptides	  69	  (pools	  5	  and	  21)	  and	  70	  (pools	  6	  
and	  21)	  (Figure	  5.22).	  	  As	  the	  peptides	  were	  adjacent	  to	  each	  other,	  a	  T	  cell	  line	  was	  
then	  screened	  by	  ELISpot	  against	  these	  15-­‐mers,	  and	  the	  two	  flanking	  15-­‐mers.	   	  As	  
shown	   in	   Figure	   5.23A,	   T	   cells	   responded	   to	   both	   peptide	   69	   (aa273–287;	  
SLESYSASKAFSVPE),	   and	   peptide	   70	   (aa277–291;	   YSASKAFSVPENGPH),	   but	   not	   the	  
flanking	  peptides.	  
From	   same	   representative	   experiment	   with	   donor	   HD24,	   the	   15-­‐mer	   peptides	   17	  
(aa65–79	   ILWLMYHYVLSKRKP),	   49	   (aa193–207	   INKLVYLGKLFVTLN)	   and	   89	   (aa353-­‐
367	   DNAGGKILIKKETLG)	   were	   also	   identified	   as	   targets	   for	   T-­‐cell	   responses	   in	   the	  
same	  way	  (Figure	  5.23	  B,	  C	  and	  D	  respectively).	  
	   	  




Figure	   5.22	   U11-­‐specifc	   T	   cells	   in	   donor	   HD24	   enriched	   by	   short	   term	   in-­‐vitro	  
reaction	  of	  PBMC	  with	  U11	  pepmix 
PBMC	  from	  donor	  HD24	  were	  stimulated	  with	  U11	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U11-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U11	  protein,	  in	  
30	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	   Polyclonal	  T	   cells	  were	  
enriched	  for	  CD8+	  T	  cells.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  105	  
CD8-­‐enriched	  T	  cells.	  	  Pepmixes	  representing	  U11	  and	  BK-­‐VP1	  were	  used	  as	  positive	  
and	  negative	  control	  respectively.	  	  The	  lower	  grid	  represents	  the	  30	  pools	  of	  U11	  15-­‐
mer	  peptides	  used	  in	  the	  screen.	   	  Positive	  pools	  5,	  6	  and	  21	  (based	  on	  cut	  off	   line)	  
are	  highlighted	   (blue	  and	  red	  respectively),	  and	   the	  15-­‐mer	  peptides	  present	   these	  
pools,	  peptide	  69	  and	  70	  is	  highlighted	  in	  yellow.	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29' 193! 194! 195! 196! 197! 198! 199! 200! 201! 202! 203! 204! 205! 206! 207! 208!
30' 209! 210! 211! 212! ! ! ! ! ! ! ! ! ! ! ! !
































Figure	  5.23	  Confirmation	  of	  U11-­‐specific	  T	  cell	  response	  to	  peptides	  17,	  49,	  70	  and	  
89	  in	  donor	  HD24 
(A)	   U11-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD24,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U11	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U11	  
15-­‐mer	  peptides	  68,	  69,	  70	  and	  71	  for	  Pools	  5,	  6	  and	  Pool	  21,	  (B)	  15-­‐mer	  peptides	  16,	  
17	  and	  18	  for	  Pool	  1	  and	  Pool	  18,	  (C)	  15-­‐mer	  peptides	  48,	  49,	  50	  and	  51	  for	  Pools	  1,	  2	  
and	  Pool	  20	  and	  (D)	  15-­‐mer	  peptides	  88,	  89	  and	  90	  for	  Pool	  9	  and	  Pool	  22.	   	  DMSO	  
pulsed	  cells	  were	  used	  as	  a	  negative	  control.	  	  Results	  are	  presented	  as	  spot-­‐forming	  











































































































1," 2" and" Pool" 20" and" (D)" 154mer" pep;des" 88," 89" and" 90" for" Pool" 9" and" Pool" 22.""
DMSO"pulsed"cells"were"used"as"a"nega;ve"control."Results"are"presented"as"spot4
forming"cells"(SCF)"per"105"CD84enriched"T"cells.""
	  	  P a g e |	  157	  
	  
5.2.3	  Mapping	  CD8+	  T	  cell	  epitopes	  in	  donor	  HD57	  
The	  final	  donor	  analysed	  was	  HD57	  (HLA-­‐A2,	  B40(60),	  B50).	  	  The	  results	  from	  the	  15-­‐
mer	  mini	  pools	  screen	  on	  a	  CD4-­‐depleted	  T	  cell	   line	  are	  shown	  in	  Figure	  5.24.	  	  U11	  
mini-­‐pools	  which	  were	  considered	  positive	  were	  pools	  5,	  6,	  12,	  20,	  21,	  23	  and	  26.	  	  To	  
confirm	   these	   peptides	   contained	   a	   CD8+	   T	   cell	   epitope,	   the	   T	   cell	   line	   was	   then	  
screened	  by	  ELISpot	  against	  these	  15-­‐mers,	  and	  the	  appropriate	  flanking	  peptides.	  	  T	  
cells	  responded	  to	  peptide	  69	  (aa273–287;	  SLESYSASKAFSVPE),	  peptide	  104	  (aa413-­‐
427;	   GILDFGVKLPAEAQS)	   and	   peptide	   60	   (aa237–251;	   NFNAVYSQRVLQTPL),	   with	  
minimal	   recognition	  of	  any	   flanking	  peptides.	   	   (Figure	  5.25A,	  B	  and	  C	  respectively).	  	  
The	   peptide	   104	   includes	   the	   sequence	   GILDFGVKL	   (aa413-­‐421,	   GIL),	   which	   while	  
these	  experiments	  were	  underway	  was	   identified	  as	  a	  HLA-­‐A2	  restricted	  peptide	   in	  
HHV6B	  U11	  (Martin	  et	  al.,	  2012).	  	  The	  expaneded	  T	  cell	  population	  from	  donor	  HD57	  
was	  tested	  and	  shown	  to	  recognise	  the	  GIL	  peptide	  (Figure	  5.25C	  right	  hand	  panel).	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Figure	   5.24	   U11-­‐specifc	   T	   cells	   in	   donor	   HD57	   enriched	   by	   short	   term	   in-­‐vitro	  
reaction	  of	  PBMC	  with	  U11	  pepmix 
PBMC	  from	  donor	  HD57	  were	  stimulated	  with	  U11	  pepmix,	  and	  cultured	  for	  10	  days	  
in	  the	  presence	  of	   IL2.	   	  U11-­‐specific	  polyclonal	  T	  cells	  were	  then	  screened	  by	   IFN-­‐γ	  
ELISpot	  against	  overlapping	  15-­‐mer	  peptides,	  representing	  the	  entire	  U11	  protein,	  in	  
30	  pools	   such	   that	  each	  15-­‐mer	  was	  present	   in	   two	  pools.	   	   Polyclonal	  T	   cells	  were	  
enriched	  for	  CD8+	  T	  cells.	  	  Results	  are	  presented	  as	  spot-­‐forming	  cells	  (SCF)	  per	  105	  
CD8-­‐enriched	  T	  cells.	  	  Pepmixes	  representing	  U11	  and	  BK-­‐VP1	  were	  used	  as	  positive	  
and	  negative	  control	  respectively.	  	  The	  lower	  grid	  represents	  the	  30	  pools	  of	  U11	  15-­‐
mer	  peptides	  used	  in	  the	  screen.	  	  Positive	  pool	  5	  and	  21	  (based	  on	  cut	  off	   line)	  are	  
highlighted	   (blue	   and	   red	   respectively),	   and	   the	   15-­‐mer	   peptide	   present	   in	   both	  
these	  pools,	  peptide	  69	  is	  highlighted	  in	  yellow.	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Figure	  5.25	  Confirmation	  of	  U11-­‐specific	  T	  cell	  response	  to	  peptides	  60,	  69	  and	  104	  
and	  confirmation	  of	  minimal	  peptide	  epitope	  to	  GILDFGVKL	  in	  donor	  HD57 
(A)	   U11-­‐specific	   polyclonal	   T	   cells	   from	   donor	   HD24,	   enriched	   by	   10-­‐day	   in-­‐vitro	  
reactivation	  using	  a	  U11	  pepmix,	  were	   then	  screened	  by	   IFN-­‐γ	  ELISpot	  against	  U11	  
15-­‐mer	  peptides	  68,	  69	  and	  70	  for	  Pools	  5	  and	  Pool	  21,	   (B)	  15-­‐mer	  peptides	  59,	  60	  
and	  61	  for	  Pool	  12	  and	  Pool	  20,	  (C)	  15-­‐mer	  peptides	  103,	  104	  and	  105	  for	  Pool	  8	  and	  
Pool	  23.	  	  (D)	  Confirmation	  of	  the	  U90-­‐specific	  CD8	  T	  cell	  response	  to	  the	  individual	  9-­‐
mer	  peptide	  GILDFGVKL.	  	  DMSO	  pulsed	  cells	  were	  used	  as	  a	  negative	  control.	  	  Results	  











































































Figure*5.24* *Confirma4on*of*U118specific*T* cell* response* to*pep4des*60,* 69*and*
104*and*confirma4on*of*minimal*pep4de*epitope*to*GILDFGVKL*in*donor*HD57*
*






nega9ve" control." Results" are" presented" as" spot2forming" cells" (SCF)" per" 105" CD82
enriched"T"cells.""
D 
	  	  P a g e |	  160	  
	  
5.3	   Characterisation	   of	   HLA	   restriction	   elements	   for	   antigenic	   peptide	  
identified	  in	  U90	  and	  U11	  
To	  determine	  the	  HLA	  restricting	  alleles	  of	  newly	  identified	  HHV6B	  peptide	  epitopes,	  
autologous,	  partially	  HLA-­‐matched	  and	  HLA	  mis-­‐matched	  PHA-­‐blasts	  (or	  PBMC)	  were	  
used	  as	  targets	  in	  T-­‐cell	  assays.	  	  T	  cell	  populations	  were	  generated	  by	  10-­‐day	  culture	  
of	   donor	   PBMC	   stimulated	   with	   individual	   9-­‐mer	   peptides	   mapped	   in	   section	   5.2	  
(peptides	  U90	  FESLLFPEL,	  NLITAAKNI,	   ITAAKNIGI,	  LNIDPSESI,	  PSKSKKIKL,	  NHCFINHFV	  
and	   U11	   LKTQRRHKF).	   	   Polyclonal	   cultures	   were	   then	   used	   as	   effectors	   in	   T	   cell	  
assays.	  	  Appropriate	  target	  cells	  were	  loaded	  with	  individual	  peptides	  and	  incubated	  
with	   an	   Effector-­‐to-­‐Target	   (E:T)	   ratio	   of	   10:1.	   	   The	   effectors	   and	   targets	   were	   co-­‐
cultured	   overnight	   for	   16h,	   before	   target	   cell	   recognition	   was	   monitored	   by	  
measuring	  release	  of	  IFN-­‐γ	  into	  the	  culture	  supernatant	  by	  ELISA.	  
	  
The	   first	   peptide	   to	   be	   analysed	   was	   U90	   FES.	   	   Responses	   to	   this	   epitope	   were	  
identified	  in	  donors	  HD05,	  HD30	  and	  HD57.	  	  The	  HLA	  types	  of	  these	  donors	  is	  HD05	  
HLA-­‐A2,	   A24,	   B40(60),	   B44;	   	   HD30	   HLA-­‐A2,	   A32,	   B7,	   B40(60)	   and	   HD57	   HLA-­‐A2,	  
B40(60),	  B50).	   	  Thus,	  based	  on	  this	   it	  was	   likely	  that	  this	  peptide	  was	  presented	  by	  
A2	   or	   B40,	   which	   are	   the	   shared	   alleles	   between	   these	   donors.	   	   However,	   as	  
described	  earlier	  (section	  5.1.3)	  this	  peptide	  had	  been	  identified	  by	  Gerdmann	  et	  al.,	  
where	  they	  showed	  that	   is	  was	  presented	  by	  HLA-­‐B40	  (Gerdmann	  et	  al.,2013).	   	  To	  
confirm	  the	  response	   identified	  here	  was	  similarly	  presented	  by	  B40,	  FES-­‐specific	  T	  
cells	  from	  donor	  HD05	  were	  used	  as	  effectors	  with	  peptide-­‐pulsed	  autologous,	  B40-­‐
matched	   or	   mis-­‐matched	   PHA	   blasts	   as	   targets.	   	   T	   cells	   reactive	   against	   FES	  
recognised	   autologous	   and	   B40-­‐matched	   targets	  matched	   at	   HLA-­‐B40(60)	  with	   no	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significant	   reactivity	  detected	  against	  mis-­‐matched	   targets	   	   (Figure	  5.26).	   	   The	  VEE	  
peptide	  was	  also	   identified	  here	   in	  the	  same	  three	  donors	   (section	  5.1.3),	  and	  also	  
mapped	  by	  Gerdemann	   to	  HLA	  B40.	   	  Experiments	  were	  not	  carried	  out	   to	  confirm	  
this,	  but	  it	  was	  assumed	  that	  the	  response	  identified	  in	  this	  thesis	  was	  also	  restricted	  
through	  HLA-­‐B40.	  
T	  cells	  recognising	  the	  U90	  peptide	  PSK	  were	  identified	  in	  donors	  HD53.	  	  Donor	  HD53	  
was	  homozygous	  for	  HLA-­‐A29	  and	  –B44.	   	  Thus,	  PSK	  peptide-­‐pulsed	  autologous	  and	  
A29-­‐	  or	  B44-­‐matched	  PHA	  blasts	  were	  used	  as	  targets	  for	  polyclonal	  T	  cell	  generated	  
by	  stimulation	  of	  PBMC	  from	  HD53	  with	  the	  9-­‐mer	  peptide	  PSK.	  	  T	  cell	  recognition	  of	  
target	  cells	  was	  determined	  by	  measuring	  the	  release	  of	  IFN-­‐γ	  in	  to	  the	  supernatant	  
by	  ELISA.	   	  T	  cells	  reactive	  against	  PSK	  recognised	  autologous	  and	  allogeneic	  targets	  
matched	  at	  HLA-­‐A29	  but	  not	  HLA-­‐B44	  (Figure	  5.27),	  implying	  that	  PSK	  was	  presented	  
in	  the	  context	  of	  HLA-­‐A29.	  
T	  cells	  recognising	  the	  U90	  peptide	  LNI	  were	  identified	  in	  donor	  HD49.	  	  Donor	  HD49	  
was	  HLA-­‐A1,-­‐A2,	  -­‐B8,	  -­‐B44.	  	  Thus,	  LNI	  peptide-­‐pulsed	  autologous	  and	  A1-­‐,	  A2-­‐,	  B8-­‐	  or	  
B44-­‐matched	   PBMC	   were	   used	   as	   targets	   this	   time,	   to	   reduce	   the	   background.	  	  
Polyclonal	  T	  cells	  generated	  by	  stimulation	  of	  PBMC	  for	  HD49	  with	  the	  9-­‐mer	  peptide	  
LNI	   were	   used	   as	   effectors.	   	   T	   cell	   recognition	   of	   target	   cells	   was	   determined	   by	  
measuring	   the	   release	   of	   IFN-­‐γ	   in	   to	   the	   supernatant	   by	   ELISA.	   	   T	   cells	   reactive	  
against	  LNI	  recognised	  autologous	  and	  allogeneic	  targets	  matched	  at	  HLA-­‐A1	  but	  not	  
others	  (Figure	  5.28),	  implying	  that	  LNI	  was	  presented	  in	  the	  context	  of	  HLA-­‐A1.	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Figure	  5.26	  Identification	  (Confirmation)	  of	  HLA-­‐B40	  as	  the	  restriction	  element	  for	  
U90	  FESLLFPEL	  (aa	  57-­‐65)	  in	  donor	  HD05	  [HLA-­‐A2,	  A24,	  B40(60),	  B44] 
Polyclonal	  T	  cell	  effectors	  generated	  by	  pulsed	  PBMC	  from	  HLA-­‐matched	  donor	  HD05	  
with	  the	  U90	  9-­‐mer	  peptide	  FESLLFPEL	  and	  cultured	  for	  10	  days	  in	  the	  presence	  of	  IL-­‐	  
2,	  were	  tested	  against	  autologous,	  B40-­‐matched	  or	  B40-­‐ve	  (mis-­‐matched)	  PHA	  blasts	  
were	  pulsed	  with	  either	  the	  FESLLFPEL	  peptide	  (2	  μg/ml)	  or	  DMSO.	  	  Polyclonal	  T	  cells	  
were	  used	  used	   in	  T	  cell	  assays	  at	  an	  E:T	   ratio	  of	  10:1.	   	  T	  cell	  recognition	  of	   target	  
cells	  was	  determined	  by	  measuring	  release	  of	   IFN-­‐γ	   in	  to	  the	  supernatant	  by	  ELISA.	  	  
Results	   are	   the	   mean	   of	   triplicated	   readings	   ±	   SD	   (errors	   bars)	   and	   expressed	   as	  
pg/ml	   IFN-­‐γ	  released	   into	  the	  supernatant.	   	  T	  cell	  effector	  cells	  alone	  were	  used	  as	  
negative	  control.	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Figure	   5.27	   HLA	   restriction	   of	   the	   U90	   peptide	   epitope	   PSKSKKIKL	   (aa758–766)	  
maps	  to	  HLA-­‐A29	  in	  donor	  HD53	  [HLA-­‐A29,	  B44] 
Polyclonal	  T	  cell	  effectors	  generated	  by	  pulsed	  PBMC	  from	  HLA-­‐matched	  donor	  HD53	  
with	   the	  U90	  9-­‐mer	  peptide	  PSK	  and	  cultured	   for	  10	  days	   in	   the	  presence	  of	   IL-­‐	  2,	  
were	   tested	   against	   autologous,	   A29-­‐matched	   or	   B44-­‐matched	   PHA	   blasts	   pulsed	  
with	  either	  the	  PSKSKKIKL	  peptide	  (2	  μg/ml)	  or	  DMSO.	  	  Polyclonal	  T	  cells	  were	  used	  
at	  an	  E:T	  ratio	  of	  10:1.	  	  T	  cell	  recognition	  of	  target	  cells	  was	  determined	  by	  measuring	  
release	  of	   IFN-­‐γ	   in	  to	  the	  supernatant	  by	  ELISA.	   	  Results	  are	  the	  mean	  of	  triplicated	  
readings	   ±	   SD	   (errors	   bars)	   and	   expressed	   as	   pg/ml	   IFN-­‐γ	   released	   into	   the	  
supernatant. 












































































with% the%U90% 99mer% pep/de% PSK% and% cultured% for% 10% days% in% the% presence% of% IL9% 2,%
were%tested%against%autologous,%A299matched%or%B449matched%PHA%blasts%pulsed%with%
either% he%PSKSKKIKL%pep/de%(2%μg/ml)%or%DMSO.% %Polyclonal%T%cells%were%used%at%an%
E:T% ra/o% of% 10:1.% % % T% cell% r cogni/on% of% target% cells%was% determined% by%mea uring%
release%of%IFN9γ% in%to%the%supernatant%by%ELISA.% % %Results%are%the%mean%of%triplicated%
readings% ±% SD% (errors% bars)% and% expressed% as% pg/ml% IFN9γ% released% into% the%
supernatant.!
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Figure	   5.28	   HLA	   restriction	   of	   the	   U90	   peptide	   epitope	   LNIDPSESI	   (aa417–425)	  
maps	  to	  HLA-­‐A1	  in	  donor	  HD49	  [HLA-­‐A1,	  A2,	  B8	  ,B44] 
Polyclonal	  T	  cell	  effectors	  generated	  by	  pulsed	  PBMC	  from	  HLA-­‐matched	  donor	  HD49	  
with	  the	  U11	  9-­‐mer	  peptide	  LNIDPSESI	  and	  cultured	  for	  10	  days	  in	  the	  presence	  of	  IL-­‐	  
2,	   were	   tested	   against	   autologous,	   A1-­‐matched,	   A2-­‐matched,	   B8-­‐matched	   or	   B44-­‐
matched	   PBMC	   pulsed	   with	   either	   the	   LNIDPSESI	   peptide	   (2	   μg/ml)	   or	   DMSO.	  	  
Polyclonal	  T	  cells	  were	  used	  at	  an	  E:T	  ratio	  of	  10:1.	  	  T	  cell	  recognition	  of	  target	  cells	  
was	   determined	   by	   measuring	   release	   of	   IFN-­‐γ	   in	   to	   the	   supernatant	   by	   ELISA.	  	  
Results	   are	   the	   mean	   of	   triplicated	   readings	   ±	   SD	   (errors	   bars)	   and	   expressed	   as	  
pg/ml	  IFN-­‐γ	  released	  into	  the	  supernatant. 

















































Polyclonal% % ll% ffectors%generated%by%pulsed%PBMC%from%HLA4matched%donor%HD49%
with%the%U11%94mer%pep.de%LNIDPSESI%and%cultured%for%10%days%in%the%presence%of%IL4%2,%
were% tested% against% autologous,% A14matched,% A24matched,% B84matched% or% B444
matched% PBMC% pulsed% with% either% the% LNIDPSESI% pep.de% (2% μg/ml)% or% DMSO.%%
Polyclonal%T%cells%were%used%at%an%E:T%ra.o%of%10:1.% % %T%cell%recogni.on%of%target%cells%
was%determined%by%measuring%release%of%IFN4γ%in%to%the%supernatant%by%ELISA.%%%Results%
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T	  cells	  recognising	  the	  U90	  peptide	  NHC	  were	  identified	  in	  donor	  HD10.	  	  Donor	  HD10	  
was	  HLA-­‐A1,	  -­‐A2,	  -­‐B8,	  -­‐B39.	  	  Thus,	  NHC	  peptide-­‐pulsed	  autologous	  and	  A1-­‐,	  A2-­‐,	  B8-­‐	  
or	   B39-­‐matched	   PBMC	   were	   used	   as	   targets	   for	   polyclonal	   T	   cells	   generated	   by	  
stimulation	  of	  PBMC	  for	  HD10	  with	  the	  9-­‐mer	  peptide	  NHC.	  	  T	  cells	  reactive	  against	  
NHC	   recognised	   autologous	   and	   allogeneic	   targets	   matched	   at	   HLA-­‐B39	   but	   not	  
others	  (Figure	  5.29),	  implying	  that	  NHC	  was	  presented	  in	  the	  context	  of	  HLA-­‐B39.	  	  	  
T	  cells	  recognising	  the	  U90	  peptides	  NLI	  and	  ITA	  were	  identified	  in	  donor	  HD27	  (HLA-­‐
A1,	  -­‐A2,	  -­‐B44)	  and	  also	  predicted	  to	  bind	  to	  HLA-­‐A2	  (see	  section	  5.1.1).	  	  To	  confirm	  
this,	  firstly	  NLI	  peptide-­‐pulsed	  autologous	  and	  A1-­‐,	  A2-­‐	  or	  B44-­‐matched	  PBMC	  were	  
used	   as	   targets	   for	   polyclonal	   T	   cells	   generated	   by	   stimulation	   of	   PBMC	   for	   HD27	  
with	  the	  9-­‐mer	  peptide	  NLI.	   	  T	  cells	  reactive	  against	  NLI	  recognised	  autologous	  and	  
allogeneic	   targets	  matched	   at	  HLA-­‐A2	  but	   not	   others	   (Figure	   5.30A),	   implying	   that	  
NLI	  was	  presented	   in	   the	   context	  of	  HLA-­‐A2.	   	   In	  a	   separate	  experiment	  with	   same	  
donor	  HD27,	  the	  U90	  peptide	  ITA	  was	  also	  shown	  to	  be	  presented	  in	  the	  context	  of	  
HLA-­‐A2	  (Figure	  5.30B).	  	  	  
T	  cells	  recognising	  the	  U11	  peptide	  LKT	  were	  identified	  in	  donor	  HD32	  (HLA-­‐A1,	  -­‐A33,	  
-­‐B37,	   -­‐B58).	   	   Thus,	   LKT	   peptide-­‐pulsed	   autologous	   and	   A1-­‐,	   A33-­‐,	   B37-­‐	   or	   B58-­‐
matched	  PBMC	  were	  used	  as	  targets	  for	  polyclonal	  T	  cells	  generated	  by	  stimulation	  
of	   PBMC	   for	   HD32	   with	   the	   9-­‐mer	   peptide	   LKT.	   	   T	   cells	   reactive	   against	   LKT	  
recognised	   autologous	   and	   allogeneic	   targets	  matched	   at	   HLA-­‐B37	   but	   not	   others	  
(Figure	  5.29),	  implying	  that	  LKT	  was	  presented	  in	  the	  context	  of	  HLA-­‐B37.	  	  	  
Overall,	  a	  number	  of	  minimal	  peptides	  were	   identified	   in	  U90	  and	  U11,	  both	  novel	  
and	  confirming	  peptides	   identified	  by	  others	  during	   the	  course	  of	   this	   thesis.	   	  HLA	  
restriction	   elements	   have	   been	   mapped	   to	   these	   peptides.	   	   Table	   5.1	   shows	   a	  
summary	  of	  this	  data	  with	  amino	  acid	  coordinates	  for	  each	  peptide.	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A	  number	  of	  15-­‐mer	  peptides	  were	  also	  identified	  but	  for	  various	  reasons	  it	  was	  not	  
possible	   to	   follow	   these	   up	   further	   to	   map	   the	   minimal	   epitopes	   or	   identify	   HLA	  
restriction	  elements.	  	  These	  may	  potentially	  contain	  novel	  CD8+	  T	  cell	  epitopes.	  	  This	  
data	   is	   summarised	   in	   Table	   5.2.	   	   However,	   towards	   the	   end	   of	   the	   thesis	   it	   was	  
possible	   to	   generate	   polyclonal	   lines	   to	   a	   number	   of	   these	   15-­‐mers	   to	   allow	   for	  
studies	  of	  whether	  these	  peptides	  were	  presented	   in	  HHV6B-­‐infected	  cells	   (section	  
5.4),	  lending	  support	  their	  identification	  as	  containing	  HHV6B	  T	  cells	  epitopes.	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Figure	   5.29	  HLA	   restriction	   of	   the	   U90	   peptide	   epitope	  NHCFINHFV	   (aa903–911)	  
maps	  to	  HLA-­‐B39	  in	  donor	  HD10	  [HLA-­‐A1,	  A2,	  B8,	  B39] 
Polyclonal	  T	  cell	  effectors	  generated	  by	  pulsed	  PBMC	  from	  HLA-­‐matched	  donor	  HD49	  
with	  the	  U90	  9-­‐mer	  peptide	  NHCFINHFV	  and	  cultured	  for	  10	  days	  in	  the	  presence	  of	  
IL-­‐	  2,	  were	  tested	  against	  autologous,	  A1-­‐matched,	  A2-­‐matched,	  B8-­‐matched	  or	  B39-­‐
matched	   PBMC	   pulsed	   with	   either	   the	   NHCFINHFV	   peptide	   (2	   μg/ml)	   or	   DMSO.	  	  
Polyclonal	  T	  cells	  were	  used	  at	  an	  E:T	  ratio	  of	  10:1.	  	  T	  cell	  recognition	  of	  target	  cells	  
was	   determined	   by	   measuring	   release	   of	   IFN-­‐γ	   in	   to	   the	   supernatant	   by	   ELISA.	  	  
Results	   are	   the	   mean	   of	   triplicated	   readings	   ±	   SD	   (errors	   bars)	   and	   expressed	   as	  
pg/ml	  IFN-­‐γ	  released	  into	  the	  supernatant.	  












































































































2,% were% t sted% against% autologous,% 7 tc ed,% A27matched,% B87matched% or% B397
matched% % % ith% either% the% NHCFINHFV% ep.de% (2% μg/ml)% or% DMSO.%%
Polyclonal%T%cells% ere% se %at%an%E:T%ra.o%of%10:1.% % %T%cell%recogni. n%of%target%cells%
was%determined%by%measuring%release%of%IFN7γ%in%to%the%supernatant%by%ELISA.%%%Results%
are% the%mean%of% triplicated% readings%±%SD% (errors%bars)% and%expressed%as%pg/ml% IFN7γ%
released%into%the%supernatant.!
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Figure	  5.30	  HLA	  restriction	  of	  the	  U90	  peptide	  epitopes	  NLITAAKNI	  (aa331-­‐339)	  and	  
ITAAKNIGI	  (aa333-­‐341)	  maps	  to	  HLA-­‐A2	  in	  donor	  HD27	  [HLA-­‐A1,	  A2,	  B44] 
Polyclonal	  T	  cell	  effectors	  generated	  by	  pulsed	  PBMC	  from	  HLA-­‐matched	  donor	  HD49	  
with	   the	  U90	  9-­‐mer	  peptides	  NLITAAKNI	   (A)	  or	   ITAAKNIGI	   (B),	   then	  cultured	   for	  10	  
days	  in	  the	  presence	  of	  IL-­‐	  2,	  were	  then	  tested	  against	  autologous,	  A1-­‐matched,	  A2-­‐
matched	  or	  B44-­‐matched	  PBMC	  pulsed	  with	  either	  the	  NLITAAKNI	  (A)	  or	   ITAAKNIGI	  
(B)	  peptides	  (2	  μg/ml)	  or	  DMSO.	  	  Polyclonal	  T	  cells	  were	  used	  at	  an	  E:T	  ratio	  of	  10:1.	  	  
T	  cell	  recognition	  of	  target	  cells	  was	  determined	  by	  measuring	  release	  of	  IFN-­‐γ	  in	  to	  
the	  supernatant	  by	  ELISA.	   	  Results	  are	  the	  mean	  of	  triplicated	  readings	  ±	  SD	  (errors	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Figure	   5.31	   HLA	   restriction	   of	   the	   U11	   peptide	   epitope	   LKTQRRHKF	   (aa338–346)	  
maps	  to	  HLA-­‐B37	  in	  donor	  HD32	  [HLA-­‐A1,	  A33,	  B37,	  B58] 
Polyclonal	  T	  cell	  effectors	  generated	  by	  pulsed	  PBMC	  from	  HLA-­‐matched	  donor	  HD32	  
with	  the	  U11	  9-­‐mer	  peptide	  LKTQRRHKF	  and	  cultured	  for	  10	  days	  in	  the	  presence	  of	  
IL-­‐	  2,	  were	   tested	   against	   autologous,	   A1-­‐matched,	   A33-­‐matched,	   B37-­‐matched	   or	  
B58-­‐matched	  PBMC	  pulsed	  with	  either	  the	  LKTQRRHKF	  peptide	  (2	  μg/ml)	  or	  DMSO.	  	  
Polyclonal	  T	  cells	  were	  used	  at	  an	  E:T	  ratio	  of	  10:1.	  	  T	  cell	  recognition	  of	  target	  cells	  
was	   determined	   by	   measuring	   release	   of	   IFN-­‐γ	   in	   to	   the	   supernatant	   by	   ELISA.	  	  
Results	   are	   the	   mean	   of	   triplicated	   readings	   ±	   SD	   (errors	   bars)	   and	   expressed	   as	  
pg/ml	  IFN-­‐γ	  released	  into	  the	  supernatant.	  































































2,! were! tested! against! autologous,! A1<matched,! A33<matched,! B37<match d! or! B58<
matched! PBMC! pulsed! with! either! the! LKTQRRHKF! pepFde! (2! μg/ l)! or! DMSO.!!
Polyclonal!T!cells!were!used!at!an!E:T!raFo!of!10:1.! ! !T!cell!recogniFon!of!target!cells!
was!determined!by!measuring!release!of!IFN<γ!in!to!the!supernatant!by!ELISA.!!!Results!
are! the!mean!of! triplicated! readings!±!SD! (errors!bars)! and!expressed!as!pg/ml! IFN<γ!
released!into!the!supernatant.!
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Table	  5.1	  CD8	  T	  cells	  9-­‐mer	  epitopes	  identified	  in	  HHV6B	  U90	  and	  U11	  
HHV6B	  
antigen	   aa	  position	   aa	  sequence	   HLA	  
U90	   	   	   	  
	   39-­‐47	   VEESIKEIL	   B40(60)	  
	   57-­‐65	   FESLLFPEL	   B40(60)	  
	   331-­‐339	   NLITAAKNI	   A2	  
	   333-­‐341	   ITAAKNIGI	   A2	  
	   417-­‐425	   LNIDPSESI	   A1	  
	   758-­‐766	   PSKSKKIKL	   A29	  
	   903-­‐911	   NHCFINHFV	   B39	  
U11	   	   	   	  
	   238-­‐246	   FNAVYSQRV	   NT*	  
	   338-­‐346	   LKTQRRHKF	   B37	  
	   413-­‐421	   GILDFGVKL	   A2	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position	   15-­‐mer	  sequence	   HLA	  
U90	   	   	   	  
	   33-­‐47	   YHPDPVVEESIKEIL*	   B40(60)	  
	   53-­‐67	   CDVSFESLLFPELEA*	   B40(60)	  
	   209-­‐223	   ASESRDLLMDLKANM	   NT**	  
	   324-­‐338	   IHINCKNLITAAKNI*	   A2	  
	   329-­‐343	   CKNLITAAKNIGIAV*	   A2	  
	   413-­‐427	   SICDLNIDPSESILL*	   A1	  
	   453-­‐467	   NVDYLKYMEVQSPTD	  	   NT	  
	   693-­‐707	   CDSTVRTNNIHMNNT	   NT	  
	   766-­‐780	   KPSKSKKIKLDRLPE*	   A29	  
	   849-­‐863	   IPIRSMPGTHDIRNK	   B44	  
	   869-­‐883	   HWLWFMRKTHKVDNC	   NT	  	  
	   874-­‐888	   FMRKTHKVDNCVIHS	   NT	  
	   901-­‐915	   EANHCFINHFVPIKT*	   B39	  
	   905-­‐919	   CFINHFVPIKTDDEE	   B44	  
	   921-­‐935	   EKENVSYTYSKIQDS	   NT	  
	   1013-­‐1027	   GNNSPILNIINDTTC	   NT	  
U11	   	   	   	  
	   29-­‐43	   ENLENVDLREHPYVT	   NT	  
	   65-­‐79	   ILWLMYHYVLSKRKP	   NT	  
	   93-­‐107	   NVVNEYLKSKGLNKG	   NT	  
	   97-­‐111	   EYLKSKGLNKGNFEN	   NT	  
	   193-­‐207	   INKLVYLGKLFVTLN	   NT	  
	   233-­‐247	   RKNENFNAVYSQRVL*	   NT	  
	   237-­‐251	   NFNAVYSQRVLQTPL	   NT	  
	   273-­‐287	   SLESYSASKAFSVPE	   NT	  
	   277-­‐291	   YSASKAFSVPENGPH	   NT	  
	   309-­‐323	   LPSISIDTKRPSADL	   NT	  
	   337-­‐351	   PLKTQRRHKFPESDS*	   B37	  
	   349-­‐363	   SDSVDNAGGKILIKK	   NT	  
	   353-­‐367	   DNAGGKILIKKETLG	   NT	  
	   413-­‐427	   GILDFGVKLPAEAQS*	   A2	  
	   433-­‐447	   DLLQDKTSIRSPSSG	   NT	  
	   749-­‐763	   ADLSRDLDSVSFKDA	   NT	  
	  	  	  	  *	  9-­‐mer	  has	  been	  mapped,	  	  	  **not	  tested	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5.4	  T	  cell	  recognition	  of	  HHV6B	  infected	  cells	  
To	   determine	   if	   T	   cells	   recognising	   the	   newly	   identified	   HHV6B	   peptide	   epitopes	  
could	   recognise	   HHV6B	   infected	   cells,	   autologous	   PHA	   blasts	   were	   infected	   with	  
HHV6B	  as	  described	   in	  the	  material	  and	  methods	  (section	  2.15),	  before	  being	  used	  
as	  targets	  for	  epitope	  specific	  polyclonal	  T	  cells	  for	  each	  newly	  identified	  epitope.	  	  In	  
addition,	  testing	  the	  recognition	  of	  HHV6B	  infected	  cells	  for	  the	  9-­‐mer	  peptides	  (U90;	  
VVEESIKEI,	  FESLLFPEL,	  NLITAAKNI,	  ITAAKNIGI,	  LNIDPSESI,	  PSKSKKIKL,	  NHCFINHFV	  and	  
U11;	   LKTQRRHKF),	   this	   was	   also	   carried	   out	   for	   15-­‐mer	   peptides	   	   (U90;	  
ASESRDLLMDLKANM,	   CDSTVRTNNIHMNNT,	   IPIRSMPGTHDIRNK	   and	  
CFINHFVPIKTDDEE	   and	   U11;	   INKLVYLGKLFVTLN,	   SLESYSASKAFSVPE,	  
YSASKAFSVPENGPH	  and	  DNAGGKILIKKETLG).	   	  T	  cells	  specific	   for	  each	  peptide	  to	  be	  
tested	   were	   generated	   by	   stimulating	   PBMC	   with	   each	   individual	   peptide,	   and	  
cultures	  were	  maintained	  for	  10	  days	  at	  37°C,	  with	  IL2	  being	  added	  to	  cultures	  from	  
day	  3.	   	   Polyclonal	   cultures	  were	   then	  used	  as	  effectors	   in	   virus	   recognition	  assays.	  	  
Target	   cells	   incubated	  with	   effectors	   at	   an	   Effector-­‐to-­‐Target	   (E:T)	   ratio	   of	   10:1	   (in	  
some	   experiments	   more	   than	   one	   E:T	   ratio	   was	   used).	   	   The	   effectors	   and	   targets	  
were	  co-­‐cultured	  overnight	  for	  16h,	  before	  target	  cell	  recognition	  was	  monitored	  by	  
measuring	  release	  of	  IFN-­‐γ	  into	  the	  culture	  supernatant	  by	  ELISA.	  
The	  first	  peptide	  to	  be	  analysed	  was	  PSK,	  which	  maps	  to	  U90	  aa758-­‐766.	  	  To	  confirm	  
this,	   polyclonal	   PSK-­‐specific	   T	   cell	   effectors	   generated	   by	   pulsed	   PBMC	   from	  HLA-­‐
matched	  donor	  HD53	  with	   the	  U90	  9-­‐mer	  peptide	  PSK	  and	  cultured	   for	  10	  days	   in	  
the	   presence	   of	   IL-­‐	   2,	   were	   tested	   against	   autologous	   PHA	   blasts	   infected	   with	  
HHV6B	   or	   mock	   infected.	   	   Or	   as	   controls	   PHA	   blasts	   pulsed	   with	   either	   the	   PSK	  
peptide	   or	   DMSO.	   	   Polyclonal	   T	   cells	   were	   used	   at	   three	   E:T	   ratio.	   	   Thus,	   HHV6B	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infected-­‐	  or	  mock	  infected-­‐autologous	  PHA	  blasts	  were	  used	  as	  targets	  for	  polyclonal	  
T	   cells	   generated	   by	   stimulation	   of	   PBMC	   for	   HD53	   with	   the	   9-­‐mer	   peptide	   PSK.	  	  
HHV6B	  infection	  was	  confirmed	  by	  immunofluorescence	  assay	  (IFA)	  analyses	  (Figure	  
5.32B)	  T	  cell	  recognition	  of	  target	  cells	  was	  determined	  by	  measuring	  the	  release	  of	  
IFN-­‐γ	   in	   to	   the	   supernatant	   by	   ELISA.	   	   T	   cells	   reactive	   against	   PSK	   recognised	  
autologous	   PHA	  blasts	   infected	  with	  HHV6B	  but	   not	  mock	   infected	   (Figure	   5.32B),	  
implying	  that	  T	  cells	  reactive	  against	  PSK	  was	  able	  to	  kill	  HHV6B	  infected	  PHA	  blasts.	  
Similar	  experiments	  were	  conducted	   for	  another	  U90	  9-­‐mer	  peptide	   identified	  and	  
associated	  with	  HLA-­‐B40	  aa57-­‐65	  FESLLFPEL	  and	  T	  cells	  expanded	  were	  able	   to	  kill	  
HHV6B	   infected	   PHA	   blasts	   (Figure	   5.33).	   	   Additionally,	   similar	   experiments	   were	  
conducted	  for	  other	  U90	  peptides	   identified	  and	  T	  cells	  expanded	  were	  able	  to	  kill	  
HHV6B	  infected	  PHA	  blasts	  (Figure	  5.34).	  	  Also,	  similar	  experiments	  were	  conducted	  
for	  another	  U11	  9-­‐mer	  peptide	   identified	  and	  associated	  with	  HLA-­‐B37	  aa338–346	  
LKTQRRHKF	  and	  T	  cells	  expanded	  were	  able	  to	  kill	  HHV6B	  infected	  PHA	  blasts	  (Figure	  
5.35A).	   	   Furthermore,	   similar	   experiments	   were	   conducted	   for	   other	   U11	   15-­‐mer	  
peptides	  identified	  and	  T	  cells	  expanded	  were	  able	  to	  kill	  HHV6B	  infected	  PHA	  blasts	  
(Figure	  5.35).	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Figure	  5.32	  Recognition	  of	  HHV6B	  infected	  cells	  by	  U90	  PSK-­‐specific	  effector	  T	  cells	  	  
(A)	   Polyclonal	   PSK-­‐specific	   T	   cell	   effectors	   generated	   by	   pulsed	   PBMC	   from	   HLA-­‐
matched	  donor	  HD53	  with	   the	  U90	  9-­‐mer	  peptide	  PSK	  and	  cultured	   for	  10	  days	   in	  
the	  presence	  of	  IL-­‐2,	  were	  tested	  against	  autologous	  PHA	  blasts	  infected	  with	  HHV6B	  
strain	  HST	  or	  mock	   infected.	   	  Or	  as	   controls	  PHA	  blasts	  pulsed	  with	  either	   the	  PSK	  
peptide	  (2	  μg/ml)	  or	  DMSO.	  	  Polyclonal	  T	  cells	  were	  used	  at	  the	  indicated	  E:T	  ratio.	  	  T	  
cell	  recognition	  of	  target	  cells	  was	  determined	  by	  measuring	  release	  of	  IFN-­‐γ	  in	  to	  the	  
supernatant	  by	  ELISA.	  	  Results	  are	  the	  mean	  of	  triplicated	  ±	  SD	  (errors	  bars)	  readings	  
and	  expressed	  as	  pg/ml	  IFN-­‐γ	  released	  into	  the	  supernatant.	  	  (B)	  To	  confirm	  efficient	  
viral	   infection	   of	   target	   cells,	   HHV6B-­‐infected	   and	  mock-­‐infected	   cells	   used	   in	   the	  
assay	   in	   (A)	   were	   stained	   with	   mouse-­‐anti–human	   HHV6B	   mAb	   (monoclonal	  
antibody	   MAB8535,	   clone	   C3108-­‐003;	   Chemicon).	   	   Immunofluorescence	   images	  




(A)! Polyclonal! PSK.specific! T! cell! effectors! generated! by! pulsed! PBMC! from! HLA.
matched!donor!HD53!with!the!U90!9.mer!pepKde!PSK!and!cultured!for!10!days! in!
the! presence! of! IL.2,! were! tested! against! autologous! PHA! blasts! infected! with!
HHV6B!strain!HST!or!mock!infected.!!Or!as!controls!PHA!blasts!pulsed!with!either!the!
PSK!pepKde!(2!μg/ml)!or!DMSO.! !Polyclonal!T!cells!were!used!at! the! indicated!E:T!
raKo.!!T!cell!recogniKon!of!target!cells!was!determined!by!measuring!relea e!of!IFN.γ!
in!to!the!sup rn tant!by!ELISA.!!R sults!are!the!mean!of!triplicated!±!SD!(errors!bars)!
readings! and! expressed! as! pg/ml! IFN.γ! released! into! the! supernatant.! ! (B)! ! To!
confirm! efficient! viral! infecKon! of! target! cells,! HHV6B.infected! and!mock.infected!
cells! used! in! the! assay! in! (A)! were! stained! with! mouse.anK–human! HHV6B! mAb!
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Figure	  5.33	  Recognition	  of	  HHV6B	  infected	  cells	  by	  U90	  FES-­‐specific	  effector	  T	  cells	  	   
Polyclonal	  FES-­‐specific	  T	  cell	  effectors	  generated	  by	  pulsed	  PBMC	  from	  HLA-­‐matched	  
donor	  HD57	  with	  the	  U90	  9mer	  peptide	  FES	  and	  cultured	  for	  10	  days	  in	  the	  presence	  
of	  IL-­‐2,	  were	  tested	  against	  autologous	  PHA	  blasts	  infected	  with	  HHV6B	  strain	  Z29	  or	  
mock	   infected.	   	   Or	   as	   controls	   PHA	   blasts	   pulsed	   with	   either	   the	   FES	   peptide	   (2	  
μg/ml)	   or	   DMSO.	   	   Polyclonal	   T	   cells	   were	   used	   at	   the	   indicated	   E:T	   ratio.	   	   T	   cell	  
recognition	  of	   target	   cells	  was	  determined	  by	  measuring	   release	  of	   IFN-­‐γ	   in	   to	   the	  
supernatant	  by	  ELISA.	  	  Results	  are	  the	  mean	  of	  triplicated	  ±	  SD	  (errors	  bars)	  readings	  
and	  expressed	  as	  pg/ml	  IFN-­‐γ released	  into	  the	  supernatant.	  	  (B)	  	  To	  confirm	  efficient	  
viral	   infection	   of	   target	   cells,	   HHV6B-­‐infected	   and	  mock-­‐infected	   cells	   used	   in	   the	  
assay	   in	   (A)	   were	   stained	   with	   mouse-­‐anti–human	   HHV6B	   mAb	   (monoclonal	  
antibody	   MAB8535,	   clone	   C3108-­‐003;	   Chemicon).	   	   Immunofluorescence	   images	  
where	  taken	  with	  a	  Nikon	  fluorescence	  microscope,	  magnification	  400x.	  




donor! HD57! with! the! U90! 9mer! pepJde! FES! and! cultured! for! 10! days! in! the!
presence! of! IL,2,!were! tested! against! autologous! PHA!blasts! infected!with!HHV6B!
strain!Z29!or!mock! infected.! !Or!as!controls!PHA!blasts!pulsed!with!either! the!FES!
pepJde!(2!μg/ml)!or!DMSO.! !Polyclonal!T!cells!were!used!at!the!indicated!E:T!raJo.!!
T!cell!recogniJon!of!target!cells!was!determined!by!measuring!release!of!IFN,γ!in!to!
the! supernatant! by! ELISA.! ! Results! are! the!mean! of! triplicated! ±! SD! (errors! bars)!
readings! and! expressed! as! pg/ml! IFN,γ  released! into! the! supernatant.! (B)! ! To!
confirm! efficient! viral! infecJon! of! target! cells,! HHV6B,infected! and!mock,infected!
cells! used! in! the! assay! in! (A)! were! stained! with! mouse,anJ–human! HHV6B! mAb!
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Figure	  5.34	  Recognition	  of	  HHV6B	  infected	  cells	  by	  U90	  peptide-­‐specific	  effector	  T	  
cells	  	   
Polyclonal	   peptide-­‐specific	   T	   cell	   effectors	   generated	   by	   pulsed	   PBMC	   from	   HLA-­‐
matched	   donor	   HD27	  with	   the	   U90	   9-­‐mer	   peptide	   NLI	   (A)	   and	   ITA	   (B),	   and	   PBMC	  
from	  HLA-­‐matched	  donor	  HD49	  with	  the	  U90	  9-­‐mer	  peptide	  LNI	  (C),	  and	  PBMC	  from	  
HLA-­‐matched	   donor	   HD10	   with	   the	   U90	   9-­‐mer	   peptide	   NHC	   (D),	   and	   PBMC	   from	  
HLA-­‐matched	  donor	  HD53	  with	  the	  U90	  15-­‐mer	  peptide	  IPI	  (F)	  and	  CFI	  (E).	  	  Then	  cells	  
cultured	   for	   10	   days	   in	   the	   presence	   of	   IL-­‐2,	   were	   tested	   against	   autologous	   PHA	  
blasts	   infected	  with	   HHV6B	   strain	   Z29	   or	  mock	   infected,	   or	   as	   controls	   PHA	   blasts	  
pulsed	  with	  either	  the	  FES	  peptide	  (2	  μg/ml)	  or	  DMSO.	  	  Polyclonal	  T	  cells	  were	  used	  
at	  an	  E:T	  ratio	  of	  10:1.	  	  T	  cell	  recognition	  of	  target	  cells	  was	  determined	  by	  measuring	  
release	  of	  IFN-­‐γ	  in	  to	  the	  supernatant	  by	  ELISA.	  	  Results	  are	  the	  mean	  of	  triplicated	  ±	  
SD	   (errors	   bars)	   readings	   and	   expressed	   as	   pg/ml	   IFN-­‐γ released	   into	   the	  


















































































































































































































Polyclonal! pep+de-specific! T! cell! effectors! generated! by! pulsed! PBMC! from! HLA-
m tch d!donor!HD27!with! the!U90!9-mer! p p+de!NLI! (A)! and! ITA! (B),! and!PBMC!
from!HLA-matched!donor!HD49!with!the!U90!9-mer!pep+de!LNI!(C),!and!PBMC!from!
HLA-matched! donor! HD10!with! the! U90! 9-mer! pep+de! NHC! (D),! and! PBMC! from!
HLA-matched!donor!HD53!with! the!U90!15-mer!pep+de! IPI! (F)!and!CFI! (E)! .! !Then!
cultured! for! 10! days! in! the! presence! of! IL-2,!were! tested! against! autologous! PHA!
blasts!infected!with!HHV6B!strain!Z29!or! ock!infected.! !Or!as!controls!PHA!blasts!
pulsed!with!either!the!FES!pep+de!(2!μg/ml)!or!DMSO.!!Polyclonal!T!cells!were!used!
at! an! E:T! ra+o! of! 10:1.! ! T! cell! recogni+on! of! target! cells! was! determined! by!
measuring!release!of!IFN-γ!in!to!the!supernatant!by!ELISA.! !Results!are!the!mean!of!
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Figure	  5.35	  Recognition	  of	  HHV6B	  infected	  cells	  by	  U11	  peptide-­‐specific	  effector	  T	  
cells	  	   
Polyclonal	   peptide-­‐specific	   T	   cell	   effectors	   generated	   by	   pulsed	   PBMC	   from	   HLA-­‐
matched	   donor	   HD32	   with	   the	   U11	   9-­‐mer	   peptide	   LKT	   (A),	   and	   PBMC	   from	   HLA-­‐
matched	  donor	  HD24	  with	  the	  U11	  15-­‐mer	  peptide	  INK	  (B),	  SLE	  (C),	  YSA	  (D)	  and	  DNA	  
(E).	   	   Then	   cells	   cultured	   for	   10	   days	   in	   the	   presence	   of	   IL-­‐	   2,	   were	   tested	   against	  
autologous	   PHA	   blasts	   infected	   with	   HHV6B	   strain	   Z29	   or	   mock	   infected,	   or	   as	  
controls	   PHA	   blasts	   pulsed	   with	   either	   the	   LKT	   peptide	   (2	   μg/ml)	   or	   DMSO.	  	  
Polyclonal	  T	  cells	  were	  used	  for	  LKT	  (A)	  at	  an	  E:T	  ratio	  of	  10:1	  and	  were	  used	  for	  the	  
15-­‐mers	  at	  the	  indicated	  E:T	  ratio.	  	  T	  cell	  recognition	  of	  target	  cells	  was	  determined	  
by	  measuring	  release	  of	  IFN-­‐γ in	  to	  the	  supernatant	  by	  ELISA.	  	  Results	  are	  the	  mean	  
of	  triplicated	  ±	  SD	  (errors	  bars)	  readings	  and	  expressed	  as	  pg/ml	  IFN-­‐γ	  released	  into	  


































































































Polyclonal! pep+de-specific! T! cell! effectors! generated! by! pulsed! PBMC! from! HLA-
matched! donor! HD32!with! the! U11! 9-mer! pep+de! LKT! (A),! and! PBMC! from!HLA-
matched!donor!HD24!with!the!U11!15-mer!pep+de!INK!(B),!SLE!(C),!YSA!(D)!and!DNA!
(E)! .! ! Then! cultured! for! 10! days! in! the! presence! of! IL-! 2,! were! tested! against!
autologous! PHA! blasts! infected! with! HHV6B! strain! Z29! or! mock! infected.! ! Or! as!
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Table	  5.3	  Summary	  of	  CD8	  T	  cells	  peptides	  identified	  in	  HHV6B	  U90	  and	  U11 
HHV6B	  







U90	   	   	   	   	  
	   YHPDPVVEESIKEIL	   33-­‐47	   VEESIKEIL	   Yes	  
	   CDVSFESLLFPELEA	   53-­‐67	   FESLLFPEL	   Yes	  
	   ASESRDLLMDLKANM	   209-­‐223	   NT*	   Yes	  
	   IHINCKNLITAAKNI	   325-­‐339	   NLITAAKNI	   Yes	  
	   CKNLITAAKNIGIAV	   329-­‐343	   ITAAKNIGI	   Yes	  
	   SICDLNIDPSESILL	   413-­‐427	   LNIDPSESI	   Yes	  
	   NVDYLKYMEVQSPTD	   453-­‐467	   NT	   NT	  
	   CDSTVRTNNIHMNNT	   693-­‐707	   NT	   Yes	  
	   KPSKSKKIKLDRLPE	   757-­‐771	   PSKSKKIKL	   Yes	  
	   IPIRSMPGTHDIRNK	   849-­‐863	   NT	   Yes	  
	   HWLWFMRKTHKVDNC	   869-­‐883	   NT	   NT	  	  
	   FMRKTHKVDNCVIHS	   874-­‐888	   NT	   NT	  
	   EANHCFINHFVPIKT	   901-­‐915	   NHCFINHFV	   Yes	  
	   CFINHFVPIKTDDEE	   905-­‐919	   NT	   Yes	  
	   EKENVSYTYSKIQDS	   921-­‐935	   NT	   NT	  
	   GNNSPILNIINDTTC	   1013-­‐1027	   NT	   NT	  
U11	   	   	   	   	  
	   ENLENVDLREHPYVT	   29-­‐43	   NT	   NT	  
	   ILWLMYHYVLSKRKP	   65-­‐79	   NT	   NT	  
	   NVVNEYLKSKGLNKG	   93-­‐107	   NT	   NT	  
	   EYLKSKGLNKGNFEN	   97-­‐111	   NT	   NT	  
	   INKLVYLGKLFVTLN	   193-­‐207	   NT	   Yes	  
	   RKNENFNAVYSQRVL	   233-­‐247	   FNAVYSQRV	   NT	  
	   NFNAVYSQRVLQTPL	   237-­‐251	   NT	   NT	  
	   SLESYSASKAFSVPE	   273-­‐287	   NT	   Yes	  
	   YSASKAFSVPENGPH	   277-­‐291	   NT	   Yes	  
	   LPSISIDTKRPSADL	   309-­‐323	   NT	   NT	  
	   PLKTQRRHKFPESDS	   337-­‐351	   LKTQRRHKF	   Yes	  
	   SDSVDNAGGKILIKK	   349-­‐363	   NT	   NT	  
	   DNAGGKILIKKETLG	   353-­‐367	   NT	   Yes	  
	   GILDFGVKLPAEAQS	   413-­‐427	   GILDFGVKL	   NT	  	  
	   DLLQDKTSIRSPSSG	   433-­‐447	   NT	   NT	  
	   ADLSRDLDSVSFKDA	   749-­‐763	   NT	   NT	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *not	  tested	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5.5	  Summary	  
In	  conclusion,	  this	  chapter	  has	  presented	  the	  Identification	  of	  HLA	  Class	  I	  restricted	  
antigenic	   peptides	   in	   HHV6B	   U11	   and	   U90.	   	   Then,	   the	   chapter	   went	   on	   to	  
characterise	   these	   responses	   in	   more	   detail,	   by	   mapping	   the	   minimal	   antigenic	  
peptides,	  identifying	  the	  HLA	  restriction	  elements	  and	  determining	  whether	  these	  T	  
cells	  were	  capable	  of	  killing	  HHV6B-­‐infected	  cells.	   	  This	   is	   important	   information	  to	  
fully	   characterise	   the	   CD8+	   T	   cells	   response	   to	   HHV6B,	   to	   support	   any	   future	  
application	  of	  such	  T	  cell	  therapy	  against	  HHV6B	  driven	  disease.	  	  	  
	   	  









	   	  
	  	  P a g e |	  181	  
	  
6.	  	  General	  discussion	  and	  conclusions	  
6.1	  Discussions	  
Viruses	  are	  major	   causes	  of	  morbidity	  and	  mortality	  after	  bone	  marrow	  transplant	  
(BMT),	   for	  example	   the	  viruses	  CMV,	  EBV,	  AdV,	  BK,	  HHV6,	  HHV7	  and	  RSV.	   	  HHV6B	  
reactivation	  can	  cause	  serious	  complications	   in	   immunocompromised	  patients	  such	  
as	   BMT	   recipients.	   	   These	   reactivations	   are	   normally	   controlled	   by	   the	   immune	  
system	   in	   immunocompetent	   subjects;	  but	   immunocompromised	  patients	   (such	  as	  
in	   BMT	   recipients)	   may	   be	   unable	   to	   contain	   them	   leading	   to	   life	   threatening	  
conditions;	  like,	  graft	  versus	  host	  disease	  (GVHD),	  delayed	  engraftment,	  encephalitis	  
and	   pneumonitis	   (De	   Bolle	   et	   al.,	   2005a).	   	   Prevention	   of	   post-­‐transplant	   viral	  
reactivation	  is	  very	  difficult.	  	  Finding	  a	  way	  to	  control	  these	  infections	  are	  becoming	  
more	  and	  more	  important	  considering	  the	  increasing	  number	  of	  transplantations	  in	  
recent	   years	   (Zerr	   et	   al.,	   2001;	   Zerr	   et	   al.,	   2002;	  Rapaport	   et	   al.,	   2002;	   Zerr	   et	   al.,	  
2005;	  Karlsson	  et	  al.,	  2007;	  De	  Pagter	  et	  al.,	  2008).	  	  	  
When	  this	  project	  was	  started	  in	  2010,	  very	  little	  information	  was	  available	  regarding	  
the	   T	   cell	   response	   to	   HHV6.	   	   The	   immunogenic	   antigens,	   potential	   antigenic	  
peptides,	  HLA	  restricting	  alleles	  and	  strength	  of	  responses	  were	  unknown.	  	  Based	  on	  
the	   well-­‐characterised	   cellular	   immune	   response	   to	   other	   human	   herpes	   viruses	  
(particularly	  HCMV	  and	  EBV),	  we	  hypothesised	  that	  HHV6	  will	  be	  immunogenic	  for	  T	  
cells.	  	  In	  this	  project	  the	  T	  cell	  responses	  to	  HHV6	  have	  been	  characterised	  in	  a	  panel	  
of	   healthy	   donors	   by	   investigating;	   direct	   ex-­‐vivo	   detection	   of	   T	   cell	   responses	   to	  
HHV6,	   in-­‐vitro	  expansion	  and	  analyses	  of	  T	  cell	   responses	  to	  HHV6B	  antigens	  (U11,	  
U39,	  U54	  and	  U90),	  and	  identification	  and	  characterisation	  of	  CD8+	  T	  cell	  responses	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to	   HHV6B	   antigens	   U11	   and	   U90.	   	   The	   findings	   contribute	   to	   the	   expansion	   of	  
existing	   information	   regarding	   the	   immune	   response	   to	  HHV6	   and	   are	   relevant	   to	  
exploration	  of	   the	  potential	  of	  developing	  adoptive	  T	  cell	   therapy	   for	  malignancies	  
linked	  to	  HHV6	  proliferation.	  
Adoptive	   T	   cell	   immunotherapy	   is	   a	   promising	   therapeutic	   approach	   for	   the	  
treatment	   of	   diseases	   associated	   with	   reactivation	   of	   herpes	   viruses	   in	  
immunosuppressed	   patients.	   	   At	   present,	   adoptive	   T	   cell	   immunotherapy	   can	  
successfully	   prevent	   and	   treat	   fatal	   infections	   in	   immunocompromised	   individuals.	  	  
However,	   benefits	   of	   these	   therapies	   have	   been	   restricted	   to	   CMV,	   EBV	   and	  
adenovirus	  (Leen	  et	  al.,	  2006;	  Karlsson	  et	  al.,	  2007;	  Leen	  et	  al.,	  2009;	  Barker	  et	  al.,	  
2010).	   	   Adoptive	   immunotherapy	   may	   be	   extended	   to	   HHV6	   to	   develop	   BMT	  
engraftment	  and	  control	  recipients’	  viral	  reactivation.	  	  Recent	  studies	  have	  shown	  an	  
HHV6	   specific	   T	   cell	   immune	   response	   (Nastke	   et	   al.,	   2012;	   Martin	   et	   al.,	   2012)	  
directed	  against	   some	  viral	  proteins	   (U11,	  U14,	  U54,	  U90)	   in	  association	  with	  HLA-­‐
A2,	   HLA-­‐A3,	   HLA-­‐B7	   or	   HLA-­‐B40	   antigens	   (Martin	   et	   al.,	   2012;	   Gerdemann	   et	   al.,	  
2013;	   Iampietro	   et	   al.,	   2014).	   	   Identification	   of	   additional	   viral	   targets	   (epitopes)	  
presented	  in	  association	  with	  other	  HLA	  class	  I	  alleles	  is	  therefore	  needed.	  	  	  
Using	   synthetic	   viral	   peptides	   to	   stimulate	   T	   cells	   and	   evaluating	   their	   ability	   to	  
produce	   IFN-­‐γ, studies	  have	   identified	  a	  number	  of	  HHV6	  antigens	   recognised	  by	  T	  
cell	  clones	  in	  peripheral	  blood	  of	  healthy	  donors	  (Nastke	  et	  al.,	  2012;	  Martin	  et	  al.,	  
2012;	  Gerdemann	  et	  al.,	  2013;	  Iampietro	  et	  al.,	  2014).	  	  	  
Using	   algorithmic	   epitope	   peptides	   prediction	   program	   (SYFPEITHI)	   Nastke	   et	   al	  
evaluated	   a	   17-­‐mer	   peptide	   with	   a	   very	   high	   affinity	   for	   binding	   to	   major	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histocompatibility	   complex	   (HLA)	   class	   II	   (HLA	   -­‐II)	  DR1.	   	  Due	   to	   the	  high	  homology	  
between	  the	  different	  HLA-­‐II,	  peptides	  capable	  of	  binding	  to	  HLA	  -­‐DR1	  may	  also	  bind	  
to	   other	   HLA-­‐II	   molecules.	   	   Screening	   was	   also	   done	   with	   a	   library	   of	   peptides	  
derived	  from	  the	  genome	  of	  HHV6B	  translated	  proteins	  and	  another	  peptide	  library	  
from	  six	  virion	  proteins	  that	  have	  been	  established	  as	  abundant	  in	  cells	  infected	  by	  
proteomics.	   	   Eleven	   peptides	   were	   found	   to	   activate	   the	   CD4+	   T	   cell	   response	   in	  
PBMC	  from	  different	  healthy	  donors.	   	  Only	  two	  of	  these	  peptides	  were	  part	  of	  the	  
peptide	   library	   from	   the	   complete	   genome	   while	   the	   other	   nine	   belonged	   to	   the	  
library	  of	  peptides	  of	  virion	  proteins:	  five	  mapped	  to	  the	  capsid	  protein	  U57,	  two	  to	  
tegument	  protein	  U11	  and	  U14,	  and	   two	  to	  glycoproteins	  U38	  and	  U48	   (Nastke	  et	  
al.,	  2012).	  	  These	  results	  confirmed	  previous	  studies	  that	  determined	  that	  the	  capsid	  
proteins	   and	   tegument	   could	   activate	   T	   cell	   immune	   response	   (Wang	   et	   al.,	   1999;	  
Tejada-­‐Simon	  et	  al.,	  2002).	  
Martin	  et	  al	  evaluated	  and	  identified	  the	  immune	  response	  specific	  to	  CD8+	  T	  cells	  in	  
HLA-­‐A2+	   donors,	   predicted	   by	   computational	   prediction	   program	   as	   theoretically	  
strong	   for	   U11,	   U54	   and	   U90	   proteins.	   	   Lines	   and	   clones	   have	   been	   shown	   to	  
recognise	   virus-­‐infected	   target	   cells	   and	   CD8	   +	   T	   cells	   were	   able	   to	   react	   strongly	  
against	   CD4+	   T	   cells	   infected	   with	   HHV6B,	   producing	   antiviral	   cytokines	   and	  
eliminating	  infected	  cells	  (Martin	  et	  al.,	  2012).	  
Gerdemann	   et	   al.	   focused	   their	   research	   on	   five	   HHV6	   proteins	   homologous	   to	  
immunodominant	   antigens	   identified	   in	   HCMV,	   and	   T	   cell	   responses	   mapped	   to	  
HHV6B	  antigens	  U11,	  U14,	  U54,	  U71	  and	  U90.	  Also,	   they	  have	  mapped	  three	  B40-­‐
restricted	  epitopes	  to	  U90	  and	  U14	  (Gerdemann	  et	  al.,	  2013).	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A	  recent	  study	  by	  Iampietro	  et	  al	  identified	  six	  epitopes	  derived	  from	  U90	  proteins	  in	  
the	   immune	   response	   of	   specific	   CD8+	   T	   cells	   restricted	   to	   HLA-­‐I	   alleles,	   HLA-­‐A2,	  
HLA-­‐A3,	   and	   HLA-­‐B7.	   	   These	   epitopes	   were	   functionally	   tested	   for	   their	   ability	   to	  
induce	  CD8+	  T	   cell	   expansion	  and	  kill	  HHV6-­‐infected	  autologous	   cells	   (Iampietro	   et	  
al.,	  2014).	  	  	  
Initially,	  in	  Chapter	  3,	  four	  HHV6B	  antigens	  U11,	  U39,	  U54	  and	  U90,	  predicted	  to	  be	  
immunogenic	  based	  on	  their	  CMV	  homologues,	  were	  focused	  upon.	  	  PBMC	  from	  30	  
healthy	   donors	   were	   stimulated	   with	   pepmixes	   corresponding	   to	   these	   four	  
antigens.	  	  Whole	  antigen	  pepmixes	  were	  used	  to	  stimulate	  PBMC.	  	  T	  cell	  responses	  
were	   analysed	   by	   intracellular	   cytokine	   staining	   (ICS)	   after	   overnight	   stimulation.	  	  
CD8+	  responses	  were	  observed	  to	  U90	  and	  U54	  respectively	  in	  a	  number	  of	  donors,	  
but	   in	   comparison	   to	   other	   control	   antigens,	   these	   responses	   were	   significantly	  
lower	   in	  magnitude	  and	  frequency	  (0.02-­‐0.2%).	   	  These	  results	  were	  consistent	  with	  
the	   findings	  of	  other	  studies	   reporting	   less	   than	  0.1%	  of	   total	  PBMC	  responding	   to	  
these	  antigens	  (Martin	  et	  al.,	  2012;	  Gerdemann	  et	  al.,	  2013).	  	  	  
However	  it	  may	  be	  that	  other	  untested	  HHV6B	  antigens	  may	  be	  more	  immunogenic,	  
or	  that	  HHV6B	  may	  be	  less	  immuno-­‐stimulatory	  than	  HCMV.	  	  Therefore,	  to	  maximise	  
the	  ability	  to	  detect	  HHV6B	  antigen-­‐specific	  T	  cells	  and	  determine	  the	  antigenicity	  of	  
the	  4	  antigens	  being	  studied,	  a	  short-­‐term	  in-­‐vitro	  reactivation	  protocol	  was	  utilised	  
to	   generate	   a	   polyclonal	   culture	   enriched	   with	   HHV6B-­‐specific	   T	   cells	   prior	   to	  
analysis	  by	  ELISpot.	  	  	  
This	  frequency	  is	  increased	  in	  transplant	  patients,	  showing	  a	  good	  response	  with	  HLA	  
tetramers	  for	  HHV6	  specific	  peptides	  (Gerdemann	  et	  al.,	  2013).	  	  Stimulation	  of	  non-­‐
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enriched	  PBMC,	  even	  using	  the	  tetramers,	   is	  unable	  to	  produce	  a	  strong	  response.	  	  
For	  this	  reason,	  enrichment	  of	  positively	  stained	  cells	  by	  tetramers	  was	  employed	  to	  
establish	  an	  association	  between	  clones	  of	  CD4+	  T	  lymphocytes	  and	  certain	  epitopes	  
(Vollers	   and	   Stern,	   2008).	   	   An	   additional	   limitation	   of	   this	   technique	   is	   that	   HLA	  
tetramers	  are	  only	  available	  for	  a	  limited	  number	  of	  HLA	  alleles	  and	  furthermore	  are	  
only	   able	   to	  be	  used	   in	  HLA	  matched	  donors.	   	   The	  ex-­‐vivo	   study	  of	   T	   cell	   immune	  
response	   to	   HHV6	   in	   PBMC	   is	   limited	   due	   to	   the	   low	   frequency	   of	   specific	   T	   cell	  
antigens.	   	   For	   this	   reason,	   researches	   focussed	   on	   in-­‐vitro	   expansion	   of	   T	   cells	   for	  
easier	  identification	  of	  epitopes.	  	  	  
The	   next	   approach	   (in	   Chapter	   4)	   included	   an	   in-­‐vitro	   stimulation	   step,	   with	  
successful	  expansion	  of	  the	  HHV6B	  (U11,	  U39,	  U54	  and	  U90)	  antigen-­‐specific	  CD8+	  T	  
cells	   in	   25	   healthy	   donors.	   	   Short-­‐term	   in-­‐vitro	   reactivations	   of	   PBMC	   were	  
performed	  with	   HHV-­‐6B	   pepmixes.	   	   Subsequently,	   HHV6B	   antigen-­‐specific	   CD8+	   T	  
cell	   responses	   were	   analysed	   by	   IFN-­‐γ	   ELISpot	   assay;	   showing	   88%	   (22/25),	   84%	  
(21/25),	  76%	   (19/22)	  and	  72%	   (18/25)	  of	   the	  donors	   responding	   to	  U54,	  U90,	  U11	  
and	  U39	  antigens	  respectively.	  	  The	  responses	  in	  this	  study	  were	  a	  little	  lower	  than	  
the	  findings	  of	  other	  studies,	  showing	  all	  of	  the	  donors	  responding	  against	  U11,	  U54	  
and	  U90	  (Gerdemann	  et	  al.,	  2013).	  	  	  
This	   analysis	   had	   not	   defined	   the	   component	   of	   the	   polyclonal	   culture	   of	   HHV6B-­‐
stimulated	  T	  cells	   in	   terms	  of	  whether	   this	  was	  mainly	  CD4+	  or	  CD8+	  T	  cells,	  or	  an	  
equal	  contribution	  from	  both	  or	  if	  they	  are	  similar	  to	  the	  normal	  reference	  range	  for	  
peripheral	  blood	  lymphocytes,	  rather	  than	  also	  determining	  antigen	  specificity.	  The	  
result	   of	   the	   frequencies	   of	   CD4+	   and	   CD8+	   T	   cells	   in	   10-­‐day	   polyclonal	   cultures,	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stimulated	   with	   each	   HHV6B	   pepmix,	   were	   measured	   by	   flow	   cytometry.	   	   These	  
expanded	   polyclonal	   cultures	   of	   HHV6B-­‐stimulated	   cells	   consist	   of	   CD3+	   T	   cells	  
(mean	  86.9%	  ±	  6%),	  with	  a	  majority	  of	  helper	   (CD4+)	  T	   cells	   (66.3%	  ±	  4.5%)	  and	  a	  
minority	  of	  CD8+	  T	   cells	   (25.9%	  ±	  3.2%).	   	   This	   is	   similar	   to	   the	   reference	  values	  of	  
CD3+	  (61	  to	  85%),	  CD4+	  (28	  to	  58%),	  and	  CD8+	  (19	  to	  48%)	  (Reichert	  et	  al.,	  1991).	  
In-­‐vitro	   stimulation	   steps	   in	   the	   presence	   of	   IL-­‐2	   can	   successfully	   expand	   HHV6B	  
antigen-­‐specific	  T	  cells.	   	  T	  cell	   responses	  were	  detected	  against	  all	  HHV6B	  antigens	  
tested,	   U11,	   U39,	   U54	   and	   U90.	   	   These	   expanded	   polyclonal	   cultures	   of	   HHV6B-­‐
specific	  T	  cells	  consist	  of	  CD3+	  T	  cells,	  with	  a	  majority	  of	  CD4+	  T	  cells	  and	  a	  minority	  
of	  CD8+	  T	  cells.	   	  Overall	  all	   the	  25	  donors	  responded	  to	  at	   least	  one	  of	  the	  HHV6B	  
antigens.	  	  In	  general	  these	  responses	  were	  of	  high	  magnitude,	  in	  comparison	  to	  ex-­‐
vivo	   responses.	   	   Therefore,	   the	   next	   stage	  was	   to	   characterise	   these	   responses	   in	  
more	   detail,	   by	   mapping	   the	   minimal	   antigenic	   peptides,	   identifying	   the	   HLA	  
restriction	  elements	  and	  determining	  whether	   these	  T	   cells	  were	  capable	  of	   killing	  
HHV6B-­‐infected	  cells.	  
Subsequently,	   in	  Chapter	  5,	   the	  breadth	  of	  epitope	   specificity	  within	  U90	  and	  U11	  
was	   screened	   for	   9	   healthy	   donors	   using	   overlapping	   peptides.	   	   The	   responses	   to	  
U11	   and	  U90	   peptides	   libraries	  were	   used	   to	  map	   CD8+	   T	   cell	   restricted	   epitopes	  
with	   characterisation	   and	   identification	   of	   HLA	   restricting	   elements	   and	   cytokine	  
profiles.	   	  We	  have	   identified	  10	  CD8+	  T	  cells	  specific	   (9-­‐mer)	  epitopes	  within	  these	  
antigens.	   	  Seven	  of	  them	  were	  within	  U90	  antigens	  and	  three	  of	  them	  were	  within	  
U11	   antigens.	   	   Allelic	   association	   of	   the	   U90	   epitopes	  were;	   VEESIKEIL	   -­‐	   B40	   (60),	  
FESLLFPEL	   -­‐	  B40	   (60),	  NLITAAKNI	   -­‐	  A2,	   ITAAKNIGI	   -­‐	  A2,	  LNIDPSESI	   -­‐	  A1,	  PSKSKKIKL	   -­‐	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A29,	  NHCFINHFV	  -­‐	  B39.	  	  Allelic	  association	  of	  the	  2	  U11	  epitopes	  were	  LKTQRRHKF	  -­‐	  
B37	   and	   GILDFGVKL	   –	   A2;	   the	   HLA	   association	   to	   FNAVYSQRV	  was	   not	   identified.	  	  
CD8+	   T	   cell	   populations	   specific	   to	   some	   of	   these	   epitopes	   were	   also	   expanded,	  
which	  were	  able	  to	  kill	  HHV6B	  infected	  cells.	   	  Characterisation	  and	  identification	  of	  
MHC	   class	   I	   restriction	  of	   these	  U90	   and	  U11	  epitopes;	   and	   their	   ability	   to	   induce	  
antigen-­‐specific	   CD8+	   T	   cells	   that	   are	   able	   to	   recognise	   HHV6+ve	   cells	   would	   be	  
helpful	  to	  possible	  future	  development	  of	  adoptive	  immune	  therapy.	  	  	  
Researchers	  have	  started	  to	  explore	  and	  identify	  HHV6	  specific	  CD8+	  T	  cell	  responses	  
in	   recent	   times.	   	   The	   specific	   immunodominant	  epitopes	   in	  HHV6B	   to	  CD8+	  T	  cells	  
was	  first	  reported	  in	  2012,	  showing	  three	  epitopes	  within	  U11	  and	  2	  epitopes	  within	  
U54	  	  (Martin	  et	  al.,	  2012).	  	  Later	  in	  2013,	  researchers	  were	  able	  to	  characterise	  three	  
HHV6	  epitopes	  within	  U14	  (1	  epitope)	  and	  U90	  (2	  epitopes)	  specific	  for	  CD8+	  T	  cells,	  
all	   restricted	   to	   HLA-­‐B40	   (Gerdemann	   et	   al.,	   2013).	   	   In	   addition,	   their	   study	  
demonstrated	  that	  these	  epitopes	  were	  polyfunctional,	  producing	  IFN-­‐γ,	  TNF-­‐α	  and	  
granzyme-­‐B	   and	   exerting	   cytotoxicity	   to	   HHV6B	   infected	   cells	   (Gerdemann	   et	   al.,	  
2013).	   	   In	   this	   study	   seven	   epitopes	   of	   U90	   were	   characterised;	   two	   of	   them	  
(restricted	  to	  HLA-­‐B40)	  were	  identical	  to	  their	  report	  and	  the	  other	  five	  restricted	  to	  
A2,	  A1,	  A29	  and	  B39.	   	  Three	  epitopes	  were	  also	   identified	  within	   the	  U11	  antigen;	  
one	  of	  them	  was	  restricted	  to	  A2,	  which	  was	   identical	  with	  reports	  of	  Martin	  et	  al.	  	  
One	   of	   the	   other	   two	   epitopes	   was	   restricted	   to	   B37	   and	   the	   third	   was	   not	  
detectable	  due	  to	  inadequate	  cell	  numbers.	   	  Very	  recently,	   in	  2014,	  Iampietro	  et	  al	  
reported	  four	  epitopes	  within	  U90,	  none	  of	  them	  matching	  with	  the	  present	  findings	  
(Iampietro	  et	  al.,	  2014).	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This	  study	  had	  a	  few	  limitations	  that	  need	  to	  be	  considered	  before	  drawing	  definitive	  
conclusions.	   	   First	   of	   all,	   it	   was	   not	   possible	   to	   ascertain	   the	   actual	   timing	   when	  
donors	   became	   infected	  with	  HHV6	  and	   also	   it	  was	  not	   possible	   to	   test	   the	  HHV6	  
seropositivity	  status.	  	  Secondly,	  cross-­‐reaction	  between	  the	  epitopes	  of	  HHV6A	  and	  
HHV6B	  could	  not	  be	  excluded.	   	  Although	  HHV6A	  and	  HHV6B	   share	  90%	  homology	  
(Dominguez	   et	   al.,	   1999),	   the	   pathophysiology	   following	   primary	   infection	   or	  
reactivation	  of	  these	  two	  strains	  are	  different.	  Because	  of	  their	  high	  homology,	  less	  
than	  10%	  of	  the	  T	  cell	  clones	  for	  the	  same	  epitope	  are	  specific	  to	  a	  single	  species	  of	  
these	  two	  (Yasukawa	  et	  al.,	  1993).	  	  A	  recent	  study	  reported	  cross-­‐reactive	  responses	  
in	  one	  of	  the	  HLA-­‐A2	  restricted	  epitopes	  (Iampietro	  et	  al.,	  2014).	  	  The	  sequences	  of	  
the	  epitopes	   identified	   in	  HHV6B	   in	   this	   study	  were	  different	   than	   those	   in	  HHV6A	  
(Shown	  in	  Table	  6.1).	  	  	  
Table	  6.1:	  Peptide	  sequences	  and	  amino	  acid	  coordinates	  of	  CD8+	  T	  cell	  epitopes	  
identified	  in	  U90	  and	  U11	  
HHV-­‐6B	  
antigen	  




U90	   VEESIKEIL	   MEESIKEIL	   B40	  (60)	   Yes	  
	   FESLLFPEL	   FDDLIIPGL	   B40	  (60)	   Yes	  
	   NLITAAKNI	   NLITAAKNL	   A2	   Yes	  
	   ITAAKNIGI	   ITAAKNLGN	   A2	   Yes	  
	   LNIDPSESI	   GNTDPSDSM	   A1	   Yes	  
	   PSKSKKIKL	   SPKNKKIKT	   A29	   Yes	  
	   NHCFINHFV	   KHCFMNHFV	   B39	   Yes	  
U11	   LKTQRRHKF	   LRMQRQPKF	   B37	   Yes	  
	   GILDFGVKL	   GILDFNVKF	   A2	   Yes	  
	   FNAVYSQRV	   FNIVYSHRV	   nt	   nt	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Three	  putative	  novel	   CD8	  T	   cell	   epitopes	  were	   identified	   in	  U90,	   named	  PSK,	  NHC	  
and	   LNI.	   These	   epitopes	  were	   predicted	   to	   be	   restricted	   via	  HLA-­‐A29,	   B39	   and	  A1	  
respectively.	  These	  HLA	  alleles	  predicted	  to	  present	  the	  novel	  HHV6B	  T	  cell	  peptides	  
are	  present	   in	  the	  caucasian	  population	  at	  average	  frequencies	  for	  A1	  14.07%,	  A29	  
3.01%	  and	  B39	  2.03%	  (Marsh	  et	  al.,	  2000),	  highlighting	  their	  therapeutic	  relevance.	  
The	  B39-­‐restricted	  NHC	  epitope	  sequence	  conforms	  to	  the	  motif	  of	  peptides	  known	  
to	  bind	  to	  HLA-­‐B*3901,	   that	  have	  a	  highly	  conserved	  His	  at	  position	  2,	  an	  aliphatic	  
anchor	  at	  position	  9.	  The	  LNI	  peptide,	  predicted	  to	  be	  restricted	  via	  HLA-­‐A1,	  gave	  a	  
weak	  response	   in	  comparison	  to	  the	  original	  15-­‐mer,	  and	  as	  HLA-­‐A1	  tends	  to	  have	  
acidic	  residues	  at	  position	  3,	  rather	  than	  position	  4	  for	  this	  peptide	  it	  is	  possible	  that	  
the	  real	  epitope	  begins	  NID	  and	  may	  be	  a	  10-­‐mer	  (Rammensee	  et	  al.,	  1999).	  	  
Moreover,	   with	   regard	   to	   the	   potential	   impact	   of	   the	   chromosomal	   insertion	   of	  
HHV6,	  it	  is	  unclear	  whether	  CIHHV6	  makes	  any	  difference	  in	  the	  immune	  response	  to	  
HHV6.	  	  For	  example,	  does	  the	  high	  virus	  load	  in	  subjects	  with	  CIHHV6	  affect	  specific	  
T	   cell	   responses	   to	   HHV6?	   Understanding	   the	   ability	   of	   the	   adaptive	   immune	  
response	  to	  HHV6	  in	  relation	  to	  CIHHV6	  would	  be	  additional	   indirect	  evidence	  that	  
the	   integrated	   HHV6	   genome	   is	   perhaps	   functionally	   active	   and	   is	   recognised	   as	  
‘non-­‐self’	   by	   the	   carrying	   individual.	   However,	   CIHHV6	   long	   term	   persistence	  
(latency)	   allows	  HHV6	   to	   reduce	   detection	   by	   immune	   cells	   (Kaufer	   and	   Flamand.,	  
2014).	  	  	  So,	  it	  would	  be	  of	  interest	  to	  investigate	  any	  fluctuations	  and	  frequencies	  of	  
HHV6	   specific	   T	   cells,	  which	  might	   protect	   against	   the	   danger	   of	   viral	   reactivation	  
and,	  perhaps,	  against	   linked	  clinical	  manifestations,	  either	   in	   immunocompromised	  
or	  immunocompetent	  CIHHV6	  individuals.	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Future	   studies	   should	   be	   undertaken	   for	   more	   detailed	   characterisation	   of	   the	  
immune	  response	  to	  HHV6,	  extending	  the	  number	  of	  antigens	  that	  have	  been	  looked	  
into,	  aiming	  to	  identify	  and	  characterise	  more	  epitopes;	  and	  to	  search	  for	  CD4+	  T	  cell	  
specific	   epitopes.	   	   In	   these	   in-­‐vitro	   studies	   only	   IFN-­‐γ	   producing	   cells	   have	   been	  
analysed.	   	  TNF-­‐α	   is	   the	  second	  major	  cytokine	  produced	  against	  viruses.	   	  Only	  one	  
published	   study	   has	   shown	   some	   HHV6	   antigens	   producing	   TNF-­‐α	   responses	  
(Gerdemann	   et	   al.,	   2013).	   	   Attempts	   to	   explore	   the	   epitopes	   inducing	   TNF-­‐α	  
responses	  would	  be	  valuable.	  	  Future	  researches	  should	  also	  be	  targeted	  for	  further	  
phenotypic	  analysis	  and	  identification	  of	  MHC	  class	  II	  restricted	  epitopes.	  
6.2	  Conclusions	  
The	   prevalence	   of	   HHV6	   infection	   is	   very	   high	   and	   over	   90%	   of	   the	   world's	  
population	   are	   at	   risk	   of	   viral	   reactivation.	   	  With	   the	   increasing	   number	   of	   tissue	  
transplantation	  procedures	  being	  performed	  in	  recent	  times,	  HHV6	  is	  considered	  as	  
one	   of	   the	   major	   threats	   for	   post-­‐transplant	   infections.	   	   Although,	   more	   than	   25	  
years	  have	  passed	  since	  the	  discovery	  of	  HHV6,	  a	  lot	  of	  areas	  regarding	  the	  potential	  
therapeutic	  targets	  remain	  elusive.	  	  	  
The	   results	   of	   this	   study	   contribute	   to	   expanding	   the	   existing	   information	   on	   the	  
interaction	  of	  human	  herpes	  virus	  6	   (HHV6)	  and	   the	  human	   immune	  system.	   	  This	  
study	  has	  identified	  and	  characterised	  immunodominant	  epitopes	  of	  HHV6B	  U90	  and	  
U11	   proteins,	   which	   were	   able	   to	   stimulate	   and	   expand	   CD8+	   T	   cell	   responses,	  
capable	  of	  killing	  HHV6	  infected	  cells.	  	  This	  information	  would	  be	  valuable	  to	  explore	  
the	   potential	   to	   develop	   adoptive	   T	   cell	   therapy	   for	   malignancies	   linked	   to	   HHV6	  
reactivation.	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8.	  	  Appendix	  
Table	  8.1	  List	  of	  donors	  with	  HLA	  typing	  and	  CMV	  seropositivity	  
Donor	  ID	   HLA-­‐A	   HLA-­‐B	   CMV	  Status	  
HD01	   2,3	   8,44	   +	  
HD02	   2,32	   27,44	   +	  
HD03	   	   	   +	  
HD04	   3,29	   44	   +	  
HD05	   2,	  24	   44,	  60	   +	  
HD06	   3	   7,51	   +	  
HD07	   3,	  25	   8,44	   +	  
HD08	   3,66	   7,27	   +	  
HD09	   2,11	   18,44	   +	  
HD10	   1,	  2	   8,	  39	   -­‐	  
HD11	   	   	   +	  
HD12	   	   	   +	  
HD13	   	   	   -­‐	  
HD14	   	   	   +	  
HD15	   1,	  2	   7,	  44	   +	  
HD16	   1,30	   13,37	   +	  
HD17	   1,3	   8,27	   -­‐	  
HD18	   1,	  24	   8,	  62	   -­‐	  
HD19	   	   	   -­‐	  
HD20	   1,3	   7,8	   -­‐	  
HD21	   24,33	   44,55	   +	  
HD22	   1,2	   8,62	   +	  
HD23	   	   	   -­‐	  
HD24	   29,74	   35,50	   +	  
HD25	   2	   8,	  62	   +	  
HD26	   	   	   +	  
HD27	   1,	  2	   44	   -­‐	  
HD28	   29,68	   7,44	   +	  
HD29	   	   	   -­‐	  
HD30	   2,	  32	   7,	  60	   +	  
HD31	   1,	  2	   8,	  57	   +	  
HD32	   1,33	   37,58	   +	  
HD33	   11,29	   39,44	   +	  
HD34	   2,30	   13,44	   -­‐	  
HD35	   	   	   -­‐	  
HD36	   	   	   -­‐	  
HD37	   2,3	   7,62	   +	  
HD38	   	   	   -­‐	  
HD39	   2,3	   7,44	   -­‐	  
HD40	   2,26	   38,44	   -­‐	  
HD41	   1	   37,57	   +	  
HD42	   	   	   -­‐	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HD43	   	   	   -­‐	  
HD44	   1	   	   +	  
HD45	   	   	   +	  
HD46	   	   	   +	  
HD47	   	   	   +	  
HD48	   	   	   +	  
HD49	   1,2	   8,44	   -­‐	  
HD50	   	   	   +	  
HD51	   3,	  26	   7,	  	  64	   +	  
HD52	   	   	   +	  
HD53	   29	   44	   -­‐	  
HD54	   	   	   +	  
HD55	   2	   7	   +	  
HD56	   2,	  30	   13,62	   -­‐	  
HD57	   2	   50,60	   -­‐	  
HD58	   	   	   +	  
HD59	   1,29	   8,45	   -­‐	  
HD60	   2,25	   44,58	   -­‐	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Table	  8.2	  Total	  data	  for	  CD8	  T	  cell	  responses	  to	  HCMV	  antigens	  by	  intracellular	  
cytokine	  staining	  for	  IFN-­‐γ∗  
 
Donor	   IE1	   IE2	   pp65	   gB	   Neg**	   Pos***	  
HD01	   0.28	   0.02	   0.12	   0.02	   0.01	   2.09	  
HD02	   0.07	   0.10	   0.35	   0.12	   0.02	   4.03	  
HD03	   1.06	   0.03	   0.11	   0.05	   0.03	   11.18	  
HD04	   0.02	   0.03	   0.01	   0.02	   0.02	   1.26	  
HD05	   1.54	   0.02	   0.83	   0.03	   0.03	   5.56	  
HD06	   0.02	   0.01	   0.03	   0.04	   0.02	   0.05	  
HD07	   0.07	   0.04	   0.05	   0.07	   0.04	   0.14	  
HD08	   0.15	   0.02	   0.11	   0.20	   0.05	   0.30	  
HD09	   8.74	   0.01	   0.16	   0.04	   0.02	   1.27	  
HD10	   NT	   NT	   NT	   NT	   NT	   NT	  
HD11	   1.03	   0.02	   0.58	   0.06	   0.02	   3.54	  
HD12	   0.15	   0.02	   0.43	   0.03	   0.04	   4.36	  
HD13	   NT	   NT	   NT	   NT	   NT	   NT	  
HD14	   0.10	   0.01	   0.09	   0.11	   0.01	   3.07	  
HD15	   0.54	   0.02	   0.16	   0.16	   0.03	   2.62	  
HD16	   0.11	   0.01	   0.03	   0.09	   0.01	   0.72	  
HD17	   0.91	   0.06	   0.27	   0.24	   0.18	   0.47	  
HD18	   NT	   NT	   NT	   NT	   NT	   NT	  
HD19	   NT	   NT	   NT	   NT	   NT	   NT	  
HD20	   NT	   NT	   NT	   NT	   NT	   NT	  
HD21	   0.20	   0.14	   0.03	   0.23	   0.06	   1.99	  
HD22	   NT	   NT	   NT	   NT	   NT	   NT	  
HD23	   NT	   NT	   NT	   NT	   NT	   NT	  
HD24	   0.32	   0.02	   1.93	   0.02	   0.01	   0.92	  
HD25	   NT	   NT	   NT	   NT	   NT	   NT	  
HD26	   NT	   NT	   NT	   NT	   NT	   NT	  
HD27	   NT	   NT	   NT	   NT	   NT	   NT	  
HD28	   NT	   NT	   NT	   NT	   NT	   NT	  
HD29	   NT	   NT	   NT	   NT	   NT	   NT	  
HD30	   NT	   NT	   NT	   NT	   NT	   NT	  
HD32	   0.01	   0.58	   0.29	   0.01	   0.01	   2.68	  
*Values	   indicated	   the	   percentages	   of	   CD8	   T	   cells	   producing	   IFN-­‐γ.	  	  
**Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	   ***Stimulated	   with	  
Concanavalin	  A	  served	  as	  a	  positive	  control.	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Table	  8.3	  Total	  data	  for	  CD8	  T	  cell	  responses	  to	  HCMV	  antigens	  by	  intracellular	  
cytokine	  staining	  for	  TNF-­‐α∗  
 
Donor	   IE1	   IE2	   pp65	   gB	   Neg**	   Pos***	  
HD01	   0.55	   0.06	   0.16	   0.10	   0.03	   4.48	  
HD02	   0.09	   0.10	   0.33	   0.19	   0.02	   2.68	  
HD03	   1.94	   0.06	   0.15	   0.09	   0.03	   6.65	  
HD04	   0.19	   0.06	   0.02	   0.07	   0.06	   2.75	  
HD05	   3.91	   0.04	   0.86	   0.07	   0.03	   5.14	  
HD06	   2.54	   0.05	   0.68	   0.25	   0.06	   4.86	  
HD07	   3.87	   0.32	   0.79	   0.15	   0.06	   3.77	  
HD08	   0.49	   0.16	   0.28	   0.30	   0.07	   3.37	  
HD09	   8.13	   0.04	   0.08	   0.05	   0.02	   0.73	  
HD10	   NT	   NT	   NT	   NT	   NT	   NT	  
HD11	   3.40	   0.04	   0.32	   0.11	   0.02	   1.14	  
HD12	   0.03	   0.03	   0.17	   0.04	   0.03	   4.25	  
HD13	   NT	   NT	   NT	   NT	   NT	   NT	  
HD14	   0.05	   0.08	   0.05	   0.27	   0.05	   1.21	  
HD15	   0.65	   0.08	   0.14	   0.16	   0.06	   1.56	  
HD16	   0.06	   0.03	   0.05	   0.05	   0.03	   0.35	  
HD17	   0.87	   0.00	   0.19	   0.11	   0.09	   0.28	  
HD18	   NT	   NT	   NT	   NT	   NT	   NT	  
HD19	   NT	   NT	   NT	   NT	   NT	   NT	  
HD20	   NT	   NT	   NT	   NT	   NT	   NT	  
HD21	   0.14	   0.37	   0.13	   0.15	   0.03	   1.33	  
HD22	   NT	   NT	   NT	   NT	   NT	   NT	  
HD23	   NT	   NT	   NT	   NT	   NT	   NT	  
HD24	   0.42	   0.00	   1.08	   0.05	   0.02	   0.86	  
HD25	   NT	   NT	   NT	   NT	   NT	   NT	  
HD26	   NT	   NT	   NT	   NT	   NT	   NT	  
HD27	   NT	   NT	   NT	   NT	   NT	   NT	  
HD28	   NT	   NT	   NT	   NT	   NT	   NT	  
HD29	   NT	   NT	   NT	   NT	   NT	   NT	  
HD30	   NT	   NT	   NT	   NT	   NT	   NT	  
*Values	   indicated	   the	   percentages	   of	   CD8	   T	   cells	   producing	   IFN-­‐γ.	  	  
**Unstimulated	   PBMC	   served	   as	   a	   negative	   control.	   	   ***Stimulated	   with	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Table	  8.4	  List	  of	  antibodies/chemicals/reagents/consumables	  	  
	  
A. Antibodies/kits	   Manufacturer	   Catalogue	  no	  
Human	  IFN-­‐γ	  ELISpot	  Kit	   Mabtech,	  UK	   3420-­‐2A	  
Mouse	  Anti-­‐human	  CD3	   BD	  Biosciences,	  UK	   552127	  	  	  	  	  	  	  	  	  
Mouse	  Anti-­‐human	  CD4	  APC	   BD	  Biosciences,	  UK	   555349	  
Mouse	  Anti-­‐human	  CD4	  PerCP-­‐Cy5.5	   BD	  Biosciences,	  UK 560650	  
Mouse	  Anti-­‐human	  CD8	  APC	   BD	  Biosciences,	  UK 555369	  
Mouse	  Anti-­‐human	  CD8	  FITC	   DAKO,	  UK 45-­‐0073	  
Mouse	  Anti-­‐human	  CD8	  PE	   DAKO,	  UK 45-­‐0037	  
Mouse	  Anti-­‐human	  CD8	  PerCP-­‐Cy5.5	   BD	  Biosciences,	  UK 560662	  
Mouse	  Anti-­‐human	  HHV-­‐6B	   Millipore,	  USA	   MAB8535	  
Mouse	  Anti-­‐human	  IFN-­‐γ	  FITC	   BD	  Biosciences,	  UK 340449	  
Mouse	  Anti-­‐human	  IFN-­‐γ	  PE	   BD	  Biosciences,	  UK 560742	  
Mouse	  Anti-­‐human	  TNF-­‐α 	   BD	  Biosciences,	  UK 554513	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B. Chemicals/reagents	   Manufacturer	   Catalogue	  no.	  
Amphotericin	  B	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Aldrich,	  UK	   A2942	  
Bovine	  serum	  albumin	  (BSA)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Aldrich,	  UK	   A8327	  
Brefeldin	  A	   eBioscience,	  UK	   00-­‐4506-­‐51	  
Celltrace	  CFSE	  cell	  proliferation	  kit	   Molecular	  Probe,	  USA	   C34554	  
Cytofix	  fixation	  buffer	   BD	  Biosciences,	  UK	   51-­‐9006613	  
Dimethyl	  sulfoxide	  (DMSO)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Aldrich,	  UK	   D2650	  
Dulbecco’s	  phosphate	  buffered	  saline	  	  	  	  	  	  	  	   Sigma	  Aldrich,	  UK	   D5652	  
Ficoll-­‐paque	  premium	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GE	  Healthcare	  Life	  
Sciences,	  UK	  
17-­‐5442-­‐03	  
Foetal	  bovine	  serum	  (FBS)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Aldrich,	  UK	   F7524	  
Golgistop	  protein	  transport	  inhibitor	  (Monensin)	   BD	  Biosciences,	  UK	   51-­‐2092KZ	  
Human	  AB	  serum	  	   Sigma	  Aldrich,	  UK	   H4522	  
Heparin	  sodium	  (mucous	  injection	  BP)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  LEO	  Pharma,	  UK	   DE0248	  
IC	  fixation	  buffer	   eBioscience,	  UK	   00-­‐8222-­‐49	  
L-­‐glutamine	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma Aldrich,	  UK	   G7513	  
Penicillin/streptomycin	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma Aldrich,	  UK	   P0781	  
Permeabilisation	  buffer	  (10x)	   eBioscience,	  UK	   00-­‐8333	  
RPMI	  1640	  media	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Aldrich,	  UK	   R5886	  
Trypan	  Blue	   Sigma	  Aldrich,	  UK	   T-­‐8154	  
Tween-­‐20	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Aldrich,	  UK	   P1379	  
Vectasheld	  (mounting	  medium	  with	  DAPI)	   Vector,	  UK	   P1203	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C. Consumables	   Manufacturer	   Catalogue	  No.	  
ELISA	  plates	  (96	  well,	  	  flat,	  high	  protein	  
binding	  EIA/RIA	  plate)	  
Corning,	  USA	  via	  Appleton	  
Woods,	  UK	  
CC679	  
ELISpot	  plates	  (Multiscreen	  HTS	  filter,	  0.45µm	  
hydrophobic,	  high	  protein	  binding	  
membrane)	  
Millipore,	  USA	   MAIPN45	  
MACS	  cell	  separation	  LD	  columns	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Myltenyi	  Biotech	  Ltd,	  
Germany	  
130-­‐042-­‐901	  
Microplate	  24-­‐Well	  with	  lid	   Sarstedt,	  USA	   82.1583	  
Microtest	  Plate	  96-­‐Well	  Vee	  Bottom	   Iwaki,	  Japan	   3820-­‐024	  
Transfer	  pipette	  (3.5ml	  sterile)	   Sarstedt,	  USA	   86.1171.001	  
 
	  
